Sage Therapeutics

Developing novel
medicines to transform
the lives of patients with
life-altering central
nervous system disorders

2015 Annual Report

“We continued to execute on our mission in 2015, taking

large steps toward becoming a fully integrated biopharma

company and establishing Sage as a leader of innovation

in CNS drug development.”

JEFF JONAS, M.D.
Chief Executive Officer

TO OUR SHAREHOLDERS

At Sage, our mission is to make life better for patients with central nervous
system disorders by discovering, developing and delivering important new
medicines for patients in need.

We continued to execute on our mission in 2015, taking large steps toward
becoming a fully integrated biopharma company and establishing Sage as a
leader of innovation in CNS drug development. This progress helped lay the
foundation for what has the potential to be a truly transformative year in 2016,
and I’m excited to tell you about the milestones ahead of us.

Our approach to treating CNS disorders remains focused on targeting and
seeking to correct imbalances in two critical neurotransmitter receptor systems,
GABA and NMDA. Both of these systems regulate essential brain and CNS
signaling, and are implicated in a broad range of CNS disorders. Our approach
continues to emphasize targeting CNS indications where patient populations
are easily identified, clinical endpoints are well-defined, and development
pathways are feasible.

2015 was a pivotal year for our lead candidate, SAGE-547, an allosteric
modulator of both synaptic and extrasynaptic GABAA receptors. We took
significant steps with our program for super-refractory status epilepticus (SRSE),
a rare and life-threatening seizure disorder for which there are no approved
therapies. After the promising results from our Phase 1/2 clinical trial of
SAGE-547 in SRSE, we initiated our Phase 3 STATUS Trial in August 2015 under
a Special Protocol Assessment with the U.S. Food and Drug Administration
(FDA). The STATUS Trial is a global, randomized, double-blind, placebo-con-
trolled clinical trial evaluating SAGE-547 as a treatment for patients with SRSE,
and is expected to enroll up to 140 patients. We currently anticipate top-line
results from this trial in the second half of 2016.

While we are preparing for a potential commercial launch of SAGE-547 if those
results are positive and we are able to obtain regulatory approval, we also
remain committed to the development of our broader pipeline. Toward this end,
we made significant progress in studying the potential of our GABA pipeline to
impact new indications where we believe GABA dysfunction plays an important
role. To accomplish this we employed a unique development approach - using
SAGE-547, our intravenous agent where we have shown brain activity through
an EEG biomarker - to find signals of activity in other specific CNS disorders we
believe have a biological rationale for treatment with a GABA modulator, and
meet our other development criteria. This led to our promising early clinical
proof-of-concept results for SAGE-547 in postpartum depression (PPD) and
essential tremor. Based on the early PPD data, we subsequently initiated a
Phase 2 placebo-controlled, proof-of-concept clinical trial of SAGE-547 in
severe PPD, which we anticipate will report out top-line data during the second
quarter of 2016.

We believe the early signs of activity in these indications support further
development activities focused on modulation of the GABA receptor system.
Our next-generation positive allosteric modulator, SAGE-217 has been
optimized for selectivity of synaptic and extra-synaptic GABAA receptors and
for a profile that allows once-daily oral dosing. We anticipate reporting the

results of the Phase 1 clinical development program for SAGE-217 in the second
quarter of 2016. Assuming positive results, we plan to initiate Phase 2 clinical
trials with SAGE-217 in essential tremor and orphan epilepsies in the second half
of 2016. We also plan to conduct a Phase 2 study of SAGE-217 in the treatment
of severe PPD if the results from our placebo-controlled, proof-of-concept trial
with SAGE-547 support further development in this indication.

In keeping with our commitment to further pipeline development, we also
anticipate initiating a Phase 1 clinical development program in the second half of
2016 for SAGE-689 if we are able to satisfy the FDA’s request for additional
non-clinical study data. This next generation positive allosteric modulator of
GABAA receptors is being developed as an acute parenteral therapy for the
treatment of indications where a high degree of anti-seizure activity and sedation
are desirable prior to the introduction of general anesthesia, such as status
epilepticus.

Beyond our GABA programs, we announced in 2015 the selection of SAGE-718
as our first NMDA development candidate. SAGE-718 is currently in
IND-enabling studies, and is a first-in-class, oxysterol-based positive allosteric
modulator of NMDA receptors, a critical excitatory receptor system implicated in
a broad range of CNS disorders and an area of research that we are seeking to
help pioneer. The initial indications selected for potential development are
Smith-Lemli-Opitz Syndrome and Anti-NMDA Receptor Encephalitis, which are
biomarker-linked orphan populations with no approved treatments that will
allow us to explore activity and potentially expand into broader CNS
populations associated with similar biomarkers. We expect that, assuming
successful completion of non-clinical work, SAGE-718 will begin clinical
development in 2017.

On the corporate side, we continued to strengthen our organizational
infrastructure, and expanded our leadership team with key development,
commercial, research, technical operations and medical affairs appointments in
2015. We also have a strong balance sheet, with a year-end cash position of
$186.8 million and an underwritten follow-on public offering in January 2016
that provided additional net proceeds of $140.4 million. This financial strength
enables us to invest in pre-commercial launch planning initiatives for SAGE-547,
while also allowing us to focus in the near-term on building a robust development
pipeline beyond our first product candidate.

As always, we are extremely grateful to our employees, clinical collaborators,
board members and stockholders for their continued support as we make
important progress toward realizing our vision of making a difference in the lives
of patients with few or inadequate treatment options.

And most importantly, we want to thank the people who have joined our clinical
trials with the hope of improving their outcomes and that of future patients.
None of the progress we have made to date would have been possible without
their support, and we look forward to providing updates on our discovery and
development work throughout 2016.

Jeff Jonas, M.D.
Chief Executive Officer

Annual Report 2015

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-K

(Mark One)
È ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2015

OR

‘ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934

For the transition period from

to

Commission file number: 001-36544

Sage Therapeutics, Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware
(State or Other Jurisdiction of
Incorporation or Organization)

215 First Street
Cambridge, Massachusetts
(Address of Principal Executive Offices)

27-4486580
(I.R.S. Employer
Identification No.)

02142
(Zip Code)

(617) 299-8380
(Registrant’s Telephone Number, Including Area Code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Name of each exchange on which registered

Common Stock, $0.0001 par value

NASDAQ Global Market

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities

Act. Yes È No ‘

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange

Act. Yes ‘ No È

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file
such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes È No ‘

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every
Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or
for such shorter period that the registrant was required to submit and post such files). Yes È No ‘

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will
not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part
III of this Form 10-K or any amendment to this Form 10-K. ‘

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2
of the Exchange Act. (Check one):
Large accelerated filer È
Non-accelerated filer ‘ (Do not check if a smaller reporting company)

‘
Accelerated filer
Smaller reporting company ‘

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange

Act). Yes ‘ No È

The aggregate market value of the registrant’s voting and non-voting common stock held by non-affiliates of the registrant

(without admitting that any person whose shares are not included in such calculation is an affiliate) as of June 30, 2015 was
approximately $903,465,958, computed by reference to the closing price of the registrant’s common stock on the NASDAQ Global
Market reported for such date.

As of February 16, 2016, there were 32,022,187 shares of common stock, $0.0001 par value per share, outstanding.

TABLE OF CONTENTS

Part I.

Item 1. Business
Item 1A. Risk Factors
Item 2.
Properties
Item 3. Legal Proceedings
Item 4. Mine Safety Disclosures

Part II.

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of

Equity Securities

Selected Consolidated Financial Data

Item 6.
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Item 7A. Quantitative and Qualitative Disclosures About Market Risk
Item 8.
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
Item 9A. Controls and Procedures
Item 9B Other Information

Financial Statements and Supplementary Data

Part III.

Item 10. Directors, Executive Officers and Corporate Governance
Item 11. Executive Compensation
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder

Matters

Item 13. Certain Relationships and Related Transactions, and Director Independence
Item 14. Principal Accounting Fees and Services

Part IV.

Item 15. Exhibits and Financial Statement Schedules

Signatures

Page

1
35
70
70
70

71
74
75
89
89
89
89
90

91
91

91
91
91

91
93

Cautionary Note Regarding Forward-Looking Statements

This Annual Report on Form 10-K, or Annual Report, contains forward-looking statements that involve
risks and uncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than
statements of historical facts contained in this Annual Report are forward-looking statements. In some cases, you
can identify forward-looking statements by terminology such as “may”, “will”, “should”, “expects”, “intends”,
“plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, “continue” or the negative of these terms
or other comparable terminology. These forward-looking statements include, but are not limited to, statements
about:

‰

‰

‰

‰

‰

‰

‰

‰

‰

‰

‰

‰

‰

our plans to develop and commercialize our product candidates in the central nervous system, or CNS,
disorders we discuss in this Annual Report, and potentially in other indications;

our ability, within the expected timeframes, to complete our ongoing non-clinical studies and clinical
trials; to announce the results of such studies and trials; to advance our product candidates into
additional clinical trials, including pivotal clinical trials; and to successfully complete such clinical
trials;

our plans with respect to filing for regulatory approval for our product candidates, if clinical trial
development is successful, and the potential to obtain such approval and to commercialize any product,
if approved

our estimates regarding expenses, the potential for future revenues and capital requirements;

our expectations with respect to the availability of supplies of our product candidates, and the expected
performance of our third-party manufacturers;

our expectations with respect to the performance of our contract research organization and other third
parties whose activities are important to our development and future commercialization efforts;

our ability to obtain and maintain intellectual property protection for our proprietary assets and other
forms of exclusivity relevant to our business;

the estimated number of patients in indications of interest to us, and the size of the potential markets
for our product candidates and our ability to serve those markets;

the anticipated rate and degree of market acceptance of our product candidates for any indication once
approved;

the level of costs we may incur in connection with our activities, and our ability to obtain additional
financing when needed;

the potential for success of competing products that are or become available for the indications that we
are pursuing;

the potential risk of loss of key scientific or management personnel; and

other risks and uncertainties, including those listed under Part II, Item 1A. Risk Factors.

Any forward-looking statements in this Annual Report reflect our current views with respect to future events

and with respect to our future financial performance and involve known and unknown risks, uncertainties and
other factors that may cause our actual results, performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by these forward-looking statements. Factors
that may cause actual results to differ materially from current expectations include, among other things, those
described under Part II, Item 1A. Risk Factors and elsewhere in this Annual Report. Given these uncertainties,
you should not place undue reliance on these forward-looking statements. Except as required by law, we assume
no obligation to update or revise these forward-looking statements for any reason, even if new information
becomes available in the future.

This Annual Report contains estimates, projections and other information concerning our industry, the
general business environment, and the markets for certain diseases, including estimates regarding the potential
size of those markets and the estimated incidence and prevalence of certain medical conditions. Information that
is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to
uncertainties and actual events, circumstances or numbers, including actual disease prevalence rates and market
size, may differ materially from the information reflected in this Annual Report. Unless otherwise expressly
stated, we obtained this industry, business information, market data, prevalence information and other data from
reports, research surveys, studies and similar data prepared by market research firms and other third parties,
industry, medical and general publications, government data, and similar sources, in some cases applying our
own assumptions and analysis that may, in the future, not prove to have been accurate.

PART I

All brand names or trademarks appearing in this report are the property of their respective owners. Unless
the context requires otherwise, references in this report to “Sage” the “Company,” “we,” “us,” and “our” refer
to Sage Therapeutics, Inc. and its subsidiaries.

Item 1. Business

Overview

We are a clinical-stage biopharmaceutical company committed to developing and commercializing novel
medicines to treat life-threatening central nervous system, or CNS, disorders, where there are inadequate or no
approved existing therapies. We are targeting CNS indications where patient populations are easily identified,
clinical endpoints are well-defined, and development pathways are feasible.

Our lead product candidate is SAGE-547, a proprietary intravenous formulation of allopregnanolone, a
naturally occurring neurosteroid that acts as a synaptic and extrasynaptic modulator of the GABAA receptor.
GABA is the major inhibitory neurotransmitter in the CNS, and mediates downstream neurologic and bodily
function via activation of GABAA receptors. We believe that allosteric modulation of the GABAA receptor has
the potential to be well-suited for the treatment of seizures and certain other CNS disorders because it allows for
the fine-tuning of neuronal signals rather than complete activation or complete inhibition. SAGE-547 is in Phase
3 clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus, or SRSE.
SRSE is a rare and life-threatening condition where a patient is in a state of continuous seizure called status
epilepticus, or SE, and all of the standard treatment regimens normally sufficient to stop the seizure activity have
failed. We expect to report top-line results from the global, randomized, double-blind, placebo-controlled Phase 3
trial of SAGE-547 in SRSE in the second half of 2016. If successful, we believe the results of the Phase 3 clinical
trial, together with other clinical data obtained from the SAGE-547 clinical program, and results of ongoing non-
clinical studies, could form the basis of a New Drug Application, or NDA submission, in the U.S. for SAGE-547.

We have also used SAGE-547 in proof-of-concept clinical trials to explore potential uses of GABAA
receptor modulators to treat post-partum depression, or PPD, a distinct and readily identified major depressive
disorder, and essential tremor, a debilitating neurological disorder that causes involuntary, rhythmic shaking with
no known cause. We are currently conducting an additional Phase 2 exploratory trial of SAGE-547 in the
treatment of severe PPD. We expect the data from these exploratory trials to guide the development of second-
generation GABAA receptor modulators for the applicable diseases.

Our next-generation product candidates, SAGE-217 and SAGE-689, also target the GABAA receptor
system. These compounds have been designed to have pharmaceutical properties that optimize both their non-
clinical profiles and potential clinical profiles for the treatment of certain seizure and non-seizure CNS disorders.
We are currently conducting a Phase 1 clinical trial of SAGE-217, which we expect to complete in the first half
of 2016. If the Phase 1 clinical trial of SAGE-217 supports further development, we plan to commence Phase 2
clinical trials of SAGE-217, initially in essential tremor and orphan epilepsies. SAGE-689 is in non-clinical
development. Our Phase 1 clinical trial of SAGE-689 has been delayed to respond to a request from the United
States Food and Drug Administration, or FDA, for additional non-clinical study data.

We are also studying novel compounds that target the NMDA receptor, a critical excitatory receptor system

in the brain implicated in a broad range of CNS disorders. The first product candidate selected for development
from this program is SAGE-718, an oxysterol-based positive allosteric modulator of NMDA receptors. We have
begun non-clinical studies of SAGE-718, with an initial development focus on two rare conditions, Smith-Lemli-
Opitz Syndrome and Anti-NMDA Receptor Encephalitis. Beyond these conditions, we believe measuring levels
of anti-NMDA antibodies or decreased levels of cerebrosterol, a naturally occurring oxysterol, may represent
biomarkers to identify for future study broader patient populations characterized by cognitive dysfunction and

1

neuropsychiatric symptoms resulting from NMDA receptor dysfunction or hypofunction. Examples of these
potential areas for future evaluation include certain types, aspects or subpopulations of a number of diseases such
as depression, Alzheimer’s disease, attention deficit hyperactivity disorder, schizophrenia, Huntington’s disease,
and neuropathic pain.

We expect to continue our focus on allosteric modulation of the GABAA and NMDA receptor systems in the

brain. The GABAA and NMDA receptor systems are broadly accepted as impacting many psychiatric and
neurological disorders, spanning disorders of mood, seizure, cognition, anxiety, sleep, pain, epilepsy, and
movement disorders among others. We believe that we will have the opportunity to develop molecules from our
internal portfolio to address a number of these disorders in the future. Our ability to identify and develop such
novel CNS therapies is enabled by our proprietary chemistry platform that is centered on a scaffold of chemically
modified endogenous neuroactive steroid compounds. We believe our know-how around the chemistry and
activity of allosteric modulators allows us to efficiently design molecules with different characteristics by
enabling us to control important properties such as half-life, brain penetration and the types of receptors with
which our compounds interact with the goal of developing product candidates that have the potential to bind with
targets in the brain with more precision, increased tolerability, and fewer off-target side effects than either current
CNS therapies or previous therapies which have failed in development.

SAGE was founded in 2010, based on leading research in the areas of brain function and neuroactive
steroids, to explore novel approaches to CNS therapeutics. Since our inception, we have continued to expand our
know-how related to CNS therapeutics through our research and development programs, and to pursue
intellectual property protection with respect to our proprietary chemistry platform. In addition, we have
assembled a world-class management team that together has been a part of the successful discovery, development
and commercialization of more than 20 marketed CNS therapies.

In January 2016, we completed a follow-on public offering of 3,157,894 shares of our common stock at a

price to the public of $47.50 per share, for net proceeds, after deducting underwriters’ discounts and
commissions and estimated offering expenses, of approximately $140.4 million.

Recent Developments

Our goal is to become a leading biopharmaceutical company focused on development and

commercialization of novel proprietary therapies for the treatment of life-threatening CNS disorders. Key
elements of our strategy are to:

Our Strategy

‰ Rapidly advance SAGE-547 as a treatment for SRSE.
‰ Utilize SAGE-547 in exploratory trials in certain diseases of interest to help guide the development of

second-generation GABAA receptor modulators for those diseases.

‰ Develop our next generation product candidates, SAGE-217, SAGE-689 and SAGE-718, in parallel

with SAGE-547.

‰

Enhance the probability of success in treating CNS disorders by developing unique assets with
differentiated features, and focus our internal development activities on CNS indications where we can
make well- informed, rapid go/no-go decisions.

‰ Grow our pipeline more broadly utilizing the strengths of our proprietary chemistry platform and

scientific know-how, to lessen our long-term reliance on a single franchise and to facilitate long-term
growth.

‰ Build a commercial capability to bring our CNS therapeutics, if and when approved, to physicians and

patients for the target indications.

2

Neurotransmission

Understanding the Foundations of Our Approach

The CNS is composed of a vast and complex network of different structures and cell types, most of which

serve directly or indirectly, to provide a means for the nervous system to signal or communicate with other nerve
cells in order to regulate and control all brain function. The cell type responsible for this signaling is called a
neuron. Chemical or electrical signals can exert their effects on neurons by traveling across a physical gap
located between two neurons, called a synapse. Presynaptic neurons transmit signals whereas postsynaptic
neurons react to the signals. The human brain contains approximately 86 billion neurons, each having hundreds
to tens of thousands of synapses to allow for this communication. This process is essential to all things, from
organ function, to movement, to memory and all behavioral processes.

Neurotransmission is the process by which signaling molecules, called neurotransmitters, are released by a

presynaptic neuron, travel over the synaptic space and bind to and interact with receptors on a postsynaptic
neuron. Depending on the nature of the neurotransmitter and receptor, this interaction results in excitation,
inhibition or modulation of the receiving neuron’s behavior.

Synaptic receptors are primarily located inside the synaptic cleft, or the space where the neurons

communicate, and have been historically considered to be the most important part of the neuron. However, recent
understanding of neurotransmission and brain function has shown there are many extrasynaptic receptors that
also respond to neurotransmitters to exert their effects. For example, it is becoming increasingly understood that
extrasynaptic GABAA receptor-mediated neurotransmission is critical to generalized neurological function and
has demonstrated influence over general physiological states such as sleep, hunger, anxiety and seizure, among
other things.

Allosteric Modulation

We are focused on developing drugs based on selective allosteric modulation of key CNS synaptic and
extrasynaptic receptors. Molecules that function directly on synaptic or extrasynaptic receptors at the site where
the native, or natural, molecule binds to inhibit or activate them are known as orthosteric molecules.
Alternatively, allosteric modulators are a class of small molecules very different from classical orthosteric drugs,
as allosteric modulators interact at a site different from the native site and allow the potential for fine-tuning of
neuronal signals.

Orthosteric drugs aimed at key synaptic receptors typically have a targeted effect of complete activation or
complete inhibition of the neuron, with little subtlety in how they exert their effect. As a result, neurons may be
unable to respond to normal stimuli, and can become over-stimulated by a neurotransmitter or be unable to
respond to normal neurotransmission, thus potentially negatively impacting both the efficacy and safety profile
of an orthosteric CNS drug development candidate. We believe that nowhere in the body is it more important to
maintain normal rhythms than in the brain, and accordingly we believe that allosteric modulation approaches are
well-suited for the treatment of seizure and other CNS diseases.

3

We utilize our proprietary chemistry capabilities to design and identify drugs that are allosteric modulators

that bind to either or both synaptic and extrasynaptic receptors, and that have properties targeted to the
indications of interest. Our current focus is on developing compounds that are positive allosteric modulators of
both synaptic and extrasynaptic sites of either the GABAA receptor or the NMDA receptor system. Our goal is to
select for development compounds that we believe are capable of varying degrees of desired activity rather than
complete activation or inhibition of the receptor as is typically observed with orthosteric drugs.

Allosteric Modulation of Extrasynaptic GABAA Receptors

GABAA receptors are the major inhibitory neurotransmitter receptors in the human brain, playing a key role
in reducing neuron excitability. Our initial focus is on the development of positive allosteric modulators of both
synaptic and extrasynaptic sites of the GABAA receptor. Benzodiazepines, or BDZs, are allosteric modulators
that primarily act at a particular receptor, the synaptic GABAA receptor, with little or no activity at extrasynaptic
sites. We believe we can enhance the potential utility of modulating the GABAA receptor for certain indications,
and effectively avoid some of the limitations of BDZs, by developing compounds that bind to both synaptic and
extrasynaptic GABAA receptors. The extrasynaptic GABAA receptor is structurally distinct from the synaptic
receptor, possesses unique pharmacology and is located in a different place than the synaptic GABAA receptor. In
addition, the extrasynaptic GABAA receptor remains intact during prolonged periods of seizure with no down-
regulation while synaptic GABAA receptors are down-regulated, or diminished in their activity causing some SE
patients to be resistant to the action, or pharmacology, of drugs that only target the synaptic GABAA receptors,
such as BDZs. Published non-clinical testing utilizing well-validated animal models of SE and sophisticated
instruments for identifying the expression of both synaptic and extrasynaptic GABAA receptors on the surface of
neurons support this hypothesis. These studies, performed in rats, showed a reduced number and activity of
synaptic GABAA receptors during SE, in contrast to the preserved number and activity of extrasynaptic GABAA
receptors under the same conditions. These studies were done by measuring the amount of GABAA synaptic and

4

GABAA extrasynaptic receptors that are present on the surface of the neurons. The analysis of protein present for
each of the respective receptors in animals in the SE-state, versus normal animals, shows the difference in
GABAA receptor expression.

The figure below shows the results of a rodent study where the subject animals were placed into an SE-like

condition of prolonged seizure resulting in continuous spontaneous seizures. SAGE-547 was then administered to
certain animals while the others received a BDZ. In this animal model, BDZs were unable to adequately control
the seizure condition which we believe is due to down-regulation of synaptic GABAA receptors. In contrast,
SAGE-547, working at both synaptic and extrasynaptic GABAA receptors, appears to have treated the seizures in
these animals and resolved their SE.

Allosteric Modulation of NMDA Receptors to Address Certain CNS Conditions

NMDA is a major excitatory receptor system in the brain. NMDA receptors serve a critical role in CNS-

related activities. Orthosteric drug candidate approaches to modulating the NMDA receptor have also been
fraught with difficulties. NMDA receptor antagonists have been explored for treating Alzheimer’s disease and
neuropathic pain and for inducing anesthesia. Drugs that antagonize NMDA receptors have generally been
limited by adverse effects, such as neurotoxicity, deteriorating mental status and psychotomimetic, or the onset of
psychotic symptoms, following the administration of the drug. NMDA receptor agonists have been tested in
schizophrenia, and many believe that they may have a role in enhancing cognition and mood. However, their
ability to be used at effective doses in humans has generally been limited by non-clinical findings indicating
these agents may induce cell death through excess excitation of nerve cells.

We have identified, and continue to evaluate, a number of positive and negative allosteric modulators of the

NMDA receptor that we believe have the potential to overcome the difficulties associated with orthosteric
approaches. Like our GABAA allosteric modulators, our NMDA receptor allosteric modulators work at sites
located in the synaptic and extrasynaptic spaces of the neuron and enhance, or modulate, the activity of the native
molecule without directly activating the NMDA receptor. Initial animal testing of our NMDA receptor allosteric
modulators has shown evidence that targeting the synaptic and extrasynaptic spaces may help avoid the
excitotoxicity and psychotomimesis observed with directly activating, orthosteric compounds. This in turn may
eventually allow us to discover and develop, alone or with partners, compounds to treat certain conditions where
NMDA receptor dysfunction may play a role in cognitive dysfunction and neuropsychiatric symptoms such as
certain types, aspects or subpopulations of depression, Alzheimer’s disease, attention deficit hyperactivity
disorder, schizophrenia, Huntington’s disease, and neuropathic pain. The first product candidate selected for
development from this program is SAGE-718. We have begun non-clinical studies of SAGE-718, with an initial
development focus on two rare conditions, Smith-Lemli-Opitz Syndrome and Anti-NMDA Receptor
Encephalitis.

5

Our proprietary chemistry platform

Our proprietary chemistry platform is centered on novel chemical scaffolds of endogenous or chemically
modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or NMDA receptors.
We have leveraged this platform to assemble a chemistry portfolio of greater than 2,000 compounds. We believe
our proprietary chemistry platform allows us to:

‰

‰

‰

optimize the properties of neuroactive steroid compounds to develop proprietary, new chemical
entities, with the potential to be used as oral, intravenous, or IV, or intramuscular therapies;

control important properties such as half-life, brain penetration and the types of receptors our drugs act
upon, thereby modulating either inhibition or excitation either acutely or chronically; and

create drugs that are designed to exert control over the intensity of receptor activation or deactivation,
with the potential to hit targets in the brain with more precision, with the goal of increased tolerability
and fewer off-target side effects than current CNS therapies.

Our Product Pipeline

The following table summarizes the status of our development programs as of the date of this Annual

Report:

SAGE-547

Overview

SAGE-547 is a proprietary IV formulation of allopregnanolone, a naturally occurring neurosteroid that acts

as a synaptic and extrasynaptic modulator of the GABAA receptor. SAGE-547 is being developed as an

6

adjunctive therapy in conjunction with underlying anesthesia, as a treatment for SRSE. In the third quarter of
2015, we initiated the STATUS Trial (SAGE-547 Treatment as Adjunctive Therapy Utilized in Status
Epilepticus), a global, randomized, double-blind, placebo-controlled Phase 3 clinical trial to evaluate SAGE-547
as a treatment for patients with SRSE. We expect to announce top-line results for the Phase 3 clinical trial in the
second half of 2016. If successful, we believe the results from this Phase 3 clinical trial, together with other
clinical data obtained from the SAGE-547 development program and results of completed and ongoing non-
clinical studies, could form the basis of an NDA submission for SAGE-547 in the U.S. The FDA granted us
orphan drug designation for SAGE-547 in the treatment of SE including SRSE, and Fast Track designation for
our investigational new drug application for SAGE-547 as a treatment for SRSE.

Super-refractory Status Epilepticus (SRSE)

SRSE is rare, life-threatening condition where a patient is in a state of SE and all standard treatment
regimens normally sufficient in stopping seizure activity have failed. The Neurocritical Care Society defines SE
as one continuous unremitting seizure lasting longer than five minutes, or recurrent seizures without regaining
consciousness between seizures for greater than five minutes. Seizures are episodes of abnormal excessive or
synchronous neuronal activity in the brain. The outward effect can vary from rapid uncoordinated movement of
the trunk and extremities, known as tonic-clonic seizure, to a brief loss of awareness, known as an absence
seizure. An electroencephalogram, or EEG, is a measurement of electrical activity within neurons of the brain.
Each line of an EEG represents a different region of the brain and becomes aberrant during a state of seizure. In
cases of recurring or frequent seizures, or with persistent and long seizures, uncontrolled neurotransmission
results in remodeling or changes to brain synaptic function. These physiological and anatomical changes to the
brain include changes to the receptor systems of neurons, and shape of the neuron thereby impacting its ability to
function, resulting in disorganization of brain proteins and potentially neuronal death.

7

Common causes of SE in adults include preexisting epilepsy, cerebrovascular disease, metabolic and
electrolyte disturbances, encephalopathies, head trauma and drug or substance intoxication. SE is more common
in children, often as a result of high fever during the first year of life. It is the most common neurologic
emergency in pediatric practice. An SE patient is first treated with BDZs, and if no response, is then treated with
other, second-line, anti-seizure drugs. If the seizure persists after second-line therapy, the patient is diagnosed as
having refractory SE, or RSE, admitted to the intensive care unit, or ICU, and placed into a medically induced
coma. Currently, there are no therapies that have been specifically approved to treat refractory SE, or RSE;
however, physicians typically use anesthetic agents to induce the coma and stop the seizure immediately. The
primary drugs used to induce coma are continuously infused IV agents such as propofol, midazolam or
pentobarbital. The RSE patient is continually monitored through EEG to ensure burst suppression is achieved.
Burst suppression is a pattern of brain waves seen on an EEG characterized by periods of activity alternating with
periods of little or no activity in the brain, informing medical personnel of the effectiveness of the medically
induced coma. The goal of burst suppression is to allow the brain and corresponding neuronal tissue to restore
function and reset to normal pre-seizure levels. After a short period of burst suppression, typically 24 hours,
physicians attempt to wean the patient from the medically induced coma to evaluate EEG activity to assess if the
neuronal activity has returned to normal levels. If unsuccessful, the patient is placed back into the medically
induced coma in order to protect underlying neurological activity and brain function. At this point, patients are
considered to be in a state of SRSE. The current standard of care for SRSE is empiric, and there are no therapies
at present that have been specifically approved for this indication. We estimate that there are approximately
150,000 cases of SE each year in the United States, of which approximately 25,000 progress to SRSE.

Clinical Trials

We are currently conducting the STATUS trial, a global, randomized, double-blind, placebo-controlled
Phase 3 clinical trial, to evaluate SAGE-547 as a treatment for patients with SRSE. We expect to enroll up to 140
patients, ages two and above, in the STATUS trial in order to obtain an estimated 126 evaluable patients. We

8

anticipate that we will qualify approximately 150 sites in the United States, Canada and Europe. The trial design,
endpoints and statistical analysis approach are based on an agreement we reached with the FDA under a Special
Protocol Assessment. Subjects will be randomized in a 1:1 ratio to receive either SAGE-547 or placebo in
addition to standard-of-care third-line anti-seizure agents for six days. The primary efficacy endpoint of the trial
is continued resolution of SE for 24 hours following wean of all third-line agents and the blinded study drug
(SAGE-547 or placebo). Patients who do not respond during the initial treatment period will be eligible for open-
labeled treatment with SAGE-547.

On August 17, 2015, we reported we had treated the first patient enrolled in the Phase 3 clinical trial. We
expect to report top-line results from this trial in the second half of 2016. If successful, we believe the results
from this Phase 3 clinical trial, together with other clinical data obtained from the SAGE-547 development
program and results of completed and ongoing non-clinical studies, could form the basis of an NDA submission
for SAGE-547 in the U.S. The FDA has granted us orphan drug designation for SAGE-547 in the treatment of SE
including SRSE, and Fast Track designation for our investigational new drug application for SAGE-547 as a
treatment for SRSE.

On May 14, 2015, we reported final results from our open-label Phase 1/2 clinical trial of SAGE-547 in

SRSE. In the Phase 1/2 clinical trial, 77% of 22 evaluable patients met the key efficacy endpoint of being
successfully weaned off their anesthetic agents while SAGE-547 was being administered at the maintenance
dose. Subsequent post-hoc analysis involving duration of the weaning period (five days versus six days) showed
that 16 of 22 (73%) evaluable subjects were successfully weaned off both anesthetic agents and SAGE-547
within five days of starting the SAGE-547 infusion without the need to reinstate anesthetic agents in the
following 24-hour period, while 18 of 22 (82%) evaluable subjects were weaned off both anesthetic agents and
SAGE-547 within six days of starting the SAGE-547 infusion without the need to reinstate anesthetic agents in
the following 24-hour period which is the key efficacy endpoint of the Phase 3 clinical trial. SAGE-547 also
showed favorable tolerability and a benefit-risk profile supporting further development for this acutely ill patient

9

population. Overall, 64% of 25 patients enrolled in the trial experienced at least one serious adverse event,
though none were drug-related as determined by the Safety Review Committee. Independent of treatment
response, six patient deaths occurred within the study period, all driven by underlying medical conditions. Safety
and tolerability were assessed by monitoring adverse events, EEG, physical examinations, neurological
examinations, vital signs, clinical laboratory measures, electrocardiograms and concomitant medication usage. In
order to allow full assessment of pharmacologic activity, the trial employed broad inclusion criteria, primarily
excluding patients only if there is major damage to the brain, such as anoxic injury, devastating stroke or the
presence of a large lesion. Other secondary objectives used to measure efficacy included scores on global and
specific scales relating to cognition, agitation and depth of coma and survival. We can provide no assurance that
the positive results observed in the Phase 1/2 trial will be replicated in the Phase 3 clinical trial.

Emergency-use experience with SAGE-547

We have compiled evidence of activity with SAGE-547 in a small number of SRSE patients, on an
emergency-use basis, in situations where administration of SAGE-547 was permitted outside of clinical trials.
The data generated from these emergency-use cases supported further clinical development of SAGE-547 in the
treatment of SRSE. We expect that there may be additional emergency-use cases, and also expect to continue
enrollment in a Phase 3 open-label expanded access trial, designated Study 302, which was initiated in April
2015. Study 302 is designed to make SAGE-547 available to patients in the U.S. who are affected by SRSE, but
who have not been admitted to, nor can be transferred to, a STATUS trial site.

SAGE-547 Proof-of-Concept Studies

We have also used SAGE-547 in proof-of-concept clinical trials to explore potential uses of GABAA
receptor modulators to treat post-partum depression, or PPD, a distinct and readily identified depressive disorder
that affects certain women following childbirth, and essential tremor, a debilitating neurological disorder that
causes involuntary, rhythmic shaking with no known cause.

On June 9, 2015, we reported top-line data from our proof-of-concept open-label clinical trial of SAGE-547

in PPD that indicated a statistically significant improvement from baseline in depression in four women within
24 hours after administration of intravenous SAGE-547. During the SAGE-547 treatment period, all four patients
rapidly achieved remission, as measured by the Hamilton Rating Scale for Depression, or HAM-D, and improved
from a mean HAM-D score of 26.5 at baseline to a mean HAM-D score of 1.8 at the end of the 60-hour treatment
period. All four patients also demonstrated consistent improvement as measured by the Clinical Global
Impression-Improvement, or CGI-I scale. SAGE-547 was well-tolerated in all patients treated with no serious
adverse events observed on therapy or during the 30-day follow-up period, and no discontinuations due to
adverse events. A total of 14 adverse events were reported in four patients. The only adverse event reported in
more than one patient was sedation (sleepiness) observed in two patients, which led to a decrease in dose. In
November 2015, we initiated a multi-center, placebo-controlled, proof-of-concept trial of SAGE-547 in severe
PPD patients. We plan to enroll up to 32 patients diagnosed with severe PPD in the trial which is intended to
validate the activity signal observed in the earlier open-label study of SAGE-547 in the treatment for PPD.

On September 3, 2015, we announced results from a proof-of-concept clinical trial of SAGE-547 to evaluate

the GABAA mechanism of action as a treatment for essential tremor. In a randomized, double-blind, placebo-
controlled, crossover trial of 25 patients affected by essential tremor, where patients were exposed to the target
steady state dose of SAGE-547 for only two hours, several clinician-rated and accelerometer-rated measures
showed significant reductions in tremor. These changes included a statistically significant reduction in
accelerometer-measured upper limb kinetic tremor (p=0.046) which is one of the major manifestations of tremor
impacting morbidity. Likewise, clinician ratings of large tremor motions, as well as smaller movements such as
writing and spiral drawing, also showed improvement approaching statistical significance (p=0.056). In addition,
SAGE-547 demonstrated a clinically meaningful reduction of tremor amplitude as measured by accelerometer (at

10

least a 30% reduction from baseline) in 33% of patients, compared with 16% of patients in the placebo arm. In
this phase of the trial, anti-tremor activity of SAGE-547 was observed at non-sedating doses, and peak anti-
tremor activity correlated with steady state SAGE-547 levels. The time points showing the greatest reductions in
tremor corresponded to peak plasma measurements. Seventeen of these patients were exposed to higher doses of
SAGE-547 in an open-label extension with 44% demonstrating at least a 30% reduction in tremor amplitude
from baseline. The most common adverse events at higher doses were fatigue and dizziness. Hypotension led to
discontinuation of one patient. No serious adverse events were observed on therapy or during the 30-day follow-
up period.

SAGE-217

SAGE-217 is a novel neuroactive steroid that is a positive allosteric modulator of GABAA receptors. Like

SAGE-547, SAGE-217 targets synaptic and extrasynaptic GABAA receptors. We are currently conducting a
Phase 1 clinical trial of SAGE-217, which we expect to complete in the first half of 2016. While SAGE-547 is an
IV infusion intended for acute administration, SAGE-217 is currently being studied as an oral solution. We are in
the process of developing a solid dosage formulation of SAGE-217 intended for chronic use. In the event the
results of the Phase 1 clinical trial of SAGE-217 support further development, we plan to commence Phase 2
clinical trials of SAGE-217 in the treatment of orphan epilepsies and essential tremor, and potentially PPD.

Orphan Epilepsies

SAGE-217 has shown dose-related anticonvulsant activity in multiple acute seizure and chronic epilepsy

models. If the results of the Phase 1 clinical trial of SAGE-217 support further development, we plan to develop
the compound as an oral therapy for rare neurologic conditions associated with high frequencies of seizures, such
as Tuberous Sclerosis and Dravet, Rett, PCDH-19, Dup15q and Lennox-Gastaut syndromes, all of which have
small patient populations and an unmet medical need for additional treatment options to treat the seizures. Dravet
syndrome, also called severe myoclonic epilepsy of infancy, is a severe form of epilepsy. It typically appears
during the first year of life with frequent fever-related seizures. Later, other types of seizures typically arise in
patients with this disease. SE may also occur. Children with Dravet syndrome typically experience poor
development of language and motor skills, hyperactivity and difficulty relating to others. Rett syndrome is a
neurodevelopmental disorder that affects girls almost exclusively. It is characterized by normal early growth and
development followed by a slowing of development, loss of focused use of the hands, distinctive hand
movements, slowed brain and head growth, problems with walking, seizures and intellectual disability. Lennox-
Gastaut Syndrome, or LGS, typically manifests in children between the ages of three and five, and is widely
considered as a catastrophic childhood epilepsy in which multiple seizure types, including tonic and atonic, are
common. LGS is typically associated with cognitive impairment and behavioral abnormalities such as
hyperactivity. PCDH-19 is a pediatric epilepsy disorder linked to the X-chromosome and characterized by
clustered seizures in girls with typical onset between ages one and three. Seizures may become infrequent or
cease completely as the child ages. The long term prognosis for PCDH-19 patients is variable though most
patients suffer from cognitive impairment. Tuberous Sclerosis, or TSC, is caused by abnormalities in the TSC1
and TSC2 gene. Seizures are common in TSC, affecting approximately 90% of patients. Approximately 50% of
patients are cognitively affected. Dup15q Syndrome is an identifiable syndrome which results from duplications
of a specific chromosome. Babies with Dup15q Syndrome typically have poor muscle tone, also known as
hypotonia. Motor milestone such as rolling over, sitting up or walking are usually significantly delayed. Over
half of patients with the Dup15q Syndrome will have at least one seizure. The majority of those patients will
experience their first seizure before the age of five. Seizures are common in dup 15q syndrome patients with the
idic(15) variant, and typically difficult to control, often presenting with infantile spasms and progressing to a
Lennox-Gastaut-type syndrome. Despite being associated with different genetics and neuropathology these
conditions both share growing evidence on the role of the GABA system in ameliorating seizures and other
behavioral features of these disorders.

11

Essential Tremor

Essential tremor, or ET, is one of the most common neurological disorders. It is a non-life threatening,
chronic, progressive disorder associated with involuntary, rhythmic shaking in the upper limbs and head that can
cause substantial disability. Some cases of ET are inherited, and for others there is no known cause. We estimate
that ET affects approximately 10 million people in the United States, a significant portion of whom are thought
to be undiagnosed and untreated. We estimate that approximately 1.5 million of those ET patients have moderate
to severe symptoms. Common treatments for ET include primidone, propranolol, gabapentin and
benzodiazepines. Current treatments are only moderately effective, reducing, but not resolving, tremor
amplitudes in approximately 50% of patients. Data suggest that ET is associated with brain neurodegeneration,
and GABAA receptor dysfunction, thus providing a rationale for studying compounds that are allosteric
modulators of the GABAA receptor and show anti-convulsant activity as potential treatments for ET. As
described above, in a randomized, double-blind, placebo-controlled, crossover trial of 25 patients affected by ET,
where patients were exposed to the target steady state dose of SAGE-547 for only two hours, several clinician-
rated and accelerometer-rated measures showed significant reductions in tremor. Given its similar mechanism of
action, we believe that SAGE-217 also has potential as a treatment for ET, but with a bioavailability and
pharmacodynamic/pharmacokinetic profile intended for once-daily oral dosing. If the Phase 1 clinical trial results
support further development, we plan to commence a Phase 2 clinical trial of SAGE-217 in the treatment of ET.

Post-partum Depression

PPD is a depressive disorder affecting a small portion of women after childbirth, and is characterized by
sadness and depressed mood, loss of interest in daily activities, changes in eating and sleeping habits, fatigue and
decreased energy, inability to concentrate, and feelings of worthlessness, shame or guilt, leading to significant
functional impairment. Without sufficient treatment, PPD has devastating consequences for the mother and for
her family. PPD inhibits the mother’s ability to perform daily activities and to bond with the baby and other
members of the family. PPD also carries an increased risk for suicide in some women.

We estimate that PPD affects 10%-15% of mothers with onset at or before 6 months postpartum. Onset of

moderate-severe symptoms is typically 2-4 weeks after birth. Initial treatment can extend for a minimum of 6
months. Current standard of care for severe PPD comprises the cautious use of pharmacological therapies.
Women with severe PPD may be hospitalized to provide a safe and stable environment for recovery if they have
suicidal ideation or attempt, are unable to function and care for themselves, or require monitoring during a
change in or trial of a new medication. There are no current approved therapies specifically for PPD.

Naturally occurring allopregnanolone is found at its highest levels in women during the third trimester of
pregnancy, returning to normal level generally within 24 hours of giving birth. Data suggest that women with
PPD may be unusually sensitive to this rapid decline in allopregnanolone, potentially causing GABAA-system
mediated mood disruption. Given this data, we believe that allosteric modulators of the GABAA receptor may
have potential in the treatment of PPD. As noted above, we have initiated a multi-center, placebo-controlled
proof-of-concept clinical trial of SAGE-547 in patients with severe PPD. We plan to enroll up to 32 patients
diagnosed with severe PPD in the trial which is intended to validate the activity signal observed in the earlier
open-label study of SAGE-547 in the treatment of PPD. If the ongoing proof-of-concept clinical trial of SAGE-
547 in severe PPD generates compelling data that confirms the potential of allosteric GABAA receptor
modulation in the treatment of severe PPD, we plan to commence development of SAGE-217 in the treatment of
PPD. SAGE-217 shares important GABA receptor pharmacology with SAGE-547.

SAGE-689

SAGE-689 is a novel positive allosteric modulator of GABAA receptors. SAGE-689 has shown

anticonvulsant, anxiolytic and sedative properties in animal models. We believe SAGE-689 has potential as an
acute adjunctive IV therapy for the treatment of indications where a high degree of anti-seizure activity and

12

sedation are desirable prior to the introduction of general anesthesia, including, for example, for the treatment of
SE patients whose seizures have not resolved after treatment with BDZs. Patients with SE at this stage have been
transported by ambulance to the hospital, and frequently have received treatment in the emergency room with
anti-seizure drugs. If their seizure does not resolve rapidly the patient must be transferred to the ICU and
immediately placed into a medically induced coma to minimize the risk of brain damage. We believe the profile
of SAGE-689 supports development as a second-line therapy for the treatment of SE patients whose seizures
have not resolved after treatment with BDZs prior to a patient being placed into a medically induced coma. These
characteristics include a wide therapeutic window to allow for modulation of the GABAA receptor without
inducing deep anesthesia, and a short half-life to permit rapid onset and loss of activity. The latter property is
intended to facilitate rapid discharge or transfer to the ICU without residual drug on board. SAGE-689 is being
formulated for IV or intramuscular administration to optimize these characteristics in a clinical setting.

In 2015, we filed an investigational new drug application, or IND, for SAGE-689, however, commencement

of our Phase 1 clinical trial of SAGE-689 has been delayed to respond to a request from the FDA for additional
non-clinical study data. There is no guarantee that we will be able to generate data that will satisfy the FDA, and
enable us to commence the Phase 1 clinical trial. If we are able to successfully address the FDA’s questions, we
plan to commence a Phase 1 clinical development program for SAGE-689 which will be designed to rapidly
assess relevant product characteristics for this compound, such as quality of sedation, impact on EEG in normal
patients and possibly in patients with epilepsy, pharmacokinetics and general safety. If early Phase 1 clinical
trials are successful we plan to use our Phase 1 clinical trials to evaluate SAGE-689’s ability to induce EEG-
confirmed effects on brain activity, including EEG burst-suppression.

SAGE-718

SAGE-718 is the first product candidate selected for development from our NMDA receptor program.
SAGE-718 is a novel oxysterol-based positive allosteric modulator of NMDA receptors. In 2013, our scientists
and collaborators published an article in The Journal of Neuroscience describing data from animal studies
demonstrating that 24(S)-Hydroxycholesterol (cerebrosterol), a naturally occurring oxysterol, shows potent and
selective activity in animal models as a positive allosteric modulator of NMDA receptors acting at a novel
oxysterol modulatory site. SAGE-718 has been designed to be a highly potent and selective modulator of NMDA
receptors with an optimized pharmacokinetic profile intended to support oral dosing. SAGE-718 has
demonstrated robust activity in preclinical models of NMDA receptor hypofunction. We have begun non-clinical
studies of SAGE-718, with an initial development focus on two rare conditions, Smith-Lemli-Opitz Syndrome
and Anti-NMDA Receptor Encephalitis for which there are currently no approved treatments. Smith-Lemli-Opitz
Syndrome, or SLOS is a rare metabolic disorder caused by a mutation in the DHCR7 (7-dehydrocholesterol
reductase) gene which codes for an enzyme that is involved in the production of cholesterol in the brain. SLOS is
associated with significantly decreased plasma levels of cerebrosterol, suggesting that normal oxysterol-based
modulation of NMDA receptors is disrupted in these patients. People affected by SLOS are unable to make
enough of the necessary cholesterol in the brain to support normal growth and development, and are affected by a
broad range of neuropsychiatric and neurodevelopmental symptoms. Anti-NMDA Receptor Encephalitis, or
ANRE, is a rare autoimmune disorder in which antibodies attack NMDA receptors. Symptoms of ANRE include
a highly characteristic set of neuropsychiatric deficits, including cognitive and behavioral disturbances,
movement disorders and loss of consciousness.

Beyond SLOS and ANRE, we believe measuring levels of anti-NMDA antibodies or decreased
cerebrosterol levels may represent biomarkers to identify for future study broader patient populations
characterized by cognitive dysfunction and neuropsychiatric symptoms resulting from NMDA receptor
dysfunction or hypofunction. Examples of these potential areas for future evaluation include certain types,
aspects or subpopulations of a number of diseases such as depression, Alzheimer’s disease, attention deficit
hyperactivity disorder, schizophrenia, Huntington’s disease, and neuropathic pain.

13

Further Exploitation of GABAA and NMDA Receptors

We expect to continue our focus on allosteric modulation of the GABAA and NMDA receptor systems in the

brain. The GABAA and NMDA receptor systems are broadly accepted as impacting many psychiatric and
neurological disorders, spanning disorders of mood, seizure, cognition, anxiety, sleep, pain, epilepsy, and
movement disorders among others. We believe that we will have the opportunity to develop molecules from our
internal portfolio to address a number of these disorders in the future. Our ability to identify and develop such
novel CNS therapies is enabled by our proprietary chemistry platform that is centered on a scaffold of chemically
modified endogenous neuroactive steroid compounds. We believe our know-how around the chemistry and
activity of allosteric modulators allows us to efficiently design molecules with different characteristics by
enabling us to control important properties such as half-life, brain penetration and the types of receptors with
which our drugs interact with the goal of developing product candidates that have the potential to bind with
targets in the brain with more precision, increased tolerability, and fewer off-target side effects than either current
CNS therapies or previous therapies which have failed in development.

Our current focus will remain on those indications where we can independently develop and commercialize
our products, if approved. We believe our broad potential pipeline lessens our reliance on the success of any one
program. We believe our ability to design and develop novel molecules with distinct profiles and receptor
subtype selectivity will also provide us, in the future, with an opportunity to create value by potentially
partnering these assets with third parties who possess the development and commercialization capabilities to
pursue these programs.

Manufacturing and Supply

We do not own nor operate, and currently have no plans to own or operate, any manufacturing facilities. We
currently resource all of our non-clinical and clinical material supply through third party contract manufacturing
organizations, or CMOs, and intend to buy all of our future commercial supplies from CMOs if our product
candidates are approved.

We have established relationships with several CMOs under which the CMOs have manufactured non-

clinical and clinical supplies of SAGE-547, SAGE-217, SAGE-689 and SAGE-718 active pharmaceutical
ingredient, or API, as well as drug product. All clinical supplies are manufactured under current Good
Manufacturing Practices, or cGMP. Starting materials and key intermediates to support the production of these
candidates are manufactured by other CMOs on a purchase order basis. We do not currently have arrangements
in place for either long-term supply or redundant supply of bulk drug substance or drug product for any of our
product candidates. It is our intent to put long-term supply agreements in place for commercial manufacturing at
the appropriate time, and to mitigate potential commercial supply risks for any products that are approved in the
future through inventory management and through exploring additional manufacturers to provide API and/or
drug product.

We currently have sufficient SAGE-547 drug product on hand for our Phase 3 clinical trial in SRSE, and

Phase 2a clinical trial in severe PPD and ongoing non-clinical studies, and are working with our CMOs to
prepare for validation and commercial manufacturing of SAGE-547. We currently have sufficient SAGE-217
drug substance on hand for our ongoing Phase 1 clinical trials using an oral solution as the dosage form. We are
developing a solid dosage form of SAGE-217 for future clinical trials. We currently have sufficient SAGE-689
drug substance on hand to support the planned Phase 1 clinical trial if we are able to satisfy the FDA’s request for
additional information sufficiently for the FDA to allow us to commence the Phase 1 trial.

SAGE-547, SAGE-217, SAGE-689 and SAGE-718 are small molecules isolated as stable crystalline solids.

We believe the syntheses of SAGE-547, SAGE-217, SAGE-689 and SAGE-718 are reliable and reproducible
from readily available starting materials, and the synthetic routes are amenable to large-scale manufacturing and
do not require unusual equipment or special handling in the manufacturing process. The enantiomeric purity of

14

SAGE-547, SAGE-217, SAGE-689 and SAGE-718 is derived from starting materials that are obtained from
natural sources. We expect to continue to identify and develop drug candidates that are amenable to cost-
effective manufacturing at contract manufacturing facilities.

Research and development expenses for the years ended December 31, 2015, 2014 and 2013 were, $69.4

million, $24.1 million and $14.4 million, respectively.

Research and Development

Sales and Marketing

Given our stage of development, we have not yet established a commercial organization or distribution

capabilities, nor have we entered into any partnership or co-promotion arrangements with an established
pharmaceutical company. We are concentrating our internal efforts on CNS disorders where we believe we can
efficiently commercialize our products, if approved, on our own. For example, in the United States we believe
that SRSE patients are easily identifiable in tertiary care centers where there are ICUs and staff trained in treating
refractory or SRSE patients. In a recent secondary analysis of Premier Network Hospitals’ 2012 billing data, we
found approximately 70% of SRSE discharges, as determined by business rules we and our consultants
established, occurred in 925 U.S. hospitals of 300 beds or more. As a result, we believe we can successfully
launch and commercialize SAGE-547 in SRSE, if approved, on our own, using a small and highly specialized
sales force similar to those of other rare-disease companies.

While we are focused on CNS disorders where we believe we can efficiently commercialize our product

candidates on our own, we may decide to establish agreements or alliances with one or more distributors or
pharmaceutical company collaborators to develop and commercialize our products, if approved, in certain
territories outside the United States where we do not believe it makes commercial sense for us to proceed on our
own. We may also consider partnering opportunities for assets geared toward treating CNS disorders such as
depression and cognition that impact large patient populations, depending on, among other things, the applicable
indications, the expected development pathway and related costs, and our available resources. In order to
effectively and efficiently develop product candidates for these larger markets or more difficult indications or
regions, we intend to partner at an appropriate stage with companies who have clinical expertise and pre-existing
commercial infrastructure in these areas.

We have entered into several license agreements to support our various programs.

Licenses

Washington University

In November 2013, we entered into a license agreement with Washington University, or WU. Under this
agreement, and subject to certain rights of the U.S. government and rights retained by WU, WU granted to us an
exclusive, worldwide license under certain patent rights to make, have made, sell, and offer for sale, use and
import products covered by certain of its patent rights. WU’s rights in a patent application disclosing and
claiming SAGE-689 are included in this license agreement. Under this agreement, WU also granted us non-
exclusive license under certain technical information and tangible research information to use such technical
information and/or tangible research information to make, have made, sell, offer for sale, use and import products
that embody or were made using a method or process covered in the technical information and/or tangible
research information. The WU license also grants us a right to sublicense our licensed rights to third parties,
provided each sublicensee enters into a written agreement with us with terms consistent with our agreement with
WU. We must pay to WU a percentage of the revenue we receive from sublicensing our rights under this
agreement, initially in the mid-teens and decreasing to the mid-single digits over time.

15

Pursuant to the WU license, we are required to use commercially reasonable efforts to continue active,
diligent development of licensed products and to use commercially reasonable efforts to manufacture, promote
and sell licensed products throughout the territory and in the field during the term of the agreement. We must
deliver written reports to WU describing our progress no later than January 31 and July 31 of the first two
calendar years of the agreement, and no later than January 31 of each calendar year thereafter.

We must pay to WU an annual maintenance fee until and including the year in which our first Phase 2
clinical trial is initiated, and we must make up to $0.7 million and $0.5 million in clinical development and
regulatory milestones, respectively, to WU, for each licensed product, upon reaching certain milestones relating
to the clinical development of our product candidates. The license agreement also requires us to make low single-
digit royalty payments to WU in connection with the sales of licensed products.

The WU agreement will expire on a licensed product-by-licensed product basis upon the later of (i) the last

day that at least one valid patent claim covering the licensed product exists, or (ii) the tenth anniversary of the
day of the first commercial sale of the licensed product. We may terminate the WU Agreement early for
convenience upon providing WU with 90 days’ written notice. WU may terminate this agreement early in the
event of our failure to cure a material breach within the applicable cure period or our bankruptcy. In the event of
early termination of this agreement before the expiration of the last to expire of the patent rights, we must
immediately discontinue manufacture, sale and distribution of any licensed products.

CyDex Pharmaceuticals

In September 2015, we amended and restated our existing commercial license agreement with CyDex
Pharmaceuticals, Inc., or CyDex. Under the terms of the commercial license agreement, as amended and restated,
CyDex has granted us an exclusive license to CyDex’s Captisol drug formulation technology and related
intellectual property for the manufacture of pharmaceutical products incorporating SAGE-547 or SAGE-689, and
the development and commercialization of the resulting products in the treatment, prevention or diagnosis of any
disease or symptom in humans or animals other than (i) the ocular treatment of any disease or condition with a
formulation, including a hormone; (ii) topical ocular treatment of inflammatory conditions; (iii) treatment and
prophylaxis of fungal infections in humans; and (iv) any ocular treatment for retinal degeneration.

Pursuant to the CyDex license, we are required during the term of the agreement to use commercially
reasonable efforts to continue active, diligent development of the licensed product, to seek regulatory approval of
the licensed product and to commercialize the licensed product following regulatory approval. We must deliver
periodic progress reports to CyDex.

We are obligated to make milestone payments under the amended and restated license agreement with
CyDex based on the achievement of clinical development and regulatory milestones in the amount of $0.8
million in clinical milestones and $3.8 million in regulatory milestones for each of the first two fields with
respect to SAGE-547; $1.3 million in clinical milestones and $8.5 million in regulatory milestones for each of
the third and fourth fields with respect to SAGE-547; and $0.8 million in clinical milestones and $1.8 million in
regulatory milestones for one field with respect to SAGE-689. The CyDex license is perpetual until terminated.
We may terminate the CyDex agreement for convenience upon providing 180 days’ prior written notice to
CyDex. Either party has the right to terminate the agreement for failure to cure a material breach in the applicable
cure period.

We will also be required to pay royalties to CyDex on sales of SAGE-547 and SAGE-689, if successfully

developed, in the low single digits based on levels of net sales. We are also party to a supply agreement with
CyDex which was amended in September 2015 to cover the supply of CyDex’s Captisol for use in the
manufacture of products incorporating SAGE-689. Under the amended supply agreement with CyDex, we are
also required to purchase all of our requirements for Captisol with respect to SAGE-547 and SAGE-689 from
CyDex, and CyDex is required to supply us with Captisol for such purposes, subject to certain limitations.

16

University of California

In October 2013, we entered into a license agreement with The Regents of the University of California, or
the Regents, which was amended in May 2014. Pursuant to this agreement, and subject to certain rights of the
U.S. government and rights retained by the Regents, the Regents granted us a non-exclusive, non-transferable
license under all personal property rights of the Regents covering the tangible personal property in an IND
application package owned by the Regents, or the Data, and a specified quantity of cGMP grade
allopregnanolone, or the Material, to (i) use the Data for reference or incorporation in an IND for the use of the
Material as a treatment of SE, essential tremor and/or severe PPD and (ii) use the Material or modifications of the
Material to develop a pharmaceutical formulation for clinical trials for SE, essential tremor and/or postpartum
depression. The rights licensed to us are not sublicenseable.

Pursuant to this agreement, we are required to use commercially reasonable efforts to proceed with the
development, manufacture and sale of one or more products containing allopregnanolone, a derived product
under the agreement, for the treatment of SE, essential tremor and/or severe PPD. As of January 1, 2014, we
must deliver written reports to the Regents describing our progress no later than 60 days subsequent to June 30
and December 31 of each fiscal year.

This agreement requires us to make up to $0.1 million in milestone payments in connection with the first
derived product that meets the relevant milestones, and we must also pay royalties of less than 1% to the Regents
for each derived product for a period of 15 years following the first commercial sale of such derived product.
This agreement will terminate on the earlier to occur of (i) 27 years after the effective date or (ii) 15 years after
the last-derived product is first commercially sold. We may terminate this agreement early for convenience upon
providing 60 days’ prior written notice to the Regents. The Regents may terminate this agreement early in the
event of material default, including failure to provide timely progress reports, after the applicable cure period, or
in the event of our bankruptcy. In the event of early termination of this agreement, we have the right to sell any
partially made derived products for a period of 120 days from the date of termination, but would not otherwise
have rights after termination under the licensed rights to make, have made, use, sell, have sold, offer for sale or
import products containing allopregnanolone.

In June 2015, we entered into an exclusive license agreement with the Regents whereby we were granted an

exclusive license to certain patent rights related to the use of allopregnanolone to treat various diseases. In
exchange for such license, we paid an upfront payment of $50,000, and will make annual maintenance fees of
$15,000 until the calendar year following the first sale, if any, of a licensed product. We are obligated to make
milestone payments following the achievement of specified regulatory and sales milestones of up to $0.7 million
and $2.0 million in the aggregate, respectively. Following the first sale, if any, of a licensed product, we are
obligated to pay royalties at a low single digit percentage of net sales, if any, subject to specified minimum
annual royalty amounts. Unless terminated by operation of law or by acts of the parties under the terms of the
agreement, the license agreement will terminate when the last-to-expire patents or last-to-be abandoned patent
applications expire, whichever is later.

Intellectual Property

We strive to protect the proprietary technology that we believe is important to our business, including
seeking and maintaining patents intended to cover our product candidates and compositions, their methods of use
and processes for their manufacture, and any other aspects of inventions that are commercially important to the
development of our business. We may also rely on trade secrets to protect aspects of our business that are not
amenable to, or that we do not consider appropriate for, patent protection.

We plan to continue to expand our intellectual property estate by filing patent applications directed to

compositions, methods of use, treatment and patient selection and formulations and manufacturing processes
created or identified from our ongoing development of our product candidates. Our success will depend on our

17

ability to obtain and maintain patent and other proprietary protection for commercially important technology,
inventions and know-how related to our business; defend and enforce our patents; preserve the confidentiality of
our trade secrets; and operate without infringing the valid and enforceable patents and proprietary rights of third
parties. We also rely on know-how, continuing technological innovation and in-licensing opportunities to
develop and maintain our proprietary position. We seek to obtain domestic and international patent protection,
and endeavor to promptly file patent applications for new commercially valuable inventions.

The patent positions of biopharmaceutical companies like us are generally uncertain and involve complex

legal, scientific and factual questions. In addition, the coverage claimed in a patent application can be
significantly reduced before the patent is issued, and patent scope can be reinterpreted by the courts after
issuance. Moreover, many jurisdictions, including the United States, permit third parties to challenge issued
patents in administrative proceedings, which may result in further narrowing or even cancellation of patent
claims. We cannot predict whether the patent applications we are currently pursuing, or may in the future pursue,
will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide
sufficient protection from competitors.

Because patent applications in the United States and certain other jurisdictions are maintained in secrecy for

18 months or potentially even longer, and since publication of discoveries in the scientific or patent literature
often lags behind actual discoveries, we cannot be certain of the priority of inventions covered by our pending
patent applications or of patent applications we may file in the future. Moreover, we may have to participate in
interference proceedings or derivation proceedings declared by the United States Patent and Trademark Office, or
U.S. PTO, to determine priority of invention.

Patents

Our patent portfolio includes patent applications in the early stages of prosecution and no patents have, as of
yet, issued from our patent application estate. These patent applications fall into three categories: (1) SAGE-547-
related; (2) GABAA receptor modulators; including genus and species claims to SAGE-217 and SAGE-689; and
(3) NMDA receptor modulators, including SAGE-718.

We own five patent families generally related to SAGE-547. One of these patent families includes a patent

application having claims to compositions containing allopregnanolone and a cyclodextrin. The compositions can
be used for the treatment of CNS disorders such as traumatic brain injury and SE. The second patent family
includes patent applications having claims directed to methods of treating seizure disorders, such as SE, by
administering allopregnanolone using particular dosing regimens or multiple dosage phases. Any U.S. patents
that may issue from these families of patent applications would have a statutory expiration date in January and
August of 2033, respectively. The applications are also pending in foreign countries, including Australia, Brazil,
Canada, China, Europe, Hong Kong, Israel, Indian, Japan, Mexico, New Zealand, Russia, Singapore, and South
Africa. A third family of patent applications includes methods of treating essential tremor and depression such as
severe PPD. A fourth family of patent applications includes claims to deuterated neuroactive steroid compounds
and compositions. A fifth family of patent applications includes claims to formulation and manufacturing of
SAGE-547. Any U.S. patents that may issue from these families of patent applications would have a statutory
expiration date in September 2035, April 2036, and June 2036, respectively. The time period for electing to
pursue foreign patent protection for the inventions disclosed in these patent applications by filing national stage
patent applications in individual jurisdictions has not yet expired, and we will need to decide whether and where
to pursue ex-U.S. protection before expiration of the applicable deadlines.

In addition to the patent applications licensed from WU, we own 23 families of patent applications, resulting
from work done exclusively by us and our contract research organizations, directed to additional GABA receptor
modulating compounds and methods of using these compounds, for example in anesthesia or treatment of
GABA-related disorders. Any U.S. patents that may issue from these patent applications would have a statutory
expiration ranging from October 2032 to November 2036. Other than SAGE-547 and SAGE-689, we have

18

pending within these families of patent applications genus and species claims to the majority of the compounds
in our GABAA receptor modulating compound collection, including SAGE-217. These families of patent
applications are in the early stages of patent prosecution and include families for which only provisional
applications have been filed. The time period for electing to pursue foreign patent protection by filing national
stage patent applications in individual jurisdictions has not yet expired for some of these patent families, and we
will need to decide whether and where to pursue ex-U.S. protection before expiration of the applicable deadlines.

We have exclusively licensed a portfolio of patent applications owned by WU, which are directed to certain

GABA receptor modulating compounds and methods of using these compounds, for example in anesthesia or
treatment of GABA-related disorders. This portfolio includes seven families of patent applications. One of these
seven families of patent applications is co-owned by us, and this co-owned family includes pending patent
applications in the United States, Australia, Brazil, Canada, China, Europe, Israel, India, Japan, Korea, Mexico,
New Zealand, Philippines, Russia, Singapore, and South Africa. This co-owned application discloses and claims
SAGE-689 and its use in anesthesia or treatment of GABA-related disorders. Any U.S. patents that may issue
from the SAGE-689 patent family would have a statutory expiration date of December 2033. In addition, U.S.
7,781,421, solely owned by WU, expires in September 2027. Any patents that may issue, if any, from the
remaining five families solely owned by WU would have statutory expiration dates that range from 2032 to 2034.

We also own nine families of applications directed to modulators of NMDA receptors. Four of these
families of patent applications are directed to compounds that modulate NMDA receptors, including SAGE-718,
which can be used to treat NMDA receptor-related disorders such as CNS related conditions. One of these
families of patent applications is directed to using a naturally occurring compound as a biomarker for a subject
who would benefit from treatment with a modulator of NMDA receptors. One of these families of patent
applications is directed to using a modulator of NMDA receptors to treat a rare NMDA loss of function disorder.
Any patents that may issue, if any, from these families of applications directed to modulators of NMDA
receptors would have statutory expiration dates in September 2032 and July 2036.

Patent term

The base term of a U.S. patent is 20 years from the filing date of the earliest-filed non-provisional patent
application from which the patent claims priority. The term of a U.S. patent can be lengthened by patent term
adjustment, which compensates the owner of the patent for administrative delays at the U.S. PTO. In some cases,
the term of a U.S. patent is shortened by terminal disclaimer that reduces its term to that of an earlier-expiring
patent.

The term of a U.S. patent may be eligible for patent term extension under the Drug Price Competition and
Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Act, to account for at least some of the
time the drug is under development and regulatory review after the patent is granted. With regard to a drug for
which FDA approval is the first permitted marketing of the active ingredient, the Hatch-Waxman Act allows for
extension of the term of one U.S. patent that includes at least one claim covering the composition of matter of an
FDA-approved drug, an FDA-approved method of treatment using the drug, and/or a method of manufacturing
the FDA-approved drug. The extended patent term cannot exceed the shorter of five years beyond the non-
extended expiration of the patent or 14 years from the date of the FDA approval of the drug. Some foreign
jurisdictions, including Europe and Japan, also have patent term extension provisions, which allow for extension
of the term of a patent that covers a drug approved by the applicable foreign regulatory agency. In the future, if
and when our pharmaceutical products receive FDA approval, we expect to apply for patent term extension on
patents covering those products, their methods of use, and/or methods of manufacture.

Trade secrets

In addition to patents, we may rely on trade secrets and know-how to develop and maintain our competitive
position. Companies typically rely on trade secrets to protect aspects of their business that are not amenable to, or

19

that they do not consider appropriate for, patent protection. We protect trade secrets, if any, and know-how by
establishing confidentiality agreements and invention assignment agreements with our employees, consultants,
scientific advisors, contractors and partners. These agreements provide that all confidential information
developed or made known during the course of an individual or entity’s relationship with us must be kept
confidential during and after the relationship. These agreements also generally provide that all relevant
inventions resulting from work performed for us or relating to our business and conceived or completed during
the period of employment or assignment, as applicable, shall be our exclusive property. In addition, we take other
appropriate precautions, such as physical and technological security measures, to guard against misappropriation
of our proprietary information by third parties.

Competition

The biopharmaceuticals industry is highly competitive. There are many public and private companies,

universities, governmental agencies and other research organizations actively engaged in the research and
development of products that may be similar to our product candidates or address similar markets. It is probable
that the number of companies seeking to develop products and therapies similar to our products will increase.

Currently, there are no therapies that have been specifically approved for treatment of SRSE. However,
many products approved for other indications, for example, general anesthetics and anti-seizure drugs, are used
off-label for various stages of SE therapy. Additionally, though not indicated, acupuncture, hypothermia, and
electroconvulsive therapy are sometimes used prior to withdrawal of care for patients with SRSE.

In the field of neuroactive steroids focused on modulation of GABAA or NMDA receptors, our principal
competitor is Marinus Pharmaceuticals, Inc., which we believe is developing a reformulated form of ganaxolone,
a known GABAA positive allosteric modulator neuroactive steroid, for the potential treatment of drug-resistant
partial complex seizures and fragile X syndrome. In addition, Marinus has announced initiation of the clinical
phase of its intravenous Ganaxolone program in SE.

Many of our potential competitors, alone or with their strategic partners, have substantially greater financial,
technical and human resources than we do and significantly greater experience in the discovery and development
of product candidates, obtaining FDA and other regulatory approvals of treatments and the commercialization of
those treatments. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even
more resources being concentrated among a smaller number of our competitors. Our commercial opportunity
could be reduced or eliminated if our competitors develop and commercialize products that are safer, more
effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that
we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more
rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market
position before we are able to enter the market.

Government Regulation

Government authorities in the United States at the federal, state and local level and in other countries
extensively regulate, among other things, the research, development, testing, manufacture, quality control,
approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval
monitoring and reporting, marketing and export and import of drug products. Generally, before a new drug can
be marketed, considerable data demonstrating its quality, safety and efficacy must be obtained, organized into a
format specific to each regulatory authority, submitted for review and approved by the regulatory authority.

U.S. drug development

In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA,

and its implementing regulations. Drugs are also subject to other federal, state and local statutes and regulations.

20

The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state,
local and foreign statutes and regulations require the expenditure of substantial time and financial resources.
Failure to comply with the applicable U.S. requirements at any time during the product development process,
approval process or after approval, may subject a company to administrative or judicial sanctions. These
sanctions could include, among other actions, the FDA’s refusal to approve pending applications, withdrawal of
an approval, a clinical hold, warning letters, product recalls or withdrawals from the market, product seizures,
total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts,
restitution, disgorgement, or civil or criminal penalties. Any agency or judicial enforcement action could have a
material adverse effect on us.

Our product candidates must be approved by the FDA through the NDA process before they may be legally

marketed in the United States. The process required by the FDA before a drug may be marketed in the United
States generally involves the following:

‰ Completion of extensive non-clinical studies and testing, sometimes referred to as non-clinical

laboratory tests, non-clinical animal studies and formulation studies, in accordance with applicable
regulations, including the FDA’s current Good Laboratory Practice, or GLP, regulations;

‰

Submission to the FDA of an IND application, which must become effective before human clinical
trials may begin;

‰ Approval by an independent institutional review board, or IRB, or ethics committee at each clinical

trial site before each trial may be initiated;

‰

‰

Performance of adequate and well-controlled human clinical trials in accordance with applicable IND
and other clinical trial-related regulations, sometimes referred to as good clinical practices, or GCPs, to
establish the safety and efficacy of the proposed drug for each proposed indication;

Submission to the FDA of an NDA, for a new drug;

‰ A determination by the FDA within 60 days of its receipt of an NDA to accept the NDA filing for

review;

‰

‰

‰

Satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities
where the drug is produced to assess compliance with cGMP requirements to assure that the facilities,
methods and controls are adequate to preserve the drug’s identity, strength, quality and purity;

Potential FDA audit of the non-clinical and/or clinical trial sites that generated the data in support of
the NDA; and

FDA review and approval of the NDA, including consideration of the views of any FDA advisory
committee, prior to any commercial marketing or sale of the drug in the United States.

The non-clinical and clinical testing and approval process requires substantial time, effort and financial
resources, and we cannot be certain that any approvals for our product candidates will be granted on a timely
basis, if at all. Non-clinical tests include laboratory evaluation of product chemistry, formulation, stability and
toxicity, as well as animal studies to assess the characteristics and potential safety and efficacy of the product.

The data required to support an NDA are generated in two distinct development stages: non-clinical and
clinical. For new chemical entities, the non-clinical development stage generally involves synthesizing the active
component, developing the formulation and determining the manufacturing process, as well as carrying out non-
human toxicology, pharmacology and drug metabolism studies in the laboratory, which support subsequent
clinical testing. Non-clinical tests include laboratory evaluation of product chemistry, formulation, stability and
toxicity, as well as animal studies to assess the characteristics and potential safety and efficacy of the product.
The conduct of the non-clinical tests must comply with federal regulations, including GLPs. The sponsor must
submit the results of the non-clinical tests, together with manufacturing information, analytical data, any

21

available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. An IND is a
request for authorization from the FDA to administer an investigational drug product to humans. Some non-
clinical testing may continue even after the IND is submitted, but an IND must become effective before human
clinical trials may begin. The central focus of an IND submission is on the general investigational plan and the
protocols for human trials. The IND automatically becomes effective 30 days after receipt by the FDA, unless the
FDA raises concerns or questions regarding the proposed clinical trials, including whether subjects will be
exposed to unreasonable health risks, and places the IND on clinical hold within that 30-day time period. In such
a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin.
The FDA may also impose clinical holds on a drug candidate at any time before or during clinical trials due to
safety concerns or non-compliance. Accordingly, we cannot be sure that submission of an IND will result in the
FDA allowing clinical trials to begin, or that, once begun, issues will not arise that could cause the trial to be
suspended or terminated.

The clinical stage of development involves the administration of the drug candidate to healthy volunteers or
patients under the supervision of qualified investigators, generally physicians not employed by or under the trial
sponsor’s control, in accordance with GCPs, which include the requirement that all research subjects provide
their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols
describing, among other details, the objectives of the clinical trial, dosing procedures, subject selection and
exclusion criteria, and the parameters to be used to monitor subject safety and assess efficacy. Each protocol, and
any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Further, each
clinical trial must be reviewed and approved by an independent institutional review board, or IRB, at or servicing
each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and
rights of trial participants, and considers such items as whether the risks to individuals participating in the
clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the
informed consent form that must be provided to each clinical trial subject or his or her legal representative and
must monitor the clinical trial until completed. There are also requirements governing the reporting of ongoing
clinical trials and completed clinical trial results to public registries.

A sponsor who wishes to conduct a clinical trial outside the United States may, but need not, obtain FDA

authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND,
the sponsor may submit data from the clinical trial to the FDA in support of an NDA so long as the clinical trial
is conducted in compliance with an international guideline for the ethical conduct of clinical research known as
the Declaration of Helsinki and/or the laws and regulations of the country or countries in which the clinical trial
is performed, whichever provides the greater protection to the participants in the clinical trial.

Clinical trials

Clinical trials are generally conducted in three sequential phases that may overlap, known as Phase 1, Phase

2 and Phase 3 clinical trials.

‰

‰

‰

Phase 1 clinical trials generally involve a small number of healthy volunteers who are initially exposed
to a single dose and then multiple doses of the product candidate. The primary purpose of these clinical
trials is to assess the metabolism, pharmacologic action, side effect tolerability and safety of the drug.

Phase 2 clinical trials typically involve studies in disease-affected patients to determine the dose
required to produce the desired benefits. At the same time, safety and further pharmacokinetic and
pharmacodynamic information is collected, as well as identification of possible adverse effects and
safety risks and preliminary evaluation of efficacy.

Phase 3 clinical trials generally involve large numbers of patients at multiple sites (typically from
several hundred to several thousand subjects), and are designed to provide the data necessary to
demonstrate the effectiveness of the product for its intended use, its safety in use, and to establish the
overall benefit/risk relationship of the product and provide an adequate basis for product approval.
Phase 3 clinical trials may include comparisons with placebo and/or other comparator treatments. The
duration of treatment is often extended to mimic the actual use of a product during marketing.

22

Post-approval trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial
marketing approval. These trials are used to gain additional experience from the treatment of patients in the
intended therapeutic indication. In certain instances, FDA may mandate the performance of Phase 4 clinical trials
as a condition of approval of an NDA.

Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and

written IND safety reports must be submitted to the FDA and the investigators for serious and unexpected
suspected adverse events, findings from other studies, or any findings from animal or in vitro testing that
suggests a significant risk for human subjects. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed
successfully within any specified period, if at all. Success in one phase does not mean that the results will be
observed in subsequent phases. Each phase may involve multiple studies. The FDA, the IRB, or the sponsor may
suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects
or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval
of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB’s
requirements or if the drug has been associated with unexpected serious harm to patients. Additionally, some
clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor,
known as a data safety monitoring board or committee. This group provides authorization for whether or not a
trial may move forward at designated check points based on access to certain data from the trial. Concurrent with
clinical trials, companies usually complete additional animal studies and must also develop additional
information about the chemistry and physical characteristics of the drug as well as finalize a process for
manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing
process must be capable of consistently producing quality batches of the drug candidate and, among other things,
we must develop methods for testing the identity, strength, quality and purity of the final drug product.
Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to
demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life.

NDA and FDA review process

The results of non-clinical studies and of the clinical trials, together with other detailed information,
including extensive manufacturing information and information on the composition of the drug and proposed
labeling, are submitted to the FDA in the form of an NDA requesting approval to market the drug for one or
more specified indications. The FDA reviews an NDA to determine, among other things, whether a drug is safe
and effective for its intended use and whether the product is being manufactured in accordance with cGMP to
assure and preserve the product’s identity, strength, quality and purity. FDA approval of an NDA must be
obtained before a drug may be offered for sale in the United States.

In addition, under the Pediatric Research Equity Act, or PREA, an NDA or supplement to an NDA must

contain data to assess the safety and efficacy of the drug for the claimed indications in all relevant pediatric
subpopulations and to support dosing and administration for each pediatric subpopulation for which the product
is safe and effective. The FDA may grant deferrals for submission of pediatric data or full or partial waivers.

Under the Prescription Drug User Fee Act, or PDUFA, as amended, each NDA must be accompanied by a

user fee. The FDA adjusts the PDUFA user fees on an annual basis. According to the FDA’s fee schedule,
effective through December 31, 2016, the user fee for an application requiring clinical data, such as an NDA, is
$2.4 million. PDUFA also imposes an annual product fee for human drugs of $0.1 million and an annual
establishment fee of $0.6 million on facilities used to manufacture prescription drugs. Fee waivers or reductions
are available in certain circumstances, including a waiver of the application fee for the first application filed by a
small business. Additionally, no user fees are assessed on NDAs for products designated as orphan drugs, unless
the product also includes a non-orphan indication.

The FDA reviews all NDAs submitted before it accepts them for filing, and may request additional
information rather than accepting an NDA for filing. The FDA must make a decision on accepting an NDA for
filing within 60 days of receipt. Once the submission is accepted for filing, the FDA begins an in-depth review of

23

the NDA. Under the goals and policies agreed to by the FDA under PDUFA, the FDA has 10 months from the
filing date in which to complete its initial review of a standard NDA and respond to the applicant, and six months
from the filing date for a priority NDA. The FDA does not always meet its PDUFA goal dates for standard and
priority NDAs, and the review process is often significantly extended by FDA requests for additional information
or clarification.

After the NDA submission is accepted for filing, the FDA reviews the NDA to determine, among other
things, whether the proposed product is safe and effective for its intended use, and whether the product is being
manufactured in accordance with cGMP to assure and preserve the product’s identity, strength, quality and
purity. Before approving an NDA, the FDA will generally conduct a pre-approval inspection of the
manufacturing facilities for the new product to determine whether they comply with cGMPs. The FDA will not
approve the product unless it determines that the manufacturing processes and facilities are in compliance with
cGMP requirements and adequate to assure consistent production of the product within required specifications.
In addition, before approving an NDA, the FDA may also audit data from clinical trials to ensure compliance
with GCP requirements. Additionally, the FDA may refer applications for novel drug products or drug products
which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes
clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be
approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee,
but it considers such recommendations carefully when making decisions. The FDA will likely re-analyze the
clinical trial data, which could result in extensive discussions between the FDA and the applicant during the
review process. The review and evaluation of an NDA by the FDA is extensive and time consuming and may
take longer than originally planned to complete, and we may not receive a timely approval, if at all.

After the FDA evaluates an NDA, it may issue an approval letter or a Complete Response Letter. An
approval letter authorizes commercial marketing of the drug with specific prescribing information for specific
indications. A Complete Response Letter indicates that the review cycle of the application is complete and the
application is not ready for approval. A Complete Response Letter usually describes all of the specific
deficiencies in the NDA identified by the FDA. The Complete Response Letter may require additional clinical
data and/or one or more additional pivotal Phase 3 clinical trials, and/or other significant and time-consuming
requirements related to clinical trials, non-clinical studies or manufacturing. If a Complete Response Letter is
issued, the applicant may either resubmit the NDA, addressing all of the deficiencies identified in the letter, or
withdraw the application. Even if such data and information are submitted, the FDA may ultimately decide that
the NDA does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive,
and the FDA may interpret data differently than we interpret the same data.

There is no assurance that the FDA will ultimately approve a drug product for marketing in the United States,

and we may encounter significant difficulties or costs during the review process. If a product receives marketing
approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may
otherwise be limited, which could restrict the commercial value of the product. Further, the FDA typically requires
that certain contraindications, warnings or precautions be included in the product labeling, and may condition the
approval of the NDA on other changes to the proposed labeling, development of adequate controls and
specifications, or a commitment to conduct post-marketing testing or clinical trials and surveillance to monitor the
effects of approved products. For example, the FDA may require Phase 4 testing which involves clinical trials
designed to further assess a drug’s safety and efficacy and may require testing and surveillance programs to monitor
the safety of approved products that have been commercialized. The FDA may also place other conditions on
approvals including the requirement for a risk evaluation and mitigation strategy, or REMS, to assure the safe use of
the drug. If the FDA concludes a REMS is needed, the sponsor of the NDA must submit a proposed REMS. The
FDA will not approve the NDA without an approved REMS, if required. A REMS could include medication guides,
physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient
registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the
commercial promotion, distribution, prescription or dispensing of products. Product approvals may be withdrawn
for non-compliance with regulatory requirements or if problems occur following initial marketing.

24

Orphan drug designation

Under the Orphan Drug Act, the FDA may grant orphan designation to a drug product intended to treat a
rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in
the United States, or more than 200,000 individuals in the United States, but for which there is no reasonable
expectation that the cost of developing and making a drug product available in the United States for this type of
disease or condition will be recovered from sales of the product. Orphan product designation must be requested
before submitting an NDA. After the FDA grants orphan product designation, the identity of the therapeutic
agent and its potential orphan use are disclosed publicly by the FDA. Orphan product designation does not
convey any advantage in or shorten the duration of the regulatory review and approval process.

If a product that has orphan designation subsequently receives the first FDA approval for the disease or

condition for which it has such designation, the product is entitled to orphan product exclusivity, which means
that the FDA may not approve any other applications to market the same drug for the same indication for seven
years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan
exclusivity. Competitors, however, may receive approval of different products for the indication for which the
orphan product has exclusivity or obtain approval for the same product but for a different indication than that for
which the orphan product has exclusivity. Orphan product exclusivity also could block the approval of one of our
products for seven years if a competitor obtains approval of the same product as defined by the FDA or if our
product candidate is determined to be contained within the competitor’s product for the same indication or
disease. If a drug designated as an orphan product receives marketing approval for an indication broader than
what is designated, it may not be entitled to orphan product exclusivity. Orphan drug status in the European
Union, or EU, has similar, but not identical, benefits.

Expedited development and review programs

The FDA has a Fast Track program that is intended to expedite or facilitate the process for reviewing new

drugs that meet certain criteria. Specifically, new drugs are eligible for Fast Track designation if they are
intended to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical
needs for the condition. Fast Track designation applies to the combination of the product and the specific
indication for which it is being studied. The sponsor of a new drug or biologic may request the FDA to designate
the drug as a Fast Track product at any time during the clinical development of the product. Unique to a Fast
Track product, the FDA may review sections of the marketing application on a rolling basis before the complete
NDA is submitted, if the sponsor provides a schedule for the submission of the sections of the application, the
FDA agrees to accept sections of the application and determines that the schedule is acceptable, and the sponsor
pays any required user fees upon submission of the first section of the application.

25

Any product submitted to the FDA for marketing, including under a Fast Track program, may be eligible for

other types of FDA programs intended to expedite development and review, such as priority review and
accelerated approval. Any product is eligible for priority review if it has the potential to provide safe and
effective therapy where no satisfactory alternative therapy exists or offers a significant improvement in the
treatment, diagnosis or prevention of a disease compared to marketed products. The FDA will attempt to direct
additional resources to the evaluation of an application for a new drug designated for priority review in an effort
to facilitate the review. A product may also be eligible for accelerated approval. Drugs studied for their safety
and efficacy in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over
existing treatments, may receive accelerated approval, which means that they may be approved on the basis of
adequate and well-controlled clinical trials establishing that the product has an effect on a surrogate endpoint that
is reasonably likely to predict a clinical benefit, or on the basis of an effect on a clinical endpoint other than
survival or irreversible morbidity. As a condition of approval, the FDA may require that a sponsor of a drug
receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. If the FDA
concludes that a drug shown to be effective can be safely used only if distribution or use is restricted, it will
require such post-marketing restrictions, as it deems necessary to assure safe use of the drug, such as:

‰

‰

distribution restricted to certain facilities or physicians with special training or experience; or

distribution conditioned on the performance of specified medical procedures.

The limitations imposed would be commensurate with the specific safety concerns presented by the drug. In

addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional
materials, which could adversely impact the timing of the commercial launch of the product. Additionally, a drug
may be eligible for designation as a breakthrough therapy if the drug is intended, alone or in combination with
one or more other drugs, to treat a serious or life-threatening disease or condition and preliminary clinical
evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or
more indications. The benefits of breakthrough therapy designation includes the same benefits as fast track
designation, plus intensive guidance from FDA to ensure an efficient drug development program. Fast Track
designation, priority review, accelerated approval and breakthrough designation do not change the standards for
approval, but may expedite the development or approval process.

Pediatric trials

The Food and Drug Administration Safety and Innovation Act, or FDASIA, which was signed into law on

July 9, 2012, amended the FDCA to require that a sponsor who is planning to submit a marketing application for
a drug that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route
of administration submit an initial Pediatric Study Plan, or PSP, within sixty days of an end-of-Phase 2 meeting
or as may be agreed between the sponsor and FDA. The initial PSP must include an outline of the pediatric study
or studies that the sponsor plans to conduct, including study objectives and design, age groups, relevant endpoints
and statistical approach, or a justification for not including such detailed information, and any request for a
deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric
studies along with supporting information. FDA and the sponsor must reach agreement on the PSP. A sponsor
can submit amendments to an agreed-upon initial PSP at any time if changes to the pediatric plan need to be
considered based on data collected from non-clinical studies, early phase clinical trials, and/or other clinical
development programs.

Post-marketing requirements

Following approval of a new product, a pharmaceutical company and the approved product are subject to

continuing regulation by the FDA, including, among other things, monitoring and recordkeeping activities,
reporting to the applicable regulatory authorities of adverse experiences with the product, providing the
regulatory authorities with updated safety and efficacy information, product sampling and distribution
requirements, and complying with promotion and advertising requirements, which include, among others,

26

standards for direct-to-consumer advertising, restrictions on promoting drugs for uses or in patient populations
that are not described in the drug’s approved labeling (known as “off-label use”), limitations on industry-
sponsored scientific and educational activities, and requirements for promotional activities involving the Internet.
Although physicians may prescribe legally available drugs for off-label uses, manufacturers may not market or
promote such off-label uses. Prescription drug promotional materials must be submitted to the FDA in
conjunction with their first use. Further, if there are any modifications to the drug, including changes in
indications, labeling, or manufacturing processes or facilities, the applicant may be required to submit and obtain
FDA approval of a new NDA or NDA supplement, which may require the applicant to develop additional data or
conduct additional non-clinical studies and clinical trials. As with new NDAs, the review process is often
significantly extended by FDA requests for additional information or clarification. Any distribution of
prescription drug products and pharmaceutical samples must comply with the U.S. Prescription Drug Marketing
Act, or the PDMA, a part of the FDCA.

In the United States, once a product is approved, its manufacture is subject to comprehensive and continuing

regulation by the FDA. The FDA regulations require that products be manufactured in specific approved
facilities and in accordance with cGMP. We rely, and expect to continue to rely, on third parties for the
production of clinical and commercial quantities of our products in accordance with cGMP regulations. NDA
holders using contract manufacturers, laboratories or packagers are responsible for the selection and monitoring
of qualified firms, and, in certain circumstances, qualified suppliers to these firms. These manufacturers must
comply with cGMP regulations that require among other things, quality control and quality assurance as well as
the corresponding maintenance of records and documentation and the obligation to investigate and correct any
deviations from cGMP. Drug manufacturers and other entities involved in the manufacture and distribution of
approved drugs are required to register their establishments with the FDA and certain state agencies, and are
subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP
and other laws. Accordingly, manufacturers must continue to expend time, money, and effort in the area of
production and quality control to maintain cGMP compliance. The discovery of violative conditions, including
failure to conform to cGMP, could result in enforcement actions that interrupt the operation of any such facilities
or the ability to distribute products manufactured, processed or tested by them. Discovery of problems with a
product after approval may result in restrictions on a product, manufacturer, or holder of an approved NDA,
including, among other things, recall or withdrawal of the product from the market.

Discovery of previously unknown problems with a product or the failure to comply with applicable FDA

requirements can have negative consequences, including adverse publicity, judicial or administrative
enforcement, warning letters from the FDA, mandated corrective advertising or communications with doctors,
and civil or criminal penalties, among others. Newly discovered or developed safety or effectiveness data may
require changes to a product’s approved labeling, including the addition of new warnings and contraindications,
and also may require the implementation of other risk management measures. Also, new government
requirements, including those resulting from new legislation, may be established, or the FDA’s policies may
change, which could delay or prevent regulatory approval of our products under development.

Other regulatory matters

Manufacturing, sales, promotion and other activities following product approval are also subject to

regulation by numerous regulatory authorities in addition to the FDA, including, in the United States, the Centers
for Medicare & Medicaid Services; other divisions of the Department of Health and Human Services; the United
States Department of Justice; the Drug Enforcement Administration; the Consumer Product Safety Commission;
the Federal Trade Commission; the Occupational Safety & Health Administration; the Environmental Protection
Agency; and state and local governments.

In the United States, sales, marketing and scientific/educational programs must also comply with state and

federal fraud and abuse laws. These laws include the federal Anti-Kickback Statute, which makes it illegal for
any person, including a company marketing a prescription drug (or a party acting on its behalf) to knowingly and

27

willfully solicit, receive, offer, or pay any remuneration that is intended to induce or reward the referral of
business, including the purchase, order, or prescription of a particular drug, for which payment may be made
under a federal healthcare program, such as Medicare or Medicaid. Violations of this law are punishable by up to
five years in prison, criminal fines, administrative civil money penalties, and exclusion from participation in
federal healthcare programs. In addition, the Patient Protection and Affordable Health Care Act, as amended by
the Health Care and Education Reconciliation Act of 2010, or collectively the ACA, among other things, amends
the intent requirement of the federal Anti-Kickback Statute and criminal healthcare fraud statutes created by the
federal Health Insurance Portability and Accountability Act of 1996, or HIPAA. A person or entity no longer
needs to have actual knowledge of the statute or specific intent to violate it. Moreover, the ACA provides that the
government may assert that a claim including items or services resulting from a violation of the federal anti-
kickback statute constitutes a false or fraudulent claim for purposes of the False Claims Act.

Although we would not submit claims directly to payors, drug manufacturers can be held liable under the

federal False Claims Act, which prohibits anyone from knowingly presenting, or causing to be presented, for
payment to federal programs (including Medicare and Medicaid) claims for items or services, including drugs,
that are false or fraudulent, claims for items or services not provided as claimed, or claims for medically
unnecessary items or services. The government may deem companies to have “caused” the submission of false or
fraudulent claims by, for example, providing inaccurate billing or coding information to customers or promoting
a product off-label. In addition, our future activities relating to the reporting of wholesaler or estimated retail
prices for our products, the reporting of prices used to calculate Medicaid rebate information and other
information affecting federal, state, and third-party reimbursement for our products, and the sale and marketing
of our products, are subject to scrutiny under this law. Penalties for a False Claims Act violation include three
times the actual damages sustained by the government, plus mandatory civil penalties of between $5,500 and
$11,000 for each separate false claim, the potential for exclusion from participation in federal healthcare
programs, and, although the federal False Claims Act is a civil statute, conduct that results in a False Claims Act
violation may also implicate various federal criminal statutes. If the government were to allege that we were, or
convict us of, violating these false claims laws, we could be subject to a substantial fine and may suffer a decline
in our stock price. In addition, private individuals have the ability to bring actions under the federal False Claims
Act and certain states have enacted laws modeled after the federal False Claims Act.

Pricing and rebate programs must comply with the Medicaid rebate requirements of the U.S. Omnibus
Budget Reconciliation Act of 1990 and more recent requirements in ACA. If products are made available to
authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and
requirements apply. Products must meet applicable child-resistant packaging requirements under the U.S. Poison
Prevention Packaging Act. Manufacturing, sales, promotion and other activities are also potentially subject to
federal and state consumer protection and unfair competition laws.

The handling of any controlled substances must comply with the U.S. Controlled Substances Act and

Controlled Substances Import and Export Act.

The distribution of pharmaceutical products is subject to additional requirements and regulations, including
extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale
of pharmaceutical products. The failure to comply with any of these laws or regulatory requirements subjects
firms to possible legal or regulatory action. Depending on the circumstances, failure to meet applicable
regulatory requirements can result in criminal prosecution, fines or other penalties, injunctions, recall or seizure
of products, total or partial suspension of production, denial or withdrawal of product approvals, or refusal to
allow a firm to enter into supply contracts, including government contracts. Any action against us for violation of
these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert
our management’s attention from the operation of our business. Prohibitions or restrictions on sales or
withdrawal of future products marketed by us could materially affect our business in an adverse way.

Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the

future by requiring, for example: (i) changes to our manufacturing arrangements; (ii) additions or modifications

28

to product labeling; (iii) the recall or discontinuation of our products; or (iv) additional record-keeping
requirements. If any such changes were to be imposed, they could adversely affect the operation of our business.

U.S. patent term restoration and marketing exclusivity

Depending upon the timing, duration and specifics of the FDA approval of our drug candidates, some of our
U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term
Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. The Hatch-Waxman
Amendments permit a patent restoration term of up to five years as compensation for patent term lost during
product development and the FDA regulatory review process. However, patent term restoration cannot extend the
remaining term of a patent beyond a total of 14 years from the product’s approval date. The patent term
restoration period is generally one-half the time between the effective date of an IND and the submission date of
an NDA plus the time between the submission date of an NDA and the approval of that application. Only one
patent applicable to an approved drug is eligible for the extension and the application for the extension must be
submitted prior to the expiration of the patent. The U.S. PTO, in consultation with the FDA, reviews and
approves the application for any patent term extension or restoration. In the future, we intend to apply for
restoration of patent term for one of our then owned or licensed patents to add patent life beyond its current
expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of
the relevant NDA.

Marketing exclusivity provisions under the FDCA can also delay the submission or the approval of certain

marketing applications. The FDCA provides a five-year period of non-patent marketing exclusivity within the
United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new
chemical entity if the FDA has not previously approved any other new drug containing the same active moiety,
which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the
FDA may not accept for review an abbreviated new drug application, or ANDA, or a 505(b)(2) NDA submitted
by another company for another drug based on the same active moiety, regardless of whether the drug is intended
for the same indication as the original innovator drug or for another indication, where the applicant does not own
or have a legal right of reference to all the data required for approval. However, an application may be submitted
after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed
with the FDA by the innovator NDA holder. The FDCA also provides three years of marketing exclusivity for an
NDA, or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that
were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the
application, for example new indications, dosages or strengths of an existing drug. This three-year exclusivity
covers only the modification for which the drug received approval on the basis of the new clinical investigations
and does not prohibit the FDA from approving ANDAs for drugs containing the active agent for the original
indication or condition of use. Five-year and three-year exclusivity will not delay the submission or approval of a
full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of
reference to all of the non-clinical studies and adequate and well-controlled clinical trials necessary to
demonstrate safety and efficacy. Orphan drug exclusivity, as described above, may offer a seven-year period of
marketing exclusivity, except in certain circumstances. Pediatric exclusivity is another type of regulatory market
exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods
and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent
term, may be granted based on the voluntary completion of a pediatric trial in accordance with an FDA-issued
“Written Request” for such a trial.

European Union drug development

In the European Union, our future products may also be subject to extensive regulatory requirements. As in

the United States, medicinal products can only be marketed if a marketing authorization from the competent
regulatory agencies has been obtained.

29

Similar to the United States, the various phases of non-clinical and clinical research in the European Union
are subject to significant regulatory controls. Although the EU Clinical Trials Directive 2001/20/EC has sought
to harmonize the EU clinical trials regulatory framework, setting out common rules for the control and
authorization of clinical trials in the EU, the EU Member States have transposed and applied the provisions of the
Directive differently. This has led to significant variations in the member state regimes. Under the current
regime, before a clinical trial can be initiated it must be approved in each of the EU countries where the trial is to
be conducted by two distinct bodies: the National Competent Authority, or NCA, and one or more Ethics
Committees, or ECs. Under the current regime all suspected unexpected serious adverse reactions to the
investigated drug that occur during the clinical trial have to be reported to the NCA and ECs of the Member State
where they occurred.

The EU clinical trials legislation is currently undergoing a revision process mainly aimed at harmonizing

and streamlining the clinical trials authorization process, simplifying adverse event reporting procedures,
improving the supervision of clinical trials, and increasing their transparency.

In the EU, pediatric data or an approved Pediatric Investigation Plan, or PIP, or waiver, is required to have

been approved by the European Medicines Agency, or EMA, prior to submission of a marketing authorization
application to the EMA. In most EU countries, we are also required to have an approved PIP before we can begin
enrolling pediatric patients in a clinical trial. We have not yet submitted a PIP to the EMA for any of our product
candidates.

European Union drug review and approval

In the European Economic Area, or EEA, (which is comprised of 27 Member States of the EU (excludes

Croatia) plus Norway, Iceland and Liechtenstein), medicinal products can only be commercialized after
obtaining a Marketing Authorization, or MA. There are two types of marketing authorizations:

The Community MA is issued by the European Commission through the Centralized Procedure, based on

the opinion of the Committee for Medicinal Products for Human Use, or CHMP, of the EMA and is valid
throughout the entire territory of the EEA. The Centralized Procedure is mandatory for certain types of products,
such as biotechnology medicinal products, orphan medicinal products, and medicinal products containing a new
active substance indicated for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, auto-
immune and viral diseases. The Centralized Procedure is optional for products containing a new active substance
not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical
innovation or which are in the interest of public health in the EU.

National MAs, which are issued by the competent authorities of the Member States of the EEA and only

cover their respective territory, are available for products not falling within the mandatory scope of the
Centralized Procedure. Where a product has already been authorized for marketing in a Member State of the
EEA, this National MA can be recognized in another Member State through the Mutual Recognition Procedure.
If the product has not received a National MA in any Member State at the time of application, it can be approved
simultaneously in various Member States through the Decentralized Procedure. Under the Decentralized
Procedure an identical dossier is submitted to the competent authorities of each of the Member States in which
the MA is sought, one of which is selected by the applicant as the Reference Member State, or RMS. The
competent authority of the RMS prepares a draft assessment report, a draft summary of the product
characteristics, or SPC, and a draft of the labeling and package leaflet, which are sent to the other Member States
(referred to as the Member States Concerned) for their approval. If the Member States Concerned raise no
objections, based on a potential serious risk to public health, to the assessment, SPC, labeling, or packaging
proposed by the RMS, the product is subsequently granted a national MA in all the Member States (i.e., in the
RMS and the Member States Concerned).

Under the above described procedures, before granting the MA, the EMA or the competent authorities of the

Member States of the EEA make an assessment of the risk-benefit balance of the product on the basis of
scientific criteria concerning its quality, safety and efficacy.

30

European Union new chemical entity exclusivity

In the European Union, new chemical entities, sometimes referred to as new active substances, qualify for
eight years of data exclusivity upon marketing authorization and an additional two years of market exclusivity.
This data exclusivity, if granted, prevents regulatory authorities in the European Union from referencing the
innovator’s data to assess a generic application for eight years, after which a generic marketing authorization
application can be submitted, and the innovator’s data may be referenced, but not approved for two years. The
overall ten-year period will be extended to a maximum of 11 years if, during the first eight years of those ten
years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications
which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit
in comparison with existing therapies.

European Union orphan designation and exclusivity

In the European Union, the EMA’s Committee for Orphan Medicinal Products grants orphan drug

designation to promote the development of products that are intended for the diagnosis, prevention or treatment
of life-threatening or chronically debilitating conditions affecting not more than 5 in 10,000 persons in the
European Union Community and for which no satisfactory method of diagnosis, prevention, or treatment has
been authorized (or the product would be a significant benefit to those affected). Additionally, designation is
granted for products intended for the diagnosis, prevention, or treatment of a life-threatening, seriously
debilitating or serious and chronic condition and when, without incentives, it is unlikely that sales of the drug in
the European Union would be sufficient to justify the necessary investment in developing the medicinal product.

In the European Union, orphan drug designation entitles a party to financial incentives such as reduction of

fees or fee waivers and ten years of market exclusivity is granted following medicinal product approval. This
period may be reduced to six years if the orphan drug designation criteria are no longer met, including where it is
shown that the product is sufficiently profitable not to justify maintenance of market exclusivity. Orphan drug
designation must be requested before submitting an application for marketing approval. Orphan drug designation
does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.

Rest of the world regulation

For other countries outside of the European Union and the United States, such as countries in Eastern
Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing,
pricing and reimbursement vary from country to country. In all cases, the clinical trials must be conducted in
accordance with cGCP requirements and the applicable regulatory requirements and the ethical principles that
have their origin in the Declaration of Helsinki.

If we fail to comply with applicable foreign regulatory requirements applicable to a given country, we may

not be able to obtain regulatory approval for our product candidates in such country if we choose to seek such
approval, or we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals,
product recalls, seizure of products, operating restrictions and criminal prosecution.

Reimbursement

If we are successful in developing and gaining regulatory approval for our product candidates, sales of our

products will be dependent on the availability and extent of coverage and reimbursement from third-party payers.
In the United States, healthcare providers are reimbursed for covered services and products they use through
Medicare, Medicaid, and other government healthcare programs as well as through commercial insurance and
managed healthcare organizations. In the United States no uniform policy of coverage and reimbursement for
drug products exists. Accordingly, decisions regarding the extent of coverage and amount of reimbursement to be
provided for any of our products will be made on a payor-by-payor basis. As a result, the coverage determination

31

process is often a time-consuming and costly process that will require us to provide scientific and clinical support
for the use of our products to each payor separately, with no assurance that coverage and adequate
reimbursement will be obtained.

Third-party payors are increasingly reducing reimbursements for medical products and services.

Additionally, the containment of healthcare costs has become a priority of federal and state governments, and the
prices of drugs have been a focus in this effort. Changes in government legislation or regulation and changes in
private third-party payers’ policies toward reimbursement for our products may reduce reimbursement of our
products’ costs to physicians, pharmacies, and distributors. The U.S. government, state legislatures and foreign
governments have shown significant interest in implementing cost-containment programs, including price
controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price
controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing
controls and measures, could further limit our net revenue and results for any products we commercialize in the
future. Decreases in third-party reimbursement for our products or a decision by a third-party payor not to cover
a product for which we received marketing approval could reduce physician usage of our products and have a
material adverse effect on our sales, results of operations and financial condition.

The pricing and reimbursement environment for our products may change in the future and become more

challenging due to, among other reasons, policies advanced by a new presidential administration, federal
agencies, new healthcare legislation passed by Congress or fiscal challenges faced by all levels of government
health administration authorities. The American Recovery and Reinvestment Act of 2009, or ARRA, for
example, allocated new federal funding to compare the effectiveness of different treatments for the same
condition. The plan for the research was published in 2012 by the Department of Health and Human Services, the
Agency for Healthcare Research and Quality and the National Institutes for Health, and periodic reports on the
status of the research and related expenditures will be made to Congress. Although ARRA does not mandate the
use of the results of comparative effectiveness studies for reimbursement purposes, it is not clear what effect, if
any, the research will have on the sales of any products for which we receive marketing approval or on the
reimbursement policies of public and private payors. It is possible that comparative effectiveness research
demonstrating benefits in a competitor’s product could adversely affect the sales of any product for which we
receive marketing approval. For example, if third-party payors find our products not to be cost-effective
compared to other available therapies, they may not cover our products after approval as a benefit under their
plans or, if they do, the level of payment may not be sufficient to allow us to sell our products on a profitable
basis.

One of the goals of the federal Patient Protection and Affordable Care Act, as amended by the Health Care

and Education Reconciliation Act of 2010, collectively referred to herein as ACA, was to expand coverage for
the uninsured while at the same time containing overall healthcare costs. With regard to pharmaceutical products,
among other things, the ACA expands and increases industry rebates for drugs covered under Medicaid. The
ACA also imposed new reporting requirements on drug manufacturers for payments made to physicians and
teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family
members. Failure to submit required information may result in civil monetary penalties of $1,000 to $10,000 for
each payment or ownership interest that is not timely, accurately, or completely reported (annual maximum of
$150,000), and $10,000 to $100,000 for each knowing failure to report (annual maximum of $1 million). The
reporting requirements apply only to manufacturers of products for which reimbursement is available under a
federal healthcare program. Other health regulatory laws, such as the federal anti-kickback statute and the federal
civil False Claims Act, have been applied to marketing and other activities engaged in by pharmaceutical
companies whose products are reimbursed by federal healthcare programs, and, in many cases, government
investigations or private lawsuits under these laws have led such companies to enter settlements that include
significant monetary and other penalties, We cannot predict the full impact of the ACA or the other laws
described above on our business until we have a marketed product. Many states have adopted laws similar to the
federal laws discussed above. Some of these state laws apply to the referral of patients for healthcare services
reimbursed by any insurer, not just federal healthcare programs such as Medicare and Medicaid. There has also

32

been a recent trend of increased federal and state regulation of payments made to physicians. Certain states
mandate implementation of compliance programs, impose restrictions on drug manufacturers’ marketing
practices and/or require the tracking and reporting of gifts, compensation and other remuneration to physicians.
In addition, other legislative changes have been proposed and adopted in the United States since the ACA was
enacted. Beginning April 1, 2013, Medicare payments for all items and services under Part A and B, including
drugs and biologicals, and most payments to plans under Medicare Part D were reduced by 2% under the
sequestration (i.e., automatic spending reductions) required by the Budget Control Act of 2011, or BCA, as
amended by the American Taxpayer Relief Act of 2012. The BCA requires sequestration for most federal
programs, excluding Medicaid, Social Security, and certain other programs. The BCA caps the cuts to Medicare
payments for items and services and payments to Part D plans at 2%. Subsequent legislation extended the 2%
reduction, on average, to 2025. As long as these cuts remain in effect, they could adversely impact payment for
any products we may commercialize in the future. We expect that additional federal healthcare reform measures
will be adopted in the future, any of which could limit the amounts that federal and state governments will pay
for healthcare products and services, and in turn could significantly reduce the projected value of certain
development projects and reduce our profitability.

In addition, in many foreign countries, the proposed pricing for a drug must be approved before it may be

lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example,
the European Union provides options for its member states to restrict the range of medicinal products for which
their national health insurance systems provide reimbursement and to control the prices of medicinal products for
human use. A member state may approve a specific price for the medicinal product or it may instead adopt a
system of direct or indirect controls on the profitability of the company placing the medicinal product on the
market. There can be no assurance that any country that has price controls or reimbursement limitations for
pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products.
Historically, products launched in the European Union do not follow price structures of the United States, and
generally prices tend to be significantly lower.

33

Employees

As of February 15, 2016, we employed 62 full-time employees, including 39 in research and development

and 23 in general and administrative and no part-time employees. 21 of our employees hold M.D. or Ph.D.
degrees. We have never had a work stoppage, and none of our employees is represented by a labor organization
or under any collective-bargaining arrangements. We consider our employee relations to be good.

Facilities

Our corporate headquarters are located in Cambridge, Massachusetts, and consist of 22,067 square feet in a

multi-tenant building. Our lease expires on February 28, 2022. We expect to lease additional space prior to the
expiration of our lease to meet the needs of the business.

Legal Proceedings

As of the date of this Annual Report on Form 10-K, we were not party to any legal matters or claims. In the
future, we may become party to legal matters and claims arising in the ordinary course of business, the resolution
of which we do not anticipate would have a material adverse impact on our financial position, results of
operations or cash flows.

Corporate Information

We were incorporated under the laws of the state of Delaware on April 16, 2010 and commenced operations

on January 19, 2011 as Sterogen Biopharma, Inc. On September 13, 2011, we changed our name to Sage
Therapeutics, Inc. under our Second Amended and Restated Certificate of Incorporation. Our mailing address
and executive offices are located at 215 First Street, Cambridge, Massachusetts and our telephone number at that
address is (617) 299-8380. We maintain an Internet website at the following address: www.sagerx.com. The
information on our website is not incorporated by reference in this annual report on Form 10-K or in any other
filings we make with the Securities and Exchange Commission.

We make available on or through our website certain reports and amendments to those reports that we file
with or furnish to the Securities and Exchange Commission in accordance with the Securities Exchange Act of
1934, as amended. These include our annual reports on Form 10-K, our quarterly reports on Form 10-Q, and our
current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or
15(d) of the Exchange Act. We make this information available on or through our website free of charge as soon
as reasonably practicable after we electronically file the information with, or furnish it to, the Securities and
Exchange Commission.

You may read and copy any materials we file with the SEC at the SEC’s Public Reference Room at

100 F Street, NE, Washington, DC 20549. You may obtain information on the operation of the Public Reference
Room by calling the SEC at 1-800-SEC-0330. The SEC also maintains an Internet website that contains reports,
proxy and information statements, and other information regarding us and other issuers that file electronically
with the SEC. The SEC’s Internet website address is http://www.sec.gov.

34

Item 1A. Risk Factors

Investing in our common stock involves a high degree of risk. You should carefully consider the following

risks and uncertainties, together with all other information in this Annual Report on Form 10-K, or Annual
Report, including our financial statements and related notes, before investing in our common stock. Any of the
risk factors we describe below could adversely affect our business, financial condition or results of operations.
The market price of our common stock could decline if one or more of these risks or uncertainties actually occur,
causing you to lose all or part of the money you paid to buy our common stock. Additional risks that we currently
do not know about, or that we currently believe to be immaterial, may also impair our business. Certain
statements below are forward-looking statements. See “Cautionary Note Regarding Forward-Looking
Statements” in this Annual Report.

Risks Related to Product Development, Regulatory Approval and Commercialization

We depend heavily on the success of our current product candidates, of which SAGE-547 is in Phase 3
clinical development for super-refractory status epilepticus; SAGE 217 is in Phase 1 clinical development; and
SAGE-689 and SAGE-718 are in non-clinical development; and other product candidates are at earlier stages.
We cannot be certain that we will be able to complete, within the expected time-frames, our non-clinical
studies or clinical trials, or to announce results on the time-lines we expect. We cannot be certain that we will
be able to advance our product candidates into additional trials, or to successfully develop, or obtain
regulatory approval for, or successfully commercialize, any of our product candidates.

We currently have no drug products for sale, and may never be able to successfully develop marketable drug

products. Our business depends heavily on our ability to successfully complete non-clinical and clinical
development of our current product candidates, and to obtain regulatory approval and successfully commercialize
those product candidates. Before obtaining regulatory approvals for the commercial sale of any product
candidate, we must demonstrate through non-clinical studies and clinical trials that the product candidate is safe
and effective for use in each target indication. Our lead product candidate, SAGE-547, is currently in Phase 3
clinical development for the treatment of super-refractory status epilepticus, or SRSE. SAGE 217 is in Phase 1
clinical development, and SAGE-689 and SAGE-718 are in non-clinical development and other product
candidates are at earlier stages. Drug development involves a high degree of risk.

We may not be able to complete our clinical trials or announce results from our clinical trials on the time-

lines we expect. For instance, we may experience slower than expected clinical site initiation, or slower than
expected identification and enrollment of evaluable patients. There is also the potential for delays or problems in
analyzing data, or the potential need for additional analysis or data or the need to enroll additional patients. We
may also encounter delays arising from unexpected adverse events in a trial or other unexpected hurdles or issues
in the conduct of any trial.

We may not be able to demonstrate the efficacy and safety of our current product candidates or any other

product candidate at each stage of clinical development. We may change formulations of our product candidates
which could delay development or require us to conduct additional clinical trials or non-clinical studies. The
results of clinical trials or non-clinical testing of our product candidates at any stage may not support further
development or may not be sufficient to obtain regulatory approval. Clinical trials of our product candidates are,
and the manufacturing and marketing of our product candidates will be, subject to extensive and rigorous review
and regulation by numerous government authorities in the United States and in other countries where we intend
to test and, if approved, market any product candidate. Drug development is a long, expensive and uncertain
process, and delay or failure can occur at any stage of our clinical trials. Success in non-clinical studies or in
earlier stage clinical trials may not be repeated or observed in ongoing or future studies involving the same
compound or other product candidates. The drug development process can take many years, and may include
post-marketing studies and surveillance, which will require the expenditure of substantial resources. Of the large
number of drugs in development in the United States, only a small percentage will successfully complete the U.S.

35

Food and Drug Administration, or FDA, regulatory approval process and will be commercialized. Accordingly,
even if we are able to obtain the requisite financing, when needed, to continue to fund our development efforts,
we cannot assure you that any of our product candidates will be successfully developed or commercialized.

We are not permitted to market our product candidates in the United States until we receive approval of a

New Drug Application, or an NDA, from the FDA, or in any foreign countries until we receive the requisite
marketing approval from such countries.

Obtaining approval of an NDA in the U.S. or marketing approval in any country outside the U.S. is a
complex, lengthy, expensive and uncertain process, and the FDA and regulatory authorities outside the U.S. may
delay, limit or deny approval of any of our product candidates for many reasons, including, among others:

‰

‰

‰

‰

‰

‰

‰

‰

‰

‰

‰

‰

‰

we may not be able to demonstrate, to the satisfaction of the FDA or other regulatory authorities that our
product candidates are safe and effective in any indication;

the results of our non-clinical studies and clinical trials may be negative, or may not meet the level of
statistical or clinical significance required by the FDA or regulatory authorities outside the U.S. for
marketing approval;

the FDA or regulatory authorities outside the U.S. may disagree with the number, design, size, conduct, or
implementation of our non-clinical studies or clinical trials or changes in drug formulation used in our non-
clinical studies or clinical trials;

the FDA or regulatory authorities outside the U.S. may require that we conduct additional non-clinical
studies and clinical trials prior to approval or post-approval;

the FDA or the applicable foreign regulatory agency may not approve the formulation, labeling or
specifications of any of our product candidates;

the contract research organizations, or CROs, that we retain to conduct our non-clinical studies and clinical
trials may take actions outside of our control that materially adversely impact our non-clinical studies and
clinical trials;

the FDA or regulatory authorities outside the U.S. may find the data from non-clinical studies and clinical
trials insufficient to demonstrate that a product candidate’s clinical and other benefits outweigh its safety
risks;

the FDA or regulatory authorities outside the U.S. may disagree with our interpretation of data from our
non-clinical studies and clinical trials;

the FDA or regulatory authorities outside the U.S. may not accept data generated at our non-clinical studies
and clinical trial sites;

if our NDA, if and when submitted, is reviewed by an advisory committee, the FDA may have difficulties
scheduling an advisory committee meeting in a timely manner or the advisory committee may recommend
against approval of our application or may recommend that the FDA require, as a condition of approval,
additional non-clinical studies or clinical trials, limitations on approved labeling or distribution and use
restrictions;

the FDA may require development of a Risk Evaluation and Mitigation Strategy, or REMS, as a condition
of approval or post-approval;

the FDA or the applicable foreign regulatory agency may determine that the manufacturing processes or
facilities of third-party contract manufacturers with which we contract do not conform to applicable
requirements, including current Good Manufacturing Practices, or cGMPs; or

the FDA or applicable foreign regulatory agency may change its approval policies or adopt new regulations.

36

Even if we receive marketing approval for our product candidates, regulatory or other governmental
authorities may still impose significant restrictions on our products, including restrictions on indicated uses or
marketing, or may impose ongoing requirements for potentially costly post-approval studies. For example, we
expect that, prior to product launch, the U.S. Drug Enforcement Agency, or DEA, will need to determine the
controlled substance schedule of SAGE-547, taking into account the recommendation of the FDA. The process
may be more time consuming than we expect, and may delay our ability to market SAGE-547 if it is approved.
Any of these factors, many of which are beyond our control, could jeopardize our ability to obtain regulatory
approval for and successfully market our product candidates. Any such setback would have a material adverse
effect on our business and prospects.

We cannot be certain that the results of our ongoing Phase 3 clinical trial of SAGE-547 will be sufficient to
support the submission of an NDA for this product candidate, and in any event we must obtain additional
clinical and non-clinical data before an NDA may be submitted.

In general, the FDA requires two pivotal trials to support approval of an NDA, but in certain circumstances,

will approve an NDA based on only one pivotal trial. If successful, we believe the results from our ongoing
Phase 3 clinical trial of SAGE-547, together with other safety and efficacy data from the SAGE-547 development
program, could form the basis of an NDA submission for SAGE-547. However, depending upon the outcome of
the Phase 3 clinical trial and the other development activities under the current program, the FDA may require
that we conduct additional pivotal trials before we can submit an NDA for SAGE-547.

Furthermore, we will need to complete several other clinical and non-clinical studies prior to submitting an
NDA to the FDA, including studies to evaluate the pharmacokinetics and/or pharmacodynamics of SAGE-547 in
special populations. If the results of these additional clinical and non-clinical studies are delayed or yield
unanticipated results, it may delay or prevent the submission or approval of an NDA for SAGE-547.

A Fast Track designation by the FDA may not actually lead to a faster development or regulatory review or
approval process.

We have received Fast Track designation for our investigational new drug application, or IND, for SAGE-

547 for the treatment of SRSE, and in the future we may seek Fast Track designation for other product candidates
as well. If a product is intended for the treatment of a serious or life-threatening condition and the product
demonstrates the potential to address unmet medical needs for this condition, the sponsor may apply for the FDA
Fast Track designation. Fast Track designation does not necessarily lead to a faster development pathway or
regulatory review process, and does not increase the likelihood of regulatory approval. The FDA may withdraw
Fast Track designation if it believes that the designation is no longer supported by data from our clinical
development programs.

The number of patients with SRSE and the other diseases and disorders for which we are developing product
candidates has not been established with precision. The number of patients suffering from SRSE is small. If
the actual number of patients with SRSE or any other diseases or disorders we elect to pursue with our
product candidates is smaller than we anticipate, we may encounter difficulties in enrolling patients in our
clinical trials, thereby delaying or preventing development of our product candidates, and even if such product
candidates are approved, our revenue and ability to achieve profitability may be materially adversely affected.

Our lead product, SAGE-547, is currently being studied in a Phase 3 clinical trial for the treatment of
patients with SRSE. There is no precise method of establishing the actual number of patients with SRSE in any
geography over any time period. Moreover, SRSE is an acute episodic condition. If we are not able to identify
patients at the time of SRSE onset, we will have difficulty completing our Phase 3 clinical trial. We estimate that
the annual incidence of SRSE in the United States is approximately 25,000 patients per year, and it may be that
only a subset of those patients would be potential candidates for treatment with SAGE-547. We plan to develop
our product candidates in certain other indications, including potentially status epilepticus, refractory status

37

epilepticus, orphan epilepsies, post-partum depression, essential tremor, Smith-Lemli-Opitz Syndrome and anti-
NMDA receptor encephalitis. We may not be able to accurately estimate the prevalence or size of the addressable
patient population for some or all of those indications or any other indication that we elect to pursue. In
estimating the potential prevalence of indications we are pursuing, or may in the future pursue, including our
estimates as to the prevalence of SRSE, we apply assumptions to available information that may not prove to be
accurate. In each case, there is a range of estimates in the published literature which include estimates within the
range that are lower than our estimates. The actual number of patients with SRSE or any other indication in
which we elect to pursue development of our product candidates may be significantly lower than we believe. If
the actual number of patients with SRSE or any other indication in which we elect to pursue development of our
product candidates is lower than our estimates, we may experience difficulty in enrolling patients in our clinical
trials, thereby delaying development of our product candidates. A prevalence calculation is an estimate of the
total number of patients with a disease or the rate of occurrence of a disease in a population. Even if our
prevalence estimates are correct, our products, if approved, may be indicated for only a subset of patients with a
particular disease or condition. If any of our product candidates are approved and our prevalence estimates with
respect to any indication or our market assumptions are not accurate, the markets for our product candidates for
these indications may be smaller than we anticipate, which could limit our revenues and our ability to achieve
profitability.

If serious adverse events or other undesirable side effects are identified during the use of SAGE-547 or any of
our other product candidates in emergency-use cases, investigator sponsored trials, expanded access
programs, or any clinical trials, it may adversely affect our development of such product candidates.

Undesirable side effects caused by our product candidates could cause us or regulatory authorities to

interrupt, delay or halt non-clinical studies and clinical trials, or could make it more difficult for us to enroll
patients in our clinical trials. If serious adverse events or other undesirable side effects, or unexpected
characteristics of SAGE-547 or any of our other product candidates are observed in emergency-use cases,
investigator sponsored clinical trials, or clinical trials, further clinical development of such product candidate
may be delayed or we may not be able to continue development of such product candidate at all, and the
occurrence of these events could have a material adverse effect on our business. Undesirable side effects caused
by our product candidates could also result in the delay or denial of regulatory approval by the FDA or other
regulatory authorities or in a more restrictive label than we expect.

Positive results from early non-clinical studies and clinical trials of our product candidates are not necessarily
predictive of the results of later non-clinical studies and clinical trials of our product candidates. If we cannot
replicate the positive results from our earlier non-clinical studies and clinical trials of our product candidates
in our later non-clinical studies and clinical trials, we may be unable to successfully develop, obtain
regulatory approval for and commercialize our product candidates.

Positive results from non-clinical studies and clinical trials, including proof-of-concept trials, of our product
candidates may not necessarily be predictive of the results we may obtain from subsequent non-clinical studies or
clinical trials using the same product candidate or other product candidates. For example, the positive results
from our Phase 1/2 clinical trial of SAGE-547 in SRSE and results from earlier emergency use cases, may not be
replicated in our ongoing Phase 3 clinical trial. Our Phase 3 clinical trial of SAGE-547 differs in important ways
from the Phase 1/2 clinical trial, which could cause the outcome of the Phase 3 clinical trial to differ from the
earlier stage clinical trial. The Phase 3 clinical trial of SAGE-547 is a placebo-controlled trial, while our Phase
1/2 clinical trial was open-label, and in our Phase 3 clinical trial an intent-to-treat statistical analysis, which is a
more rigorous statistical analysis, will be employed in evaluating the Phase 3 data. In addition, the formulation of
SAGE-547 we are using in our Phase 3 trial is somewhat different than the formulation used in the Phase 1/2
trial. We do not believe the change in formulation will negatively affect trial results, but we cannot be sure.
Similarly, the results from our early-stage proof-of-concept clinical trials of SAGE-547 in essential tremor and
post-partum depression may not be replicated in subsequent clinical trials of SAGE-547 or other product
candidates in those indications even if the mechanism of action of the product candidates is the same. Many

38

companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in later-stage
clinical trials after achieving positive results in early-stage development, and we cannot be certain that we will
not face similar setbacks. These setbacks have been caused by, among other things, non-clinical findings made
while clinical trials were underway or safety or efficacy observations made in non-clinical studies and clinical
trials that are different than in earlier trials, including previously unreported adverse events. For example, we
may observe safety issues in clinical studies of our product candidates that we did not observe or appreciate in
non-clinical studies. The results from non-clinical animal models may not be replicated in clinical trials. Many
drug candidates, including many targeting CNS disorders, with promising non-clinical profiles have failed to
demonstrate similar safety, non-toxicity and efficacy in humans. Moreover, non-clinical and clinical data are
often susceptible to varying interpretations and analyses, and many companies that believed their product
candidates performed satisfactorily in non-clinical studies and clinical trials nonetheless failed to obtain FDA
approval. If we fail to produce positive results in our planned non-clinical studies or clinical trials of any of our
product candidates, the development timeline and regulatory approval and commercialization prospects for our
product candidates, and, correspondingly, our business and financial prospects, would be materially adversely
affected.

Failures or delays in the commencement or completion of our planned clinical trials of our product
candidates could result in increased costs to us and could delay, prevent or limit our ability to generate
revenue and continue our business.

Successful completion of clinical trials at each applicable stage of development is a prerequisite to
submitting an NDA to the FDA and, consequently, the ultimate approval and commercial marketing of SAGE-
547 for SRSE and our other product candidates for the indications in which we develop them. We do not know
whether any of our clinical trials will begin or be completed on schedule, if at all, as the commencement and
completion of clinical trials can be delayed or prevented for a number of reasons, including, among others:
‰

the FDA may deny permission to proceed with our planned clinical trials or any other clinical trials we may
initiate, or may place a clinical trial on hold;

‰

‰

‰

‰

‰

‰

‰

‰

‰

delays in filing or receiving approvals of additional INDs that may be required;

negative results from our ongoing non-clinical studies or clinical trials;

challenges in identifying, recruiting and enrolling patients to participate in clinical trials, including, in the
case of SAGE-547, due to the small size of the patient population and acute nature of SRSE; the proximity
of patients to trial sites; the requirement for a pediatric investigation plan to enroll pediatric patients in most
EU countries; challenges in meeting regulatory requirements to commence clinical trials in countries outside
the U.S.; eligibility criteria for the clinical trial; the nature of the clinical trial protocol; the availability of
approved effective treatments for the relevant disease; and competition from other clinical trial programs for
similar indications;

delays in reaching or failing to reach agreement on acceptable terms with prospective CROs and clinical
trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among
different CROs and trial sites;

inadequate quantity or quality of a product candidate or other materials necessary to conduct clinical trials,
for example delays in the manufacturing of sufficient supply of finished drug product;

difficulties obtaining Institutional Review Board, or IRB, approval, and equivalent approval for sites outside
the U.S., to conduct a clinical trial at a prospective site or sites;

delays or problems in analyzing data, or the need for additional analysis or data or the need to enroll
additional patients;

the occurrence of severe or unexpected drug-related side effects experienced by patients in a clinical trial or
unexpected results in ongoing non-clinical studies;

delays in validating any endpoints utilized in a clinical trial;

39

‰

‰

‰

‰

our inability to satisfy the CMC requirements of the FDA or file amendments to our IND as requested by the
FDA prior to the initiation of a clinical trial;

the FDA and applicable regulatory authorities outside the U.S. disagreeing with our clinical trial design and
our interpretation of data from clinical trials, or changing the requirements for approval even after the
regulatory authority has reviewed and commented on the design for our clinical trials;

reports from non-clinical or clinical testing of other CNS therapies that raise safety or efficacy concerns; and

difficulties retaining patients who have enrolled in a clinical trial but may be prone to withdraw due to rigors
of the clinical trials, lack of efficacy, side effects, personal issues or loss of interest.

Clinical trials may also be delayed or terminated as a result of ambiguous or negative interim results. For

example, commencement of a Phase 1 clinical trial of SAGE-689 has been delayed to respond to a request from
the FDA for additional non-clinical study data. There is no guarantee that we will be able to generate data that
will satisfy the FDA, and enable us to commence the Phase 1 clinical trial. In addition, a clinical trial may be
suspended or terminated by us, the FDA, the IRBs at the sites where the IRBs are overseeing a clinical trial, a
data and safety monitoring board, or DSMB, overseeing the clinical trial at issue or other regulatory authorities
due to a number of factors, including, among others:

‰

‰

‰

‰

‰

‰

failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols;

inspection of the clinical trial operations or trial sites by the FDA or other regulatory authorities that reveals
deficiencies or violations that require us to undertake corrective action, including the imposition of a clinical
hold;

unforeseen safety issues, including any that could be identified in our ongoing non-clinical studies, or
adverse side effects or lack of effectiveness identified in ongoing clinical trials;

changes in government regulations or administrative actions;

problems with clinical supply materials; and

lack of adequate funding to continue clinical trials.

Changes in regulatory requirements, FDA guidance or unanticipated events during our non-clinical studies
and clinical trials of our product candidates may occur, which may result in changes to non-clinical studies
and clinical trial protocols or additional non-clinical studies and clinical trial requirements, which could
result in increased costs to us and could delay our development timeline.

Changes in regulatory requirements, FDA guidance or unanticipated events during our non-clinical studies

and clinical trials may force us to amend non-clinical studies and clinical trial protocols or the FDA or applicable
regulatory authorities outside the U.S. may impose additional non-clinical studies and clinical trial requirements.
Amendments or changes to our clinical trial protocols would require resubmission to the FDA and IRBs for
review and approval, which may adversely impact the cost, timing or successful completion of clinical trials.
Similarly, amendments to our non-clinical studies may adversely impact the cost, timing, or successful
completion of those non-clinical studies. If we experience delays completing, or if we terminate, any of our non-
clinical studies or clinical trials, or if we are required to conduct additional non-clinical studies or clinical trials,
the commercial prospects for our product candidates may be harmed and our ability to generate product revenue
will be delayed.

40

We rely, and expect that we will continue to rely, on third parties to conduct any clinical trials for our product
candidates. If these third parties do not successfully carry out their contractual duties or meet expected
deadlines, we may not be able to obtain regulatory approval for or commercialize products, if approved, and
our business could be substantially harmed.

We do not have the ability to independently conduct clinical trials. We rely on medical institutions, clinical
investigators, contract laboratories and other third parties, such as CROs, to conduct clinical trials of our product
candidates. We enter into agreements with third-party CROs to provide monitors for and to manage data for our
ongoing clinical trials. We rely heavily on these parties for execution of clinical trials for our product candidates
and control only certain aspects of their activities. As a result, we have less direct control over the conduct,
timing and completion of these clinical trials and the management of data developed through clinical trials than
would be the case if we were relying entirely upon our own staff. Communicating with outside parties can also
be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. Outside parties
may:

‰

‰

‰

‰

‰

have staffing difficulties;

fail to comply with contractual obligations;

experience regulatory compliance issues;

undergo changes in priorities or become financially distressed; or

form relationships with other entities, some of which may be our competitors.

These factors may materially adversely affect the willingness or ability of third parties to conduct our
clinical trials, and may subject us to unexpected cost increases that are beyond our control. Nevertheless, we are
responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol,
legal, regulatory and scientific requirements and standards, and our reliance on CROs does not relieve us of our
regulatory responsibilities. We and our CROs are required to comply with regulations and guidelines, including
current Good Clinical Practices, or cGCPs, for conducting, monitoring, recording and reporting the results of
clinical trials to ensure that the data and results are scientifically credible and accurate, and that the trial patients
are adequately informed of the potential risks of participating in clinical trials. These regulations are enforced by
the FDA, the Competent Authorities of the Member States of the European Economic Area and comparable
foreign regulatory authorities for any products in clinical development. The FDA enforces cGCP regulations
through periodic inspections of clinical trial sponsors, principal investigators and trial sites. If we or our CROs or
clinical sites fail to comply with applicable cGCPs, the clinical data generated in our clinical trials may be
deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform
additional clinical trials before approving our marketing applications. We cannot assure you that, upon
inspection, the FDA or applicable regulatory authorities outside the U.S. will determine that our clinical trials
comply with cGCPs. In addition, our clinical trials must be conducted with product candidates produced under
cGMPs regulations. Our failure or the failure of our CROs or contract manufacturers to comply with these
regulations may require us to repeat clinical trials, which would delay the regulatory approval process, and could
also subject us to enforcement action up to and including civil and criminal penalties.

If any of our relationships with these third-party CROs terminate, we may not be able to enter into

arrangements with alternative CROs. If CROs do not successfully carry out their contractual duties or obligations
or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they
obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other
reasons, and we are unable to rely on clinical data collected, we could be required to repeat, extend the duration
of, or increase the size of our clinical trials and this could significantly delay commercialization and require
significantly greater expenditures. As a result, we believe that our financial results and the commercial prospects
for our product candidates in the subject indication would be harmed, our costs could increase and our ability to
generate revenue could be delayed.

41

We rely completely on third-party suppliers to manufacture our clinical drug supplies for our product
candidates, and we intend to rely on third parties to produce non-clinical, clinical and commercial supplies of
our product candidates in the future.

We do not currently have, nor do we plan to acquire, the infrastructure or capability internally to

manufacture supplies of our product candidates, or any future product candidates, for use in the conduct of our
non-clinical studies and clinical trials, or for future commercial use, and we rely completely on third-party
suppliers for both active drug substances and finished drug products. For example, SAGE-547 used in the
emergency-use cases was manufactured at an academic site, the active pharmaceutical ingredient for SAGE-547
for our Phase 1/2 clinical trial was manufactured at an academic site and SAGE-547 as formulated for our Phase
1/2 clinical trial was manufactured at a third-party manufacturer’s site. SAGE-547, as formulated for our Phase 3
clinical trial, is also manufactured at a third-party manufacturer’s site.

We will rely on our contract manufacturers to manufacture registration batches of both active drug

substances and finished drug products required for regulatory approval as well as validation batches required for
commercial manufacture. We expect our contract manufacturers to comply with cGMPs in the manufacture of
our products. The facilities used by our contract manufacturers to manufacture the active pharmaceutical
ingredient and final drug product must typically complete a pre-approval inspection by the FDA and other
comparable foreign regulatory agencies to assess compliance with applicable requirements, including cGMPs,
after we submit our NDA or equivalent foreign regulatory submission to the applicable regulatory agency. If our
contract manufacturers cannot successfully manufacture material that conforms to our specifications and the
strict regulatory requirements of the FDA or applicable foreign regulatory agencies, and pass regulatory
inspections, they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities.
In addition, we have no direct control over our contract manufacturers’ ability to maintain adequate quality
control, quality assurance and qualified personnel. Furthermore, all of our third-party contract manufacturers are
engaged with other companies to supply and/or manufacture materials or products for such companies, which
exposes our third-party contract manufacturers to regulatory risks for the production of such materials and
products. As a result, failure to satisfy the regulatory requirements for the production of those materials and
products may affect the regulatory clearance of our contract manufacturers’ facilities generally. If the FDA or an
applicable foreign regulatory agency determines now or in the future that these facilities for the manufacture of
our product candidates are noncompliant, we may need to find alternative manufacturing facilities, which would
adversely impact our ability to develop and obtain regulatory approval for our product candidates and to market
any approved products in the future. Our reliance on contract manufacturers also exposes us to the possibility that
they, or third parties with access to their facilities, will have access to and may appropriate our trade secrets or
other proprietary information.

We do not have long-term supply agreements in place with our contract manufacturers, and each batch of
our product candidates is individually contracted under a quality agreement and purchase order. If our existing
contract manufacturers are not willing to enter into long-term supply agreements, or are not willing or are unable
to supply drug substance or drug product to us, and we engage new contract manufacturers, such contractor
manufacturers must scale up the manufacturing process, complete validation batches, pass an inspection by the
FDA and other applicable foreign regulatory agencies, and be approved by regulatory authorities as our
manufacturer before we are able to use drug product or drug substance they manufacture for commercial
purposes which could result in significant delays or gaps in product availability. We plan to continue to rely upon
contract manufacturers and, potentially, collaboration partners, to manufacture commercial quantities of our
products, if approved. If we are unable to maintain arrangements for third-party manufacturing, or are unable to
do so on commercially reasonable terms, or are unable to obtain timely regulatory approvals in connection with
our contract manufacturers, we may not be able to successfully complete development of our product candidates
or commercialize our products, if approved.

42

Even if we receive marketing approval for our product candidates in the United States, we may never receive
regulatory approval to market our product candidates outside of the United States.

Even if we receive marketing approval for our product candidates in the United States, we may never
receive regulatory approval to market our product candidates outside of the United States. In order to market any
product outside of the United States, we must establish and comply with the numerous and varying safety,
efficacy and other regulatory requirements of other countries. Approval procedures vary among countries and can
involve additional product candidate testing and additional administrative review periods. The time required to
obtain approvals in other countries might differ from that required to obtain FDA approval. Marketing approval
in one country does not ensure marketing approval in another, but a failure or delay in obtaining marketing
approval in one country may have a negative effect on the regulatory process in others. The marketing approval
processes in other countries may implicate all of the risks detailed above regarding FDA approval in the United
States as well as other risks. In particular, in many countries outside of the United States, products must receive
pricing and reimbursement approval before the product can be commercialized. Obtaining this approval can
result in substantial delays in bringing products to market in such countries. Even if we are able to successfully
develop our product candidates and obtain marketing approval in a country, we may not be able to obtain pricing
and reimbursement approvals in such country at acceptable levels or at all, and any pricing and reimbursement
approval we may obtain may be subject to onerous restrictions such as caps or other hurdles or restrictions on
reimbursement. Failure to obtain marketing and pricing approval in countries outside the U.S. or any delay or
other setback in obtaining such approval would impair our ability to market our product candidates in such
foreign markets. Any such impairment would reduce the size of our potential market, which could have a
material adverse impact on our business, results of operations and prospects.

If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to
market and sell our product candidates, we may not be able to generate any revenue.

We do not currently have an infrastructure for the sales, marketing and distribution of pharmaceutical
products. In order to market our product candidates, if approved by the FDA or any other regulatory body, we
must build our sales, marketing, managerial and other non-technical capabilities or make arrangements with third
parties to perform these services. If we are unable to establish adequate sales, marketing and distribution
capabilities, whether independently or with third parties, or if we are unable to do so on commercially reasonable
terms, our business, results of operations, financial condition and prospects will be materially adversely affected.

Even if we receive marketing approval for our product candidates, our approved products may not achieve
broad market acceptance, which would limit the revenue that we generate from their sales.

The commercial success of our product candidates, if approved by the FDA or other applicable regulatory

authorities, will depend upon the awareness and acceptance of our approved products among the medical
community, including physicians, patients and healthcare payors. Market acceptance of our products, if
approved, will depend on a number of factors, including, among others:

‰

‰

‰

‰

‰

the efficacy of our products as demonstrated in clinical trials, and, if required by any applicable regulatory
authority in connection with the approval for the applicable indications, to provide patients with incremental
health benefits, as compared with other available CNS therapies;

limitations or warnings contained in the labeling approved for our products by the FDA or other applicable
regulatory authorities;

the clinical indications for which our products are approved;

availability of alternative treatments already approved or expected to be commercially launched in the near
future;

the potential and perceived advantages of our products over current treatment options or alternative
treatments, including future alternative treatments;

43

‰

‰

‰

‰

‰

‰

‰

‰

the willingness of the target patient population to try new therapies and of physicians to prescribe these
therapies;

the strength of marketing and distribution support and timing of market introduction of competitive
products;

publicity concerning our products or competing products and treatments;

pricing and cost effectiveness;

the effectiveness of our sales and marketing strategies;

our ability to increase awareness of our approved products through marketing efforts;

our ability to obtain sufficient third-party coverage or reimbursement; or

the willingness of patients to pay out-of-pocket in the absence of third-party coverage.

If our product candidates are approved, but do not achieve an adequate level of acceptance by patients,
physicians and payors, we may not generate sufficient revenue from our products to become or remain profitable.
Before granting reimbursement approval, healthcare payors may require us to demonstrate that our product
candidates, in addition to treating these target indications, also provide incremental health benefits to patients.
Our efforts to educate the medical community and third-party payors about the benefits of our products, if
approved, may require significant resources and may never be successful.

Our product candidates may cause undesirable side effects that could delay or prevent their regulatory
approval, limit the commercial profile of an approved label, or result in significant negative consequences
following marketing approval, if any.

Undesirable side effects caused by our product candidates could cause us or regulatory authorities to
interrupt, delay or halt non-clinical studies and clinical trials and could result in a more restrictive label or the
delay or denial of regulatory approval by the FDA or other regulatory authorities.

Further, clinical trials by their nature utilize a sample of the potential patient population. With a limited
number of patients and limited duration of exposure, rare and severe side effects of our product candidates may
only be uncovered with a significantly larger number of patients exposed to the product candidate. If our product
candidates receive marketing approval and we or others identify undesirable side effects caused by such products
(or any other similar products) after such approval, a number of potentially significant negative consequences
could result, including:

‰

‰

‰

‰

‰

‰

‰

regulatory authorities may withdraw or limit their approval of such products;

regulatory authorities may require the addition of labeling statements, such as a “boxed” warning or a
contraindication;

we may be required to change the way such products are distributed or administered, conduct additional
clinical trials or change the labeling of the products;

we may be subject to regulatory investigations and government enforcement actions;

we may decide to remove such products from the marketplace;

we could be sued and held liable for injury caused to individuals exposed to or taking our product
candidates; and

our reputation may suffer.

We believe that any of these events could prevent us from achieving or maintaining market acceptance of
the affected products and could substantially increase the costs of commercializing our products and significantly
impact our ability to successfully commercialize our products and generate revenues.

44

Even if we receive marketing approval for our product candidates, we may still face future development and
regulatory difficulties.

Even if we receive marketing approval for our product candidates, regulatory authorities may still impose

significant restrictions on our products, indicated uses or marketing or impose ongoing requirements for
potentially costly post-approval studies. For example, we expect that, prior to product launch, the U.S. Drug
Enforcement Agency, or DEA, will need to determine the controlled substance schedule of SAGE-547, taking
into account the recommendation of the FDA. The DEA process may be more time consuming than we expect.
Our products, if approved, will also be subject to ongoing FDA requirements governing the labeling, packaging,
storage and promotion of the product and record keeping and submission of safety and other post-market
information. The FDA has significant post-marketing authority, including, for example, the authority to require
labeling changes based on new safety information and to require post-marketing studies or clinical trials to
evaluate serious safety risks related to the use of a drug. The FDA also has the authority to require, as part of an
NDA or post-approval, the submission of a REMS. Any REMS required by the FDA may lead to increased costs
to assure compliance with additional post-approval regulatory requirements and potential requirements or
restrictions on the sale of approved products, all of which could lead to lower sales volume and revenue.

Manufacturers of drug products and their facilities are subject to continual review and periodic inspections

by the FDA and other regulatory authorities for compliance with cGMPs and other regulations. If we or a
regulatory agency discover problems with our products, if approved, such as adverse events of unanticipated
severity or frequency, or problems with the facility where our products are manufactured, a regulatory agency
may impose restrictions on our products, the manufacturer or us, including requiring withdrawal of such products
from the market or suspension of manufacturing. If we, our product candidates or approved products or the
manufacturing facilities for our product candidates or products fail to comply with applicable regulatory
requirements, a regulatory agency may, among other things:

‰

‰

‰

‰

‰

‰

‰

issue warning letters or untitled letters;

seek an injunction or impose civil or criminal penalties or monetary fines;

suspend or withdraw marketing approval;

suspend any ongoing clinical trials;

refuse to approve pending applications or supplements to applications submitted by us;

suspend or impose restrictions on operations, including costly new manufacturing requirements; or

seize or detain products, refuse to permit the import or export of products, or require that we initiate a
product recall.

Competing therapies could emerge adversely affecting our opportunity to generate revenue from the sale of
our product candidates, if approved.

The biopharmaceuticals industry is highly competitive. There are many public and private companies,

universities, governmental agencies and other research organizations actively engaged in the research and
development of products that may be similar to our product candidates or address similar markets. It is probable
that the number of companies seeking to develop products and therapies similar to our products will increase.

Currently, there are no therapies specifically approved for SRSE or RSE. However, many products approved
for other indications, including general anesthetics and anti-seizure drugs, are used off-label for various stages of
SE therapy. Additionally, though not indicated, acupuncture, hypothermia, and electroconvulsive therapy are
sometimes used prior to withdrawal of care for patients with SRSE.

In the field of neuroactive steroids focused on modulation of GABAA or NMDA receptors, our principal

competitor is Marinus Pharmaceuticals, Inc., or Marinus, which is developing a reformulated form of

45

Ganaxolone, a known GABAA positive allosteric modulator neuroactive steroid, for potential treatment of drug-
resistant partial complex seizures and fragile X syndrome. In addition, Marinus has announced initiation of the
clinical phase of its intravenous Ganaxolone program in SE.

Many of our potential competitors, alone or with their strategic partners, have substantially greater financial,
technical and human resources than we do, and significantly greater experience in the discovery and development
of product candidates, obtaining FDA and other regulatory approvals of treatments and the commercialization of
those treatments. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even
more resources being concentrated among a smaller number of our competitors. Our commercial opportunity
could be reduced or eliminated if our competitors develop and commercialize products that are safer, more
effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that
we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more
rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market
position before we are able to enter the market.

We may seek to establish collaborations, and, if we are not able to establish them on commercially reasonable
terms, we may have to alter our development and commercialization plans.

Our drug development programs and the potential commercialization of our product candidates will require

substantial additional cash to fund expenses. For some of our product candidates, we may decide to collaborate
with pharmaceutical and biotechnology companies for the development and potential commercialization of those
product candidates in some or all markets.

We face significant competition in seeking appropriate collaborators. Whether we reach a definitive
agreement for a collaboration will depend, among other things, upon our assessment of the collaborator’s
resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator’s
evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood
of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the
subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to
patients, the potential of competing products, the existence of uncertainty with respect to our ownership of
technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge
and industry and market conditions generally. The collaborator may also consider alternative product candidates
or technologies for similar indications that may be available to collaborate on and whether such collaboration
could be more attractive than the one with us for our product candidate. The terms of any collaboration or other
arrangements that we may establish may not be favorable to us.

We may also be restricted under existing license agreements from entering into future agreements on certain

terms with potential collaborators. Collaborations are complex and time-consuming to negotiate and document.
In addition, there have been a significant number of recent business combinations among large pharmaceutical
companies that have resulted in a reduced number of potential future collaborators.

We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are
unable to do so, we may have to curtail the development of the product candidate for which we are seeking to
collaborate, reduce or delay its development program or one or more of our other development programs, delay
its potential commercialization or reduce the scope of any sales or marketing activities, or increase our
expenditures and undertake development or commercialization activities at our own expense. If we elect to
increase our expenditures to fund development or commercialization activities on our own, we may need to
obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have
sufficient funds, we may not be able to further develop our product candidates or bring them to market and
generate product revenue.

In addition, any future collaborations that we enter into may not be successful. The success of our

collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborators

46

generally have significant discretion in determining the efforts and resources that they will apply to these
collaborations. Disagreements between parties to a collaboration arrangement regarding clinical development and
commercialization matters can lead to delays in the development process or commercializing the applicable
product candidate and, in some cases, termination of the collaboration arrangement. These disagreements can be
difficult to resolve if neither of the parties has final decision-making authority. Collaborations with
pharmaceutical or biotechnology companies and other third parties often are terminated or allowed to expire by
the other party. Any such termination or expiration would adversely affect us financially and could harm our
business reputation.

We may not be successful in our efforts to identify or discover additional product candidates or we may
expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on
product candidates or indications that may be more profitable or for which there is a greater likelihood of
success.

The success of our business depends primarily upon our ability to identify, develop and commercialize
products based on our proprietary chemistry platform. Although some of our product candidates are in non-
clinical and clinical development, our research programs may fail to identify other potential product candidates
for clinical development for a number of reasons. Our research methodology may be unsuccessful in identifying
potential product candidates or our potential product candidates may be shown to have harmful side effects or
may not have a positive risk/benefit profile or may have other characteristics that may make the product
candidates unmarketable or unlikely to receive marketing approval.

Because we have limited financial and management resources, we focus on a limited number of research
programs and product candidates and are currently focused on certain CNS disorders. As a result, we may forego
or delay pursuit of opportunities with other product candidates or for other indications that later prove to have
greater commercial potential. Research programs to identify new product candidates require substantial technical,
financial and human resources. We may focus our efforts and resources on potential programs or product
candidates that ultimately prove to be unsuccessful. Our resource allocation decisions may cause us to fail to
capitalize on viable commercial drugs or profitable market opportunities. Our spending on current and future
research and development programs and product candidates for specific indications may not yield any
commercially viable drugs. If we do not accurately evaluate the commercial potential or target market for a
particular product candidate, we may relinquish valuable rights to that product candidate through future
collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous
for us to retain sole development and commercialization rights to such product candidate.

If any of these events occur, we may be forced to abandon our development efforts for a program or

programs, which would have a material adverse effect on our business.

We are subject to healthcare laws and regulations, which could expose us to criminal sanctions, civil
penalties, contractual damages, reputational harm and diminished profits and future earnings.

Although we do not currently have any products on the market, once we begin commercializing our
products, we will be subject to additional healthcare statutory and regulatory requirements and enforcement by
the federal government and the states and foreign governments in which we conduct our business. Healthcare
providers, physicians and others will play a primary role in the recommendation and prescription of our product
candidates, if approved. Our future arrangements with third-party payors will expose us to broadly applicable
fraud and abuse and other healthcare laws and regulations that may constrain the business or financial
arrangements and relationships through which we market, sell and distribute our product candidates, if we obtain
marketing approval. Restrictions under applicable federal and state healthcare laws and regulations include the
following:

‰

The federal anti-kickback statute prohibits, among other things, persons from knowingly and willfully
soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce

47

‰

‰

‰

‰

‰

or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or
service, for which payment may be made under federal healthcare programs such as Medicare and
Medicaid.

The federal False Claims Act imposes criminal and civil penalties, including those from civil whistleblower
or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the
federal government, claims for payment that are false or fraudulent or making a false statement to avoid,
decrease, or conceal an obligation to pay money to the federal government.

The federal Health Insurance Portability and Accountability Act of 1996, as amended by the Health
Information Technology for Economic and Clinical Health Act, imposes criminal and civil liability for
executing a scheme to defraud any healthcare benefit program and also imposes obligations, including
mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of
individually identifiable health information.

The federal false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a
material fact or making any materially false statement in connection with the delivery of or payment for
healthcare benefits, items or services.

The federal transparency requirements, sometimes referred to as the “Sunshine Act,” under the Patient
Protection and Affordable Care Act, require manufacturers of drugs, devices, biologics and medical supplies
that are reimbursable under Medicare, Medicaid, or the Children’s Health Insurance Program to report to the
Department of Health and Human Services information related to physician payments and other transfers of
value and physician ownership and investment interests.

Analogous state laws and regulations, such as state anti-kickback and false claims laws and transparency
laws, may apply to sales or marketing arrangements and claims involving healthcare items or services
reimbursed by non-governmental third-party payors, including private insurers, and some state laws require
pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines
and the relevant compliance guidance promulgated by the federal government in addition to requiring drug
manufacturers to report information related to payments to physicians and other healthcare providers or
marketing expenditures and drug pricing.

Ensuring that our future business arrangements with third parties comply with applicable healthcare laws

and regulations could be costly. It is possible that governmental authorities will conclude that our business
practices do not comply with current or future statutes, regulations or case law involving applicable fraud and
abuse or other healthcare laws and regulations. If our operations, including anticipated activities to be conducted
by our sales team, were found to be in violation of any of these laws or any other governmental regulations that
may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines and
exclusion from government funded healthcare programs, such as Medicare and Medicaid, any of which could
substantially disrupt our operations. If any of the physicians or other providers or entities with whom we expect
to do business is found not to be in compliance with applicable laws, they may be subject to criminal, civil or
administrative sanctions, including exclusions from government funded healthcare programs.

The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of
off-label uses. If we are found to have improperly promoted off-label uses, we may become subject to
significant liability.

The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about
prescription products, if approved. In particular, a product may not be promoted for uses that are not approved by
the FDA or such other regulatory agencies as reflected in the product’s approved labeling. If we are found to
have promoted off-label uses for any product, we may become subject to significant liability. The federal
government has levied large civil and criminal fines against companies for alleged improper promotion and has
enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies

48

enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or
curtailed. If we cannot successfully manage the promotion of our product candidates, if approved, we could
become subject to significant liability, which would materially adversely affect our business and financial
condition.

SAGE-547 will, and our other product candidates may, contain controlled substances, the manufacture, use,
sale, importation, exportation, prescribing and distribution of which are subject to regulation by the DEA.

Before we can commercialize SAGE-547, and potentially our other product candidates, it is expected that
the DEA will need to determine the controlled substance schedule, taking into account the recommendation of
the FDA. This could delay our marketing of a product candidate and could potentially shorten the benefit of any
regulatory exclusivity periods for which we may be eligible. If approved, SAGE-547 is expected to be, and our
other product candidates may be, regulated as “controlled substances” as defined in the Controlled Substances
Act of 1970, or CSA, and the implementing regulations of the DEA, which establish registration, security,
recordkeeping, reporting, storage, distribution, importation, exportation, inventory, quota and other requirements
administered by the DEA. These requirements are applicable to us, to our third-party manufacturers and to
distributors, prescribers and dispensers of our product candidates. The DEA regulates the handling of controlled
substances through a closed chain of distribution. This control extends to the equipment and raw materials used
in their manufacture and packaging, in order to prevent loss and diversion into illicit channels of commerce. A
number of states and foreign countries also independently regulate these drugs as controlled substances.

The DEA regulates controlled substances as Schedule I, II, III, IV or V substances. Schedule I substances by

definition have no established medicinal use, and may not be marketed or sold in the United States. A
pharmaceutical product may be listed as Schedule II, III, IV or V, with Schedule II substances considered to
present the highest risk of abuse and Schedule V substances the lowest relative risk of abuse among such
substances.

We expect that SAGE-547 will, and our other product candidates may, be listed by the DEA as Schedule IV

controlled substances under the CSA. Consequently, the manufacturing, shipping, storing, selling and using of
the products will be subject to an additional regulation. Distribution, prescribing and dispensing of these drugs
are also regulated. Other Schedule IV compounds include sedative hypnotics such as benzodiazepines.

Annual registration is required for any facility that manufactures, distributes, dispenses, imports or exports
any controlled substance. The registration is specific to the particular location, activity and controlled substance
schedule.

Because of their restrictive nature, these laws and regulations could limit commercialization of our product
candidates containing controlled substances. Failure to comply with these laws and regulations could also result
in withdrawal of our DEA registrations, disruption in manufacturing and distribution activities, consent decrees,
criminal and civil penalties and state actions, among other consequences.

Even if approved, reimbursement policies could limit our ability to sell our product candidates.

Market acceptance and sales of our product candidates will depend on reimbursement policies and may be
affected by healthcare reform measures. Government authorities and third-party payors, such as private health
insurers and health maintenance organizations, decide which medications they will pay for and establish
reimbursement levels for those medications. Cost containment is a primary concern in the U.S. healthcare
industry and elsewhere. Government authorities and these third-party payors have attempted to control costs by
limiting coverage and the amount of reimbursement for particular medications. We cannot be sure that
reimbursement will be available for our product candidates and, if reimbursement is available, the level of such
reimbursement. Reimbursement may impact the demand for, or the price of, our product candidates. If

49

reimbursement is not available or is available only at limited levels, we may not be able to successfully
commercialize our product candidates.

In some foreign countries, particularly in Canada and European countries, the pricing of prescription

pharmaceuticals is subject to strict governmental control. In these countries, pricing negotiations with
governmental authorities can take six to twelve months or longer after the receipt of regulatory approval and
product launch. To obtain favorable reimbursement for the indications sought or pricing approval in some
countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product
candidates with other available therapies. If reimbursement for our product candidates is unavailable in any
country in which we seek reimbursement, if it is limited in scope or amount, if it is conditioned upon our
completion of additional clinical trials, if it is conditioned on unreasonable caps or rebates, or if pricing is set at
unsatisfactory levels, our operating results could be materially adversely affected.

Even though we have obtained orphan drug designation for SAGE-547 as a treatment for SE, including
SRSE, there may be limits to the regulatory exclusivity afforded by such designation.

Even though we have obtained orphan drug designation for SAGE-547 for treatment of SE, including SRSE,

from the FDA, there are limitations to exclusivity afforded by such designation. In the United States, the
company that first obtains FDA approval for a designated orphan drug for the specified rare disease or condition
receives orphan drug marketing exclusivity for that drug for a period of seven years. This orphan drug exclusivity
prevents the FDA from approving another application, including a full NDA to market the same drug for the
same orphan indication, except in very limited circumstances, including when the FDA concludes that the later
drug is safer, more effective or makes a major contribution to patient care. For purposes of small molecule drugs,
the FDA defines “same drug” as a drug that contains the same active moiety and is intended for the same use as
the drug in question. To obtain approval for a drug that shares the same active moiety as an already approved
orphan-designated drug, it must be demonstrated to the FDA that the drug is safer or more effective than the
approved orphan designated drug, or that it makes a major contribution to patient care. In addition, a designated
orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication
for which it received orphan designation. In addition, orphan drug exclusive marketing rights in the United States
may be lost if the FDA later determines that the request for designation was materially defective or if the
manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease
or condition.

Our future growth may depend, in part, on our ability to penetrate foreign markets, where we would be subject
to additional regulatory burdens and other risks and uncertainties.

Our future profitability may depend, in part, on our ability to gain approval of, and commercialize, our
product candidates in foreign markets for which we may rely on collaboration with third parties. If we are able to
gain approval for, and commercialize our product candidates in foreign markets, we would be subject to
additional risks and uncertainties, including:

‰

‰

‰

‰

‰

‰

‰

our customers’ ability to obtain reimbursement for our product candidates in foreign markets;

our inability to directly control commercial activities to the extent we are relying on third parties;

the burden of complying with complex and changing foreign regulatory, tax, accounting and legal
requirements;

different medical practices and customs in foreign countries affecting acceptance in the marketplace;

import or export licensing requirements;

longer accounts receivable collection times;

longer lead times for shipping;

50

‰

‰

‰

‰

‰

language barriers for technical training;

reduced protection of intellectual property rights in some foreign countries;

the existence of additional potentially relevant third party intellectual property rights;

foreign currency exchange rate fluctuations; and

the interpretation of contractual provisions governed by foreign laws in the event of a contract dispute.

Foreign sales of our product candidates could also be adversely affected by the imposition of governmental

controls, political and economic instability, trade restrictions and changes in tariffs.

Risks Related to Our Intellectual Property Rights

If we are unable to adequately protect our proprietary technology, or obtain and maintain issued patents that
are sufficient to protect our product candidates, others could compete against us more directly, which would
have a material adverse impact on our business, results of operations, financial condition and prospects.

We strive to protect and enhance the proprietary technologies that we believe are important to our business,

including seeking patents intended to cover our products and compositions, their methods of use and any other
inventions that are important to the development of our business. We may also rely on trade secrets to protect
aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection.

Our success will depend significantly on our ability to obtain and maintain patent and other proprietary
protection for commercially important technology, inventions and know-how related to our business, defend and
enforce our patents, should they issue, preserve the confidentiality of our trade secrets and operate without
infringing the valid and enforceable patents and proprietary rights of third parties. We also rely on know-how,
continuing technological innovation and in-licensing opportunities to develop, strengthen and maintain the
proprietary position of our product candidates. Our owned and licensed patent applications relate to SAGE-547,
GABAA receptor modulators, including genus and species claims to SAGE-217, SAGE-689 and NMDA receptor
modulators, including SAGE-718.

We currently have no issued patents covering any of our lead product candidates, SAGE-547, SAGE-217,

SAGE-689 or SAGE-718. We cannot provide any assurances that any of our pending patent applications will
mature into issued patents and, if they do, that such patents will include, claims with a scope sufficient to protect
our product candidates or otherwise provide any competitive advantage. For example, the patent applications that
may provide coverage for SAGE-547, only cover particular formulations and particular methods of using such
formulations to treat seizure conditions, such as SE. As a result, if a patent issues from such patent applications,
it would not prevent third-party competitors from creating, making and marketing alternative formulations, that
fall outside the scope of our patent claims or practicing alternative methods. There can be no assurance that any
such alternative formulations will not be equally effective as our formulation of SAGE-547. Moreover, other
parties have developed technologies that may be related or competitive to our approach, and may have filed or
may file patent applications and may have received or may receive patents that may overlap or conflict with our
patent applications, either by claiming the same methods or formulations or by claiming subject matter that could
dominate our patent position. Such third-party patent positions may limit or even eliminate our ability to obtain
patent protection for certain inventions.

The patent positions of biotechnology and pharmaceutical companies, including our patent position, involve
complex legal and factual questions, and, therefore, the issuance, scope, validity and enforceability of any patent
claims that we may obtain cannot be predicted with certainty. Patents, if issued, may be challenged, deemed
unenforceable, invalidated, or circumvented. U.S. patents and patent applications may also be subject to
interference proceedings, ex parte reexamination, or inter partes review proceedings, supplemental examination
and challenges in district court. Patents may be subjected to opposition, post-grant review, or comparable

51

proceedings lodged in various foreign, both national and regional, patent offices. These proceedings could result
in either loss of the patent or denial of the patent application or loss or reduction in the scope of one or more of
the claims of the patent or patent application. In addition, such proceedings may be costly. Thus, any patents,
should they issue, that we may own or exclusively license may not provide any protection against competitors.
Furthermore, an adverse decision in an interference proceeding can result in a third party receiving the patent
right sought by us, which in turn could affect our ability to develop, market or otherwise commercialize our
product candidates.

Furthermore, though a patent, if it were to issue, is presumed valid and enforceable, its issuance is not
conclusive as to its validity or its enforceability, and it may not provide us with adequate proprietary protection
or competitive advantages against competitors with similar products. Even if a patent issues, and is held to be
valid and enforceable, competitors may be able to design around our patents, such as using pre-existing or newly
developed technology. Other parties may develop and obtain patent protection for more effective technologies,
designs or methods. We may not be able to prevent the unauthorized disclosure or use of our technical
knowledge or trade secrets by consultants, vendors, former employees and current employees. The laws of some
foreign countries do not protect our proprietary rights to the same extent as the laws of the United States, and we
may encounter significant problems in protecting our proprietary rights in these countries. If these developments
were to occur, they could have a material adverse effect on our sales if any of our product candidates are
approved in those countries.

Our ability to enforce our patent rights depends on our ability to detect infringement. It is difficult to detect
infringers who do not advertise the components that are used in their products. Moreover, it may be difficult or
impossible to obtain evidence of infringement in a competitor’s or potential competitor’s product. Any litigation
to enforce or defend our patent rights, even if we were to prevail, could be costly and time-consuming, and would
divert the attention of our management and key personnel from our business operations. We may not prevail in
any lawsuits that we initiate and the damages or other remedies awarded if we were to prevail may not be
commercially meaningful.

In addition, proceedings to enforce or defend our patents, if and when issued, could put our patents at risk of
being invalidated, held unenforceable, or interpreted narrowly. Such proceedings could also provoke third parties
to assert claims against us, including that some or all of the claims in one or more of our patents are invalid or
otherwise unenforceable. If any of our patents, if and when issued, covering our product candidates are
invalidated or found unenforceable, our financial position and results of operations would be materially and
adversely impacted. In addition, if a court found that valid, enforceable patents held by third parties covered our
product candidates, our financial position and results of operations would also be materially and adversely
impacted.

The degree of future protection for our proprietary rights is uncertain, and we cannot ensure that:

any of our pending patent applications, if issued, will include claims having a scope sufficient to protect our
current product candidates or any other products or product candidates;

any of our pending patent applications will issue as patents at all;

we will be able to successfully commercialize our product candidates, if approved, before our relevant
patents expire;

we were the first to make the inventions covered by each of our pending patent applications and any patents
that may issue in the future;

we were the first to file patent applications for these inventions;

others will not develop similar or alternative technologies that do not infringe any patents that may be issued
to us;

others will not use pre-existing technology to effectively compete against us;

‰

‰

‰

‰

‰

‰

‰

52

‰

‰

‰

‰

any of our patents, if issued, will be found to ultimately be valid and enforceable;

any patents issued to us will provide a basis for an exclusive market for our commercially viable products,
will provide us with any competitive advantages or will not be challenged by third parties;

we will develop additional proprietary technologies or product candidates that are separately patentable; or

that our commercial activities or products will not infringe upon the patents or proprietary rights of others.

We may rely upon unpatented trade secrets, and depend on unpatented know-how and continuing

technological innovation to develop and maintain our competitive position, which we seek to protect, in part, by
confidentiality agreements with our employees and our collaborators and consultants. It is possible that
technology relevant to our business will be independently developed by a person that is not a party to such an
agreement. Furthermore, if the employees and consultants who are parties to these agreements breach or violate
the terms of these agreements, we may not have adequate remedies for any such breach or violation, and we
could lose our trade secrets through such breaches or violations. Further, our trade secrets could otherwise
become known or be independently discovered by our competitors.

We may infringe the intellectual property rights of others, which may prevent or delay our product
development efforts and stop us from commercializing or increase the costs of commercializing our product
candidates, if approved.

Our success will depend in part on our ability to operate without infringing the intellectual property and

proprietary rights of third parties. We cannot assure you that our business, products and methods do not or will
not infringe the patents or other intellectual property rights of third parties.

The pharmaceutical industry is characterized by extensive litigation regarding patents and other intellectual

property rights. Other parties may allege that our product candidates or the use of our technologies infringes
patent claims or other intellectual property rights held by them or that we are employing their proprietary
technology without authorization. As we continue to develop and, if approved, commercialize our current
product candidates and future products, competitors may claim that our technology infringes their intellectual
property rights as part of business strategies designed to impede our successful commercialization. There may be
third-party patents or patent applications with claims to materials, formulations, methods of manufacture or
methods for treatment related to the use or manufacture of our product candidates. Because patent applications
can take many years to issue, third parties may have currently pending patent applications which may later result
in issued patents that our product candidates may infringe, or which such third parties claim are infringed by our
technologies. The outcome of intellectual property litigation is subject to uncertainties that cannot be adequately
quantified in advance. The coverage of patents is subject to interpretation by the courts, and the interpretation is
not always uniform. If we are sued for patent infringement, we would need to demonstrate that our product
candidates, products or methods either do not infringe the patent claims of the relevant patent or that the patent
claims are invalid, and we may not be able to do this. Even if we are successful in these proceedings, we may
incur substantial costs and the time and attention of our management and scientific personnel could be diverted in
pursuing these proceedings, which could have a material adverse effect on us. In addition, we may not have
sufficient resources to bring these actions to a successful conclusion.

Patent and other types of intellectual property litigation can involve complex factual and legal questions,

and their outcome is uncertain. Patent litigation is costly and time-consuming. Any claim relating to intellectual
property infringement that is successfully asserted against us may require us to pay substantial damages,
including treble damages and attorney’s fees if we are found to be willfully infringing another party’s patents, for
past use of the asserted intellectual property and royalties and other consideration going forward if we are forced
to take a license. In addition, if any such claim were successfully asserted against us and we could not obtain
such a license, we may be forced to stop or delay developing, manufacturing, selling or otherwise
commercializing our product candidates. In the case of trademark claims, if we are found to be infringing, we

53

may be required to redesign, or rename, some or all of our product candidates to avoid infringing the intellectual
property rights of third parties, which may not be possible and, even if possible, could be costly and time-
consuming. Even if we are successful in these proceedings, we may incur substantial costs and divert
management time and attention in pursuing these proceedings, which could have a material adverse effect on us.

Any of these risks coming to fruition could have a material adverse effect on our business, results of

operations, financial condition and prospects.

We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual
property.

We enter into confidentiality and intellectual property assignment agreements with our employees,
consultants, outside scientific collaborators, sponsored researchers and other advisors. These agreements
generally provide that inventions conceived by the party in the course of rendering services to us will be our
exclusive property. However, these agreements may not be honored and may not effectively assign intellectual
property rights to us. For example, even if we have a consulting agreement in place with an academic advisor
pursuant to which such academic advisor is required to assign to us any inventions developed in connection with
providing services to us, such academic advisor may not have the right to assign such inventions to us, as it may
conflict with his or her obligations to assign all such intellectual property to his or her employing institution.

Litigation may be necessary to defend against these and other claims challenging inventorship or ownership.

If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable
intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such
an outcome could have a material adverse effect on our business. Even if we are successful in defending against
such claims, litigation could result in substantial costs and be a distraction to management and other employees.

Obtaining and maintaining our patent protection depends on compliance with various procedural, document
submission, fee payment and other requirements imposed by governmental patent agencies, and our patent
protection could be reduced or eliminated for non-compliance with these requirements.

The U.S. Patent and Trademark Office, or U.S. PTO, and various foreign governmental patent agencies
require compliance with a number of procedural, documentary, fee payment and other provisions during the
patent process. There are situations in which noncompliance can result in abandonment or lapse of a patent or
patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an
event, competitors might be able to enter the market earlier than would otherwise have been the case.

We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could
be expensive, time-consuming and unsuccessful.

Even if the patent applications we own or license are issued, competitors may infringe these patents. To

counter infringement or unauthorized use, we may be required to file infringement claims, which can be
expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of
ours or our licensors is not valid, is unenforceable and/or is not infringed, or may refuse to stop the other party
from using the technology at issue on the grounds that our patents do not cover the technology in question. An
adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being
invalidated or interpreted narrowly and could put our patent applications at risk of not issuing.

Interference proceedings provoked by third parties or brought by us may be necessary to determine the
priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable
outcome could require us to cease using the related technology or to attempt to license rights to it from the
prevailing party. Our business could be harmed if the prevailing party does not offer us a license on
commercially reasonable terms. Our defense of litigation or interference proceedings may fail and, even if

54

successful, may result in substantial costs and distract our management and other employees. We may not be able
to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in
countries where the laws may not protect those rights as fully as in the United States.

Furthermore, because of the substantial amount of discovery required in connection with intellectual
property litigation, there is a risk that some of our confidential information could be compromised by disclosure
during this type of litigation. There could also be public announcements of the results of hearings, motions or
other interim proceedings or developments. If securities analysts or investors perceive these results to be
negative, it could have a material adverse effect on the price of our common stock.

Issued patents covering our product candidates could be found invalid or unenforceable if challenged in
court.

If we or one of our licensing partners initiated legal proceedings against a third party to enforce a patent, if

and when issued, covering one of our product candidates, the defendant could counterclaim that the patent
covering our product candidate is invalid and/or unenforceable. In patent litigation in the United States,
defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity
challenge include alleged failures to meet any of several statutory requirements, including lack of novelty,
obviousness or non-enablement. Grounds for unenforceability assertions include allegations that someone
connected with prosecution of the patent withheld relevant information from the U.S. PTO, or made a misleading
statement, during prosecution. Third parties may also raise similar claims before administrative bodies in the
United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post
grant review, ex parte reexamination, or inter partes review and equivalent proceedings in foreign jurisdictions,
e.g., opposition proceedings. Such proceedings could result in revocation or amendment of our patents in such a
way that they no longer cover our product candidates or competitive products. The outcome following legal
assertions of invalidity and unenforceability is unpredictable. With respect to validity, for example, we cannot be
certain that there is no invalidating prior art, of which we and the patent examiner were unaware during
prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would
lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent
protection would have a material adverse impact on our business.

We will not seek to protect our intellectual property rights in all jurisdictions throughout the world and we
may not be able to adequately enforce our intellectual property rights even in the jurisdictions where we seek
protection.

Filing, prosecuting and defending patents on product candidates in all countries and jurisdictions throughout

the world would be prohibitively expensive, and our intellectual property rights in some countries outside the
United States could be less extensive than those in the United States, assuming that rights are obtained in the
United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the
same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third
parties from practicing our inventions in all countries outside the United States, or from selling or importing
products made using our inventions in and into the United States or other jurisdictions. The statutory deadlines
for pursuing patent protection in individual foreign jurisdictions are based on the priority date of each of our
patent applications.

Competitors may use our technologies in jurisdictions where we do not pursue and obtain patent protection
to develop their own products and further, may export otherwise infringing products to territories where we have
patent protection, but enforcement is not as strong as that in the United States. These products may compete with
our products and our patents or other intellectual property rights may not be effective or sufficient to prevent
them from competing. Even if we pursue and obtain issued patents in particular jurisdictions, our patent claims or
other intellectual property rights may not be effective or sufficient to prevent third parties from so competing.

55

The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws

of the United States. Many companies have encountered significant problems in protecting and defending
intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, particularly
developing countries, do not favor the enforcement of patents and other intellectual property protection,
especially those relating to biotechnology. For example, an April 2014 report from the Office of the United
States Trade Representative identified a number of countries, including India and China, where challenges to the
procurement and enforcement of patent rights have been reported. Several countries, including India and China,
have been listed in the report every year since 1989. This could make it difficult for us to stop the infringement of
our patents, if obtained, or the misappropriation of our other intellectual property rights. For example, many
foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties.
In addition, many countries limit the enforceability of patents against third parties, including government
agencies or government contractors. In these countries, patents may provide limited or no benefit. Patent
protection must ultimately be sought on a country-by-country basis, which is an expensive and time-consuming
process with uncertain outcomes. Accordingly, we may choose not to seek patent protection in certain countries,
and we will not have the benefit of patent protection in such countries.

Furthermore, proceedings to enforce our patent rights in foreign jurisdictions could result in substantial
costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being
invalidated or interpreted narrowly, could put our patent applications at risk of not issuing and could provoke
third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or
other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our
intellectual property rights around the world may be inadequate to obtain a significant commercial advantage
from the intellectual property that we develop or license.

We are dependent on licensed intellectual property. If we were to lose our rights to licensed intellectual
property, we may not be able to continue developing or commercializing our product candidates, if approved.
If we breach any of the agreements under which we license the use, development and commercialization rights
to our product candidates or technology from third parties or, in certain cases, we fail to meet certain
development deadlines, we could lose license rights that are important to our business.

We are a party to a number of license agreements under which we are granted rights to intellectual property
that are important to our business and we expect that we may need to enter into additional license agreements in
the future. Our existing license agreements impose, and we expect that future license agreements will impose on
us, various development, regulatory and/or commercial diligence obligations, payment of milestones and/or
royalties and other obligations. If we fail to comply with our obligations under these agreements, or we are
subject to a bankruptcy, the licensor may have the right to terminate the license, in which event we would not be
able to market products covered by the license. Our business could suffer, for example, if any current or future
licenses terminate, if the licensors fail to abide by the terms of the license, if the licensed patents or other rights
are found to be invalid or unenforceable, or if we are unable to enter into necessary licenses on acceptable terms.

As we have done previously, we may need to obtain licenses from third parties to advance our research or

allow commercialization of our product candidates, and we cannot provide any assurances that third-party
patents do not exist that might be enforced against our current product candidates or future products in the
absence of such a license. We may fail to obtain any of these licenses on commercially reasonable terms, if at all.
Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the
same technologies licensed to us. In that event, we may be required to expend significant time and resources to
develop or license replacement technology. If we are unable to do so, we may be unable to develop or
commercialize the affected product candidates, which could materially harm our business and the third parties
owning such intellectual property rights could seek either an injunction prohibiting our sales, or, with respect to
our sales, an obligation on our part to pay royalties and/or other forms of compensation.

56

Licensing of intellectual property is of critical importance to our business and involves complex legal,
business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property
subject to a license agreement, including:

‰

‰

‰

‰

‰

the scope of rights granted under the license agreement and other interpretation-related issues;

whether and the extent to which our technology and processes infringe on intellectual property of the
licensor that is not subject to the licensing agreement;

our right to sublicense patent and other rights to third parties under collaborative development relationships;

our diligence obligations with respect to the use of the licensed technology in relation to our development
and commercialization of our product candidates, and what activities satisfy those diligence obligations; and

the ownership of inventions and know-how resulting from the joint creation or use of intellectual property
by our licensors and us and our partners.

If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our

current licensing arrangements on acceptable terms, we may be unable to successfully develop and
commercialize the affected product candidates.

We have entered into several licenses to support our various programs. We completed an exclusive license

agreement with Washington University, or WU, under certain patent families that comprise a variety of small
molecule allosteric modulators of GABAA receptors and for which we have the worldwide right to develop and
commercialize. A patent family that discloses and claims SAGE-689 is licensed to us under this agreement. We
are obligated to pay WU certain clinical/regulatory milestones and single-digit royalties on products developed
from this technology. Termination of our license agreement with WU would have a material adverse impact on
our ability to develop and commercialize SAGE-689.

We have also entered into an exclusive license agreement with CyDex Pharmaceuticals, Inc., or CyDex, a
wholly owned subsidiary of Ligand Pharmaceuticals, Inc., to use its Captisol technology to develop SAGE-547
and SAGE-689 for the field of use, which includes all fields for the treatment, prevention or diagnosis of any
disease or symptom in humans or animals other than (i) the ocular treatment of any disease or condition with a
formulation, including a hormone; (ii) topical ocular treatment of inflammatory conditions; (iii) treatment and
prophylaxis of fungal infections in humans; and (iv) any ocular treatment for retinal degeneration. We are
obligated to pay CyDex certain clinical/regulatory milestones and, if approved and marketed, single-digit
royalties on SAGE-547 and SAGE-689. In addition, we have entered into a supply agreement with CyDex,
pursuant to which CyDex supplies us with Captisol to formulate both products. Absent an alternative agreement
by the parties, our rights under our exclusive license agreement terminate in the event that the supply agreement
terminates. Currently, our SAGE-547 and SAGE-689 product candidates are formulated in Captisol. Termination
of our license agreement with CyDex would have a material adverse impact on our ability to develop and
commercialize SAGE-547 and SAGE-689 in their current formulations.

We also entered into a non-exclusive license with The Regents of the University of California, or the
Regents. Pursuant to this agreement the Regents granted us a non-exclusive, non-transferable license under all
personal property rights of the Regents covering the tangible personal property in an IND application package
owned by the Regents, or the Data, and a specified quantity of cGMP grade allopregnanolone, or the Material, to
(i) use the Data for reference or incorporation in an IND for use of the Material as a treatment of SE, essential
tremor and/or postpartum depression and (ii) use the Material or modifications of the Material to develop a
pharmaceutical formulation for clinical trials for SE, essential tremor and/or postpartum depression. This
agreement requires us to pay milestone payments in connection with the first derived product, which would
include SAGE-547, that meets the relevant milestones and we must also pay single-digit royalties for each
derived product for a period of 15 years following the first commercial sale of such derived product. Termination
of our license agreement with the Regents would have a material adverse impact on our ability to develop and
commercialize derived products, which would include SAGE-547.

57

In June 2015, we entered into an exclusive license agreement with the Regents under which we were
granted an exclusive license to certain patent rights related to the use of allopregnanolone to treat various
diseases. In exchange for such license, we paid an upfront payment and will pay annual maintenance fees until
the calendar year following the first sale, if any, of a licensed product. We are obligated to make milestone
payments following the achievement of specified regulatory and sales milestones. Following the first sale, if any,
of a licensed product, we are obligated to pay royalties at a low single digit percentage of net sales, if any, of
licensed products, subject to specified minimum annual royalty amounts.

We may enter into additional licenses to third-party intellectual property that are necessary or useful to our

business. Our current licenses and any future licenses that we may enter into impose various royalty payment,
milestone, and other obligations on us. For example, as is the case for the Washington University license, the
licensor may retain control over patent prosecution and maintenance under a license agreement, in which case,
we may not be able to adequately influence patent prosecution or prevent inadvertent lapses of coverage due to
failure to pay maintenance fees. If we fail to comply with any of our obligations under a current or future license
agreement, the licensor may allege that we have breached our license agreement, and may accordingly seek to
terminate our license. In addition, future licensors may decide to terminate their licenses with us at will.
Termination of any of our current or future licenses could result in our loss of the right to use the licensed
intellectual property, which could materially adversely affect our ability to develop and commercialize a product
candidate or product, if approved, as well as harm our competitive business position and our business prospects.

In addition, if our licensors fail to abide by the terms of the license, if the licensors fail to prevent

infringement by third parties, if the licensed patents or other rights are found to be invalid or unenforceable, or if
we are unable to enter into necessary licenses on acceptable terms, our business could suffer.

Some intellectual property which we have licensed may have been discovered through government funded
programs and thus may be subject to federal regulations such as “march-in” rights, certain reporting
requirements, and a preference for U.S. industry. Compliance with such regulations may limit our exclusive
rights, subject us to expenditure of resources with respect to reporting requirements, and limit our ability to
contract with non-U.S. manufacturers.

Some of the intellectual property rights we have licensed may have been generated through the use of U.S.

government funding and may therefore be subject to certain federal regulations. For example, some of the
intellectual property rights licensed to us under the license agreements with WU and the Regents may have been
generated using U.S. government funds. As a result, the U.S. government may have certain rights to intellectual
property embodied in our current or future product candidates pursuant to the Bayh-Dole Act of 1980, or Bayh-
Dole Act. These U.S. government rights in certain inventions developed under a government-funded program
include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental
purpose. In addition, the U.S. government has the right to require us to grant exclusive, partially exclusive, or
non-exclusive licenses to any of these inventions to a third party if it determines that: (i) adequate steps have not
been taken to commercialize the invention; (ii) government action is necessary to meet public health or safety
needs; or (iii) government action is necessary to meet requirements for public use under federal regulations (also
referred to as “march-in rights”). The U.S. government also has the right to take title to these inventions if we
fail, or the applicable licensor fails, to disclose the invention to the government and fail to file an application to
register the intellectual property within specified time limits. In addition, the U.S. government may acquire title
to these inventions in any country in which a patent application is not filed within specified time limits.
Intellectual property generated under a government funded program is also subject to certain reporting
requirements, compliance with which may require us, or the applicable licensor, to expend substantial resources.
In addition, the U.S. government requires that any products embodying the subject invention or produced through
the use of the subject invention be manufactured substantially in the United States. The manufacturing preference
requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful
efforts have been made to grant licenses on similar terms to potential licensees that would be likely to
manufacture substantially in the United States or that under the circumstances domestic manufacture is not

58

commercially feasible. This preference for U.S. manufacturers may limit our ability to contract with non-U.S.
product manufacturers for products covered by such intellectual property.

If we enter into future arrangements involving government funding, and we discover compounds or drug

candidates as a result of such funding, intellectual property rights to such discoveries may be subject to the
applicable provisions of the Bayh-Dole Act.

If we do not obtain additional protection under the Hatch-Waxman Amendments and similar foreign
legislation by extending the patent terms and obtaining data exclusivity for our product candidates, our
business may be materially harmed.

Depending upon the timing, duration and specifics of FDA marketing approval of our product candidates,
one or more of the future U.S. patents we own or license may be eligible for limited patent term restoration under
the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman
Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as
compensation for patent term lost during product development and the FDA regulatory review process. However,
we may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing
to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. For
example, we may not be granted an extension if the active ingredient of SAGE-547, allopregnanolone, is used in
another drug company’s product candidate and that product candidate is the first to obtain FDA approval.
Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If
we are unable to obtain patent term extension or restoration or the term of any such extension is less than we
request, and we do not have any other exclusivity, our competitors may obtain approval of competing products
following our patent expiration, and our ability to generate revenues could be materially adversely affected.

Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to
protect our products.

As is the case with other biotechnology companies, our success is heavily dependent on intellectual
property, particularly patents. Obtaining and enforcing patents in the biotechnology industry involve both
technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. In addition,
the United States has recently enacted and is currently implementing wide-ranging patent reform legislation: the
Leahy-Smith America Invents Act, referred to as the America Invents Act. The America Invents Act includes a
number of significant changes to U.S. patent law. These include provisions that affect the way patent applications
will be prosecuted and may also affect patent litigation. It is not yet clear what, if any, impact the America
Invents Act will have on the operation of our business. However, the America Invents Act and its implementation
could increase the uncertainties and costs surrounding the prosecution of our patent applications and the
enforcement or defense of any patents that may issue from our patent applications, all of which could have a
material adverse effect on our business and financial condition.

In addition, recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in
certain circumstances and weakened the rights of patent owners in certain situations. The full impact of these
decisions is not yet known. For example, on March 20, 2012 in Mayo Collaborative Services, DBA Mayo
Medical Laboratories, et al. v. Prometheus Laboratories, Inc., the Court held that several claims drawn to
measuring drug metabolite levels from patient samples and correlating them to drug doses were not patentable
subject matter. The decision appears to impact diagnostics patents that merely apply a law of nature via a series
of routine steps and it has created uncertainty around the ability to obtain patent protection for certain inventions.
Additionally, on June 13, 2013 in Association for Molecular Pathology v. Myriad Genetics, Inc., the Court held
that claims to isolated genomic DNA are not patentable, but claims to complementary DNA molecules are patent
eligible because they are not a natural product. The effect of the decision on patents for other isolated natural
products is uncertain. On June 19, 2014 in Alice Corporation Pty. Ltd. v. CLS Bank International, et al., a case
involving patent claims directed to a method for mitigating settlement risk, the Court held that the patent

59

eligibility of claims directed to abstract ideas, products of nature, and laws of nature should be determined using
the same framework set forth in Prometheus. The U.S. PTO recently issued a set of guidelines setting forth
procedures for determining subject matter eligibility of claims directed to abstract ideas, products of nature, and
laws of nature in line with the Prometheus, Myriad, and Alice decisions. The guidance does not limit the
application of Myriad to DNA but, rather, applies the decision to other natural products.

In addition to increasing uncertainty with regard to our ability to obtain future patents, this combination of
events has created uncertainty with respect to the value of patents, once obtained. Depending on these and other
decisions by the U.S. Congress, the federal courts and the U.S. PTO, the laws and regulations governing patents
could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce any patents
that may issue in the future.

We may be subject to damages resulting from claims that we or our employees have wrongfully used or
disclosed alleged confidential information or trade secrets of their former employers.

Most of our employees have been previously employed at other biotechnology or pharmaceutical

companies, including our competitors or potential competitors. We also engage advisors and consultants who are
concurrently employed at universities or who perform services for other entities.

Although we are not aware of any claims currently pending against us, we may be subject to claims that we
or our employees, advisors or consultants have inadvertently or otherwise used or disclosed intellectual property,
including trade secrets or other proprietary information, of a former employer or other third party. We have and
may in the future also be subject to claims that an employee, advisor or consultant performed work for us that
conflicts with that person’s obligations to a third party, such as an employer, and thus, that the third party has an
ownership interest in the intellectual property arising out of work performed for us. Litigation may be necessary
to defend against these claims. Even if we are successful in defending against these claims, litigation could result
in substantial costs and be a distraction to management. If we fail in defending such claims, in addition to paying
monetary claims, we may lose valuable intellectual property rights or personnel. A loss of key personnel or their
work product could hamper or prevent our ability to develop and commercialize our product candidates, which
would materially adversely affect our efforts and results.

Numerous factors may limit any potential competitive advantage provided by our intellectual property rights.

The degree of future protection afforded by our intellectual property rights is uncertain because intellectual
property rights have limitations, and may not adequately protect our business, provide a barrier to entry against
our competitors or potential competitors, or permit us to maintain our competitive advantage. Moreover, if a third
party has intellectual property rights that cover the practice of our technology, we may not be able to fully
exercise or extract value from our intellectual property rights. The following examples are illustrative:

‰

‰

‰

‰

‰

‰

others may be able to develop and/or practice technology that is similar to our technology or aspects of our
technology but that is not covered by the claims of patents, should such patents issue from our patent
applications;

we might not have been the first to make the inventions covered by a pending patent application that we
own;

we might not have been the first to file patent applications covering an invention;

others may independently develop similar or alternative technologies without infringing our intellectual
property rights;

pending patent applications that we own or license may not lead to issued patents;

patents, if issued, that we own or license may not provide us with any competitive advantages, or may be
held invalid or unenforceable, as a result of legal challenges by our competitors;

60

‰

‰

‰

‰

‰

third parties may compete with us in jurisdictions where we do not pursue and obtain patent protection;

we may not be able to obtain and/or maintain necessary or useful licenses on reasonable terms or at all;

third parties may assert an ownership interest in our intellectual property and, if successful, such disputes
may preclude us from exercising exclusive rights over that intellectual property;

we may not develop or in-license additional proprietary technologies that are patentable; and

the patents of others may have an adverse effect on our business.

Should any of these events occur, they could significantly harm our business and results of operations.

General Company-Related Risks

As our product candidates reach later stage clinical development, we will need to develop and expand our
company, and we may encounter difficulties in managing this development and expansion, which could
disrupt our operations.

As our product candidates reach later stage clinical development and, as we plan for a potential commercial
launch of products, if approved, we expect to increase our number of employees and the scope of our operations.
To successfully execute our activities, and to manage our anticipated expansion, we must continue to implement
and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and
train additional qualified personnel. In addition, our management may need to divert a disproportionate amount
of its attention away from its day-to-day activities, and devote a substantial amount of time to managing these
expansion activities. Due to our limited resources, we may not be able to effectively manage the expansion of our
operations or recruit and train additional qualified personnel. This may result in weaknesses in our infrastructure,
give rise to operational mistakes or delays, loss of business opportunities, loss of employees and reduced
productivity among remaining employees. The physical expansion of our operations may lead to significant
costs, and may divert financial resources from other projects, such as the development of our product candidates.
If our management is unable to effectively manage our expected expansion, our expenses may increase more than
expected, and our ability to successfully develop and gain regulatory approval of our product candidates and
generate or increase our revenue, if such product candidates are approved, could be reduced and we may not be
able to implement our business strategy. Our future financial performance and our ability to commercialize our
product candidates, if approved, and compete effectively will depend, in part, on our ability to effectively
manage the future expansion of our company.

Our future success depends on our ability to retain our President and Chief Executive Officer and to attract,
retain and motivate qualified personnel.

We are highly dependent on Dr. Jeffrey M. Jonas, our Chief Executive Officer, President, and Director. We
have entered into an employment agreement with Dr. Jonas, but he may terminate his employment with us at any
time. Although we do not have any reason to believe that we will lose the services of Dr. Jonas in the foreseeable
future, the loss of his services might impede the achievement of our research, development and
commercialization objectives. We also do not have any key-man life insurance on Dr. Jonas. We rely on
consultants and advisors, including scientific, clinical and regulatory advisors, to assist us in formulating and
implementing our development and commercialization strategy. Our consultants and advisors may be employed
by employers other than us and may have commitments under consulting or advisory contracts with other entities
that may limit their availability to us and may not be subject to our standard non-compete agreements. Recruiting
and retaining qualified personnel will also be critical to our success. We may not be able to attract and retain
these personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology
companies for similar personnel. We also experience competition for the hiring of scientific personnel from
universities and research institutions. Failure to succeed in clinical trials may make it more challenging to recruit
and retain qualified scientific personnel.

61

Our employees may engage in misconduct or other improper activities, including violating applicable
regulatory standards and requirements or engaging in insider trading, which could significantly harm our
business.

We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include

intentional failures to: comply with the regulations of the FDA and applicable non-U.S. regulators; provide
accurate information to the FDA and applicable non-U.S. regulators; comply with healthcare fraud and abuse and
anti-kick-back laws and regulations, in the United States and abroad; comply with anti-bribery and anti-
corruption laws and regulations in the United States and abroad; report financial information or data accurately;
or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the
healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct,
kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range
of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other
business arrangements. Employee misconduct could also involve the improper use of, including trading on,
information obtained in the course of clinical trials or other material information, which could result in regulatory
sanctions and serious harm to our reputation. We have adopted a code of conduct, but it is not always possible to
identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may be
ineffective in controlling unknown or unmanaged risks or losses or in protecting us from governmental
investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If
any such actions are instituted against us, and we are not successful in defending ourselves or asserting our
rights, those actions could have a significant impact on our business, including the imposition of significant fines
or other sanctions.

We face potential product liability exposure, and, if claims are brought against us, we may incur substantial
liability.

The use of our product candidates in clinical trials and the sale of our products, if approved, expose us to the

risk of product liability claims. Product liability claims might be brought against us by patients, healthcare
providers or others selling or otherwise coming into contact with our product candidates. For example, we may
be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during clinical
trials, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in
manufacturing, defects in design, a failure to warn of dangers inherent in the product, including as a result of
interactions with alcohol or other drugs, negligence, strict liability and a breach of warranties. Claims could also
be asserted under state consumer protection acts. If we become subject to product liability claims and cannot
successfully defend ourselves against them, we could incur substantial liabilities. In addition, regardless of merit
or eventual outcome, product liability claims may result in, among other things:

‰

‰

‰

‰

‰

‰

‰

‰

‰

withdrawal of patients from our clinical trials, or difficulty in enrolling clinical trials;

substantial monetary awards to patients or other claimants;

decreased demand for our products following marketing approval, if obtained;

damage to our reputation and exposure to adverse publicity;

increased FDA warnings on product labels;

litigation costs;

distraction of management’s attention from our primary business;

loss of revenue; and

the inability to successfully gain approval and commercialize our product candidates or any future product
candidates, if approved.

We maintain product liability insurance coverage for our clinical trials with a $10 million annual aggregate

coverage limit. Nevertheless, our insurance coverage may be insufficient to reimburse us for any expenses or

62

losses we may suffer. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable
cost or in sufficient amounts to protect us against losses, including if insurance coverage becomes increasingly
expensive. If and when we obtain marketing approval for our product candidates, we intend to expand our
insurance coverage to include the sale of commercial products; however, we may not be able to obtain this
product liability insurance on commercially reasonable terms. Large judgments have been awarded in class
action lawsuits based on drugs that had unanticipated side effects. The cost of any product liability litigation or
other proceedings, even if resolved in our favor, could be substantial, particularly in light of the size of our
business and financial resources. A product liability claim or series of claims brought against us could cause our
stock price to decline and, if we are unsuccessful in defending such a claim or claims and the resulting judgments
exceed our insurance coverage, our financial condition, business and prospects could be materially adversely
affected.

We will continue to incur significant costs as a result of operating as a public company, and our management
team will be required to devote substantial time to compliance initiatives.

As a public company, we incur significant legal, accounting and other expenses that we did not incur as a

private company. In addition, the Sarbanes-Oxley Act of 2002 and rules subsequently implemented by the
Securities and Exchange Commission and The NASDAQ Stock Market have imposed various requirements on
public companies, including establishment and maintenance of effective disclosure and financial controls and
corporate governance practices. Our management and other personnel devote a substantial amount of time to
these compliance initiatives. Moreover, these rules and regulations cause us to incur significant legal and
financial compliance costs, and make some activities more time-consuming and costly.

Pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, or Section 404, we are required to furnish a
report by our management on our internal control over financial reporting, including an attestation report on
internal control over financial reporting issued by our independent registered public accounting firm. To achieve
compliance with Section 404 within the prescribed period, we conduct a process each year to document and
evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we
dedicate internal resources, engage outside consultants and adopt a detailed work plan to assess and document the
adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate,
validate through testing that controls are functioning as documented and implement a continuous reporting and
improvement process for internal control over financial reporting. Despite our efforts, there is a risk that neither
we nor our independent registered public accounting firm will be able to conclude that our internal control over
financial reporting is effective as required by Section 404. This could result in an adverse reaction in the financial
markets due to a loss of confidence in the reliability of our consolidated financial statements.

As we continue to grow, we will need to hire additional qualified accounting and financial personnel with
appropriate public company experience.

As we continue to grow our organization, we will need to establish and maintain effective disclosure and

financial controls, and make changes in our corporate governance practices. We will need to hire additional
accounting and financial personnel with appropriate public company experience and technical accounting
knowledge, and it may be difficult to recruit and maintain such personnel. Even if we are able to hire appropriate
personnel, our existing operating expenses and operations will be impacted by the direct costs of their
employment and the indirect consequences related to the diversion of management resources from product
development efforts.

Our ability to use our net operating loss carryforwards and certain tax credit carryforwards may be subject to
limitation.

As of December 31, 2015, we had federal and state net operating loss carryforwards of $131.5 million and
$130.7 million, respectively, which begin to expire in 2031. As of December 31, 2015, we also had federal and

63

state research and development tax credit carryforwards of $1.6 million and $0.7 million, respectively, which
begin to expire in 2031 and 2027, respectively. As of December 31, 2015, we had federal orphan drug tax credit
carryforwards of $16.4 million, which begin to expire in 2034. Under Section 382 of the Internal Revenue Code
of 1986, as amended, or the Code, changes in our ownership may limit the amount of our net operating loss
carryforwards and tax credit carryforwards that could be utilized annually to offset our future taxable income, if
any. This limitation would generally apply in the event of a cumulative change in ownership of our company of
more than 50% within a three-year period. Any such limitation may significantly reduce our ability to utilize our
net operating loss carryforwards and research and development tax credit carryforwards before they expire. The
completion of follow-on public offerings in April 2015 and January 2016 and our initial public offering, or IPO,
together with private placements and other transactions that have occurred since our inception, may have
triggered such an ownership change pursuant to Section 382. Any such limitation, whether as the result of our
IPO, follow-on offerings, prior private placements, sales of our common stock by our existing stockholders or
additional sales of our common stock by us, could have a material adverse effect on our results of operations in
future years. We have not completed a study to assess whether an ownership change for purposes of Section 382
has occurred, or whether there have been multiple ownership changes since our inception, due to the significant
costs and complexities associated with such study.

Unfavorable global economic conditions could adversely affect our business, financial condition or results of
operations.

Our results of operations could be adversely affected by general conditions in the global economy and in the

global financial markets. A severe or prolonged economic downturn could result in a variety of risks to our
business, including, weakened demand for our product candidates and our ability to raise additional capital when
needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers, possibly
resulting in supply disruption, or cause our customers to delay making payments for our products if we receive
marketing approval. Any of the foregoing could harm our business and we cannot anticipate all of the ways in
which the current economic climate and financial market conditions could adversely impact our business.

We or the third parties upon whom we depend may be adversely affected by natural disasters and our business
continuity and disaster recovery plans may not adequately protect us from a serious disaster.

Natural disasters could severely disrupt our operations, and have a material adverse effect on our business,

results of operations, financial condition and prospects. If a natural disaster, power outage or other event
occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical
infrastructure, such as the manufacturing facilities of our third-party contract manufacturers, or that otherwise
disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a
substantial period of time. The disaster recovery and business continuity plans we have in place may prove
inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the
limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect
on our business.

Our internal computer systems, or those of our third-party CROs or other contractors or consultants, may fail
or suffer security breaches, which could result in a material disruption of our development programs.

Despite the implementation of security measures, our internal computer systems and those of our third-party

CROs and other contractors and consultants are vulnerable to damage from computer viruses, unauthorized
access, natural disasters, terrorism, war and telecommunication and electrical failures. While we have not
experienced any such system failure, accident, or security breach to date, if such an event were to occur and
cause interruptions in our operations, it could result in a material disruption of our programs. For example, the
loss of clinical trial data for our product candidates could result in delays in our regulatory approval efforts and
significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security
breach results in a loss of or damage to our data or applications or other data or applications relating to our

64

technology or product candidates, or inappropriate disclosure of confidential or proprietary information, we
could incur liabilities and the further development of our product candidates could be delayed.

We may acquire businesses or products, or form strategic alliances, in the future, and we may not realize the
benefits of such acquisitions.

We may acquire additional businesses or products, form strategic alliances or create joint ventures with third

parties that we believe will complement or augment our existing business. If we acquire businesses with
promising markets or technologies, we may not be able to realize the benefit of acquiring such businesses if we
are unable to successfully integrate them with our existing operations and company culture. We may encounter
numerous difficulties in developing, manufacturing and marketing any new products resulting from a strategic
alliance or acquisition that delay or prevent us from realizing their expected benefits or enhancing our business.
We cannot assure you that, following any such acquisition, we will achieve the expected synergies to justify the
transaction.

Risks Related to Our Financial Position and Need for Capital

We are a biopharmaceutical company with a limited operating history, and have not generated any revenue
from product sales. We have incurred significant operating losses since our inception, and anticipate that we
will incur continued losses for the foreseeable future.

We are a biopharmaceutical company with a limited operating history on which investors can base an
investment decision. Biopharmaceutical product development is a highly speculative undertaking and involves a
substantial degree of risk. We were incorporated in April 2010. Our operations to date have been limited
primarily to organizing and staffing our company, raising capital and conducting research and development
activities for our product candidates. We have never generated any revenue from product sales. We have not
obtained regulatory approvals for any of our product candidates.

We have funded our operations to date through proceeds from sales of common stock, redeemable

convertible preferred stock and, to a lesser extent, the issuance of convertible notes. On July 23, 2014, we
completed the sale of 5,750,000 shares of our common stock in our IPO, at a price to the public of $18.00 per
share, resulting in net proceeds of $94.0 million after deducting underwriting discounts and commissions and
offering expenses paid by us. On April 20, 2015, we completed the sale of 2,628,571 shares of our common stock
in a public offering, at a price to the public of $52.50 per share, resulting in net proceeds of $129.1 million after
deducting underwriting discounts and commissions and offering expenses paid by us. On January 12, 2016, we
completed the sale of 3,157,894 shares of our common stock in a public offering, at a price to the public of
$47.50 per share, resulting in net proceeds of $140.4 million after deducting underwriting discounts and
commissions and estimated offering expenses paid by us. From our inception through December 31, 2015, we
had received net proceeds of $313.7 million from such transactions. As of December 31, 2015, our cash and cash
equivalents were $186.8 million. We have incurred significant net losses in each year since our inception,
including net losses of $94.5 million, $33.8 million, and $18.3 million for the years ended December 31, 2015,
2014, and 2013 respectively. Substantially all of our operating losses have resulted from costs incurred in
connection with our research and development programs and from general and administrative costs associated
with our operations. We expect to incur increasing levels of operating losses over the next several years and for
the foreseeable future. Our prior losses, combined with expected future losses, have had, and will continue to
have, an adverse effect on our stockholders’ deficit and working capital. We expect our research and
development expenses to significantly increase in connection with our clinical trials of our product candidates. In
addition, if we obtain marketing approval for our product candidates, we will incur significant sales, marketing
and outsourced-manufacturing expenses. As a public company, we incur additional costs associated with
operating as a public company. As a result, we expect to continue to incur significant and increasing operating
losses for the foreseeable future. Because of the numerous risks and uncertainties associated with developing
pharmaceutical products, we are unable to predict the extent of any future losses or when we will become

65

profitable, if at all. Even if we do become profitable, we may not be able to sustain or increase our profitability
on a quarterly or annual basis.

Our ability to become profitable depends upon our ability to generate revenue. To date, we have not

generated any revenue from our product candidates, and we do not know when, or if, we will generate any
revenue. We do not expect to generate significant revenue unless and until we obtain marketing approval of, and
begin to sell a product. Our ability to generate revenue depends on a number of factors, including, but not limited
to, our ability to:

‰

‰

‰

initiate and successfully complete all efficacy and safety clinical trials and non-clinical studies required to
file for, and obtain, U.S. and foreign marketing approval for our product candidates

commercialize our product candidates, if approved, by developing a sales force or entering into
collaborations with third parties; and

achieve market acceptance of our product candidates in the medical community and with third-party payors.

Absent our entering into a collaboration or partnership agreement, we expect to incur significant sales and

marketing costs as we prepare to commercialize our product candidates, if and when approved. Even if we
successfully complete clinical development of our product candidates, and our product candidates are approved
for commercial sale, and despite expending these costs, our product candidates may not be commercially
successful. We may not achieve profitability soon after generating product sales, if ever. If we are unable to
generate product revenue, we will not become profitable, and may be unable to continue operations without
continued funding.

We will need to raise additional funding, which may not be available on acceptable terms, or at all. Failure to
obtain this necessary capital when needed may force us to delay, limit or terminate our product development
efforts or other operations.

We are currently advancing our product candidates through non-clinical and clinical development.
Developing small molecule products is expensive, and we expect our research and development expenses to
increase substantially in connection with our ongoing activities, particularly as we continue to advance our
product candidate in clinical trials. Depending on the status of regulatory approval or, if approved,
commercialization of our product candidates, as well as the progress we make in selling our products, if
approved, we may also require additional capital to fund operating needs even after approval. We may also need
to raise additional funds if we choose to pursue additional indications and/or geographies for our product
candidates, identify new potential opportunities or otherwise expand our activities more rapidly than we
presently anticipate.

As of December 31, 2015, our cash and cash equivalents were $186.8 million. Based on our current
operating plan, we expect that our existing cash and cash equivalents, including cash generated in the follow-on
offering in January 2016, will be sufficient to fund our current operations into the beginning of 2018. Our current
operating plan does not contemplate that all of the planned activities will proceed at the same pace, or that all of
the activities will be fully initiated or completed during that time. We may use available capital resources sooner
than we expect under our current operating plan. In addition, our operating plan may change as a result of many
factors currently unknown to us. We may need or choose to seek additional funds sooner than planned, through
public or private equity or debt financings, government or other third-party funding, marketing and distribution
arrangements and other collaborations, strategic alliances and licensing arrangements or a combination of these
approaches. In any event, we expect to require additional capital to obtain regulatory approval for, and to
commercialize, our product candidates. Raising funds in the current economic environment may present
additional challenges. Even if we believe we have sufficient funds for our current or future operating plans, we
may seek additional capital if market conditions are favorable or if we have specific strategic considerations.

66

Any additional fundraising efforts may divert our management from their day-to-day activities, which may

adversely affect our ability to develop and commercialize our product candidates. In addition, we cannot
guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all.
Moreover, the terms of any financing may adversely affect the holdings or the rights of our stockholders and the
issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the
market price of our shares to decline. The sale of additional equity or convertible securities would dilute all of
our stockholders. The incurrence of indebtedness would result in increased fixed payment obligations and we
may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional
debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating
restrictions that could adversely impact our ability to conduct our business. We could also be required to seek
funds through arrangements with collaborative partners or otherwise at an earlier stage than otherwise would be
desirable and we may be required to relinquish rights to some of our technologies or product candidates or
otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business,
operating results and prospects.

If we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay or
discontinue one or more of our research or development programs or the commercialization of any product, if
approved, or be unable to expand our operations or otherwise capitalize on our business opportunities, as desired,
which could materially affect our business, financial condition and results of operations.

Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us
to relinquish rights.

We may seek additional capital through a combination of private and public equity offerings, debt

financings, collaborations and strategic and licensing arrangements. To the extent that we raise additional capital
through the sale of common stock or securities convertible or exchangeable into common stock, the ownership
interest of our stockholders in our company will be diluted. In addition, the terms of any such securities may
include liquidation or other preferences that materially adversely affect the rights of our stockholders. Debt
financing, if available, would increase our fixed payment obligations and may involve agreements that include
covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making
capital expenditures or declaring dividends. If we raise additional funds through collaboration, strategic
partnerships and licensing arrangements with third parties, we may have to relinquish valuable rights to our
product candidates, our intellectual property, future revenue streams or grant licenses on terms that are not
favorable to us.

Risks Related to Our Common Stock

Market volatility may affect our stock price and the value of an investment in our stock.

The market price for our common stock, similar to that of other biopharmaceutical companies, is volatile.
The market price of our common stock may fluctuate significantly in response to a number of factors, most of
which we cannot control, including, among others:

‰

‰

‰

‰

‰

plans for, progress of, timing of, changes to, delays in or results from, non-clinical studies and clinical trials
of our product candidates, including any adverse events or announcements related to such studies or trials;

any delay in filing for regulatory approval of our product candidates;

the failure or delay of the FDA or any other regulatory authority to approve our product candidates, or any
unexpected limitation on the approved indication or onerous condition of approval;

announcements of new products, technologies, commercial relationships, acquisitions or other events by us
or our competitors;

the success or failure of our CNS therapies;

67

‰

‰

‰

‰

‰

‰

‰

‰

‰

‰

‰

‰

‰

regulatory or legal developments in the United States and other countries;

adverse developments with respect to our intellectual property portfolio

failure of our product candidates, if approved, to achieve commercial success;

fluctuations in stock market prices and trading volumes of similar companies;

general market conditions and overall fluctuations in U.S. equity markets;

variations in our quarterly operating results;

changes in our financial guidance or securities analysts’ estimates of our financial performance;

changes in accounting principles;

our ability to raise additional capital and the terms on which we can raise it;

sales of large blocks of our common stock, including sales by our executive officers, directors and
significant stockholders;

additions or departures of key personnel;

discussion of us or our stock price by the press and by online investor communities; and

other risks and uncertainties described in these risk factors.

We have a significant stockholder, which will limit a stockholder’s ability to influence corporate matters and
may give rise to conflicts of interest.

A fund affiliated with Third Rock Ventures LLC, or TRV, is our largest stockholder. As of December 31,
2015, TRV beneficially owned approximately 16.4% of our common stock. Accordingly, TRV exerts and will
continue to exert significant influence over us and any action requiring the approval of the holders of our
common stock, including the election of directors and amendments to our organizational documents, such as
increases in our authorized shares of common stock and approval of significant corporate transactions.
Furthermore, the interests of TRV may not always coincide with the interests of other stockholders and TRV may
act in a manner that advances its best interests and not necessarily those of other stockholders, including seeking
a premium value for its common stock, which might affect the prevailing market price for our common stock.

Our executive officers, directors, principal stockholders and their affiliates will continue to exercise
significant control over our company, which will limit the ability of our stockholders to influence corporate
matters and could delay or prevent a change in corporate control.

As of December 31, 2015, existing holdings of our executive officers, directors, principal stockholders and

their affiliates, including investment funds affiliated with ARCH Venture Fund VII, L.P., or ARCH, TRV, and
entities affiliated with Fidelity Investment, or Fidelity, represent beneficial ownership, in the aggregate, of
approximately 35% of our outstanding common stock. As a result, these stockholders, if they act together, will be
able to influence significantly our management and affairs and the outcome of matters submitted to our
stockholders for approval, including the election of directors and any sale, merger, consolidation, or sale of all or
substantially all of our assets. These stockholders acquired some or all of their shares of common stock for
substantially less than the price of the shares of common stock acquired in the our IPO or any follow-on offering,
and these stockholders may have interests, with respect to their common stock, that are different from those of
investors in our IPO or any follow-on offering and the concentration of voting power among these stockholders
may have an adverse effect on the price of our common stock. In addition, this concentration of ownership might
adversely affect the market price of our common stock by:

‰

‰

‰

delaying, deferring or preventing a change of control of us;

impeding a merger, consolidation, takeover or other business combination involving us; or

discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of us.

68

Future sales of our common stock may cause our stock price to decline.

Sales of a substantial number of shares of our common stock in the public market or the perception that
these sales might occur could significantly reduce the market price of our common stock, and impair our ability
to raise adequate capital through the sale of additional equity securities.

We have broad discretion in how we use the proceeds from our IPO and follow-on public offerings, and may
not use these proceeds effectively, which could affect our results of operations and cause our stock price to
decline.

We have considerable discretion in the application of the net proceeds from our follow-on public offerings
and our IPO. We may use the net proceeds for purposes that do not yield a significant return or any return at all
for our stockholders. In addition, pending their use, we may invest the net proceeds from the follow-on offerings
or from the IPO in a manner that does not produce income or that loses value.

Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us,
even one that may be beneficial to our stockholders, more difficult and may prevent attempts by our
stockholders to replace or remove our current management.

Provisions in our amended and restated certificate of incorporation and amended and restated bylaws may

delay or prevent an acquisition of us or a change in our management. These provisions include a classified board
of directors, a prohibition on actions by written consent of our stockholders and the ability of our board of
directors to issue preferred stock without stockholder approval. In addition, because we are incorporated in
Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which
limits the ability of stockholders owning in excess of 15% of our outstanding voting stock to merge or combine
with us. Although we believe these provisions collectively provide for an opportunity to obtain greater value for
stockholders by requiring potential acquirers to negotiate with our board of directors, they would apply even if an
offer rejected by our board were considered beneficial by some stockholders. In addition, these provisions may
frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it
more difficult for stockholders to replace members of our board of directors, which is responsible for appointing
the members of our management.

We do not intend to pay dividends on our common stock and, consequently, the ability of our stockholders to
achieve a return on their investment will depend on appreciation in the price of our common stock.

We have never declared or paid any cash dividend on our common stock, and do not currently intend to do

so in the foreseeable future. We currently anticipate that we will retain future earnings for the development,
operation and expansion of our business, and do not anticipate declaring or paying any cash dividends in the
foreseeable future. Therefore, the success of an investment in shares of our common stock will depend upon any
future appreciation in their value. There is no guarantee that shares of our common stock will appreciate in value
or even maintain the price at which you purchased them.

If equity research analysts stop publishing research or reports about our business or if they issue unfavorable
commentary or downgrade our common stock, the price of our common stock could decline.

The trading market for our common stock relies in part on the research and reports that equity research
analysts publish about us and our business. We do not control these analysts. The price of our common stock
could decline if one or more equity research analysts downgrade our common stock or if analysts issue other
unfavorable commentary or cease publishing reports about us or our business.

Item 1B. Unresolved Staff Comments

None.

69

Item 2. Properties

Our corporate headquarters are located in Cambridge, Massachusetts, and consist of 22,067 square feet in a

multi-tenant building. Our lease expires on February 28, 2022. We expect to lease additional space prior to
expiration of our existing lease to meet the needs of the business.

Item 3. Legal Proceedings

We are not a party to any legal proceedings, and we are not aware of any claims or actions pending or
threatened against us. In the future, we might from time to time become involved in litigation relating to claims
arising from our ordinary course of business, the resolution of which we do not anticipate would have a material
adverse impact on our financial position, results of operations or cash flows.

Item 4. Mine Safety Disclosures

Not applicable.

70

PART II

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of
Equity Securities

Market Information

On July 18, 2014, our common stock began trading on the NASDAQ Global Market under the symbol
“SAGE”. Prior to that time, there was no public market for our common stock. Shares sold in our initial public
offering on July 17, 2014 were priced at $18.00 per share.

On February 16, 2016, the closing price for our common stock as reported on the NASDAQ Global Market

was $32.69. The following table sets forth the high and low sales prices per share of our common stock as
reported on the NASDAQ Global Market for the period indicated.

First Quarter
Second Quarter
Third Quarter
Fourth Quarter

Stockholders

Years Ended December 31,

2015

2014

High

Low

High

Low

$53.38
$86.71
$76.98
$60.95

$36.99
$46.26
$40.75
$41.09

—
—
$33.40
$43.75

—
—
$25.86
$30.50

As of February 16, 2016, there were 20 stockholders of record of our common stock. The actual number of

holders of our common stock is greater than this number of record holders, and includes stockholders who are
beneficial owners, but whose shares are held in street name by brokers or held by other nominees. This number
of holders of record also does not include stockholders whose shares may be held in trust by other entities.

71

Performance Graph

The following graph illustrates a comparison of the total cumulative stockholder return for our common
stock since July 18, 2014, which is the date our shares began trading, through December 31, 2015, to two indices:
the NASDAQ Composite Index and the NASDAQ Biotechnology Index. The graph assumes an initial
investment of $100 on July 18, 2014, in our common stock, the stocks comprising the NASDAQ Composite
Index, and the stocks comprising the NASDAQ Biotechnology Index. Historical stockholder return is not
necessarily indicative of the performance to be expected for any future periods.

Comparison of Cumulative Total Return*
Among Sage Therapeutics, Inc., the NASDAQ Composite Index and the NASDAQ Biotechnology Index

* $100 invested on July 18, 2014 in stock or index.

The performance graph shall not be deemed to be incorporated by reference by means of any general

statement incorporating by reference this Form 10-K into any filing under the Securities Act of 1933, as amended
or the Exchange Act, except to the extent that we specifically incorporate such information by reference, and
shall not otherwise be deemed filed under such acts.

Dividend Policy

We have never paid or declared any cash dividends on our common stock, and we do not anticipate paying

any cash dividends on our common stock in the foreseeable future. We intend to retain all available funds and
any future earnings to fund the development and expansion of our business. Any future determination to pay
dividends will be at the discretion of our board of directors and will depend upon a number of factors, including
our results of operations, financial condition, future prospects, contractual restrictions, restrictions imposed by
applicable law and other factors our board of directors deems relevant.

Equity Compensation Plans

The information required by Item 5 of Form 10-K regarding equity compensation plans is incorporated

herein by reference to Item 12. of Part III of this Annual Report.

72

Issuer Purchases of Equity Securities

We did not purchase any of our registered equity securities during the period covered by this Annual Report.

Use of Proceeds from Registered Securities

On July 23, 2014, we closed the sale of 5,750,000 shares of common stock to the public at an initial public

offering price of $18.00 per share, including the exercise in full by the underwriters of their over-allotment
option, pursuant to which we sold an additional 750,000 shares of common stock at a price of $18.00 per share.
The offer and sale of the shares in the IPO were registered under the Securities Act pursuant to registration
statements on Form S-1 (File No. 333-196849), which was filed with the SEC on June 17, 2014 and amended
subsequently and declared effective on July 17, 2014. Following the sale of the shares in connection with the
closing of our IPO, the offering terminated. The offering did not terminate before all the securities registered in
the registration statements were sold. The underwriters of the offering were JP Morgan and Goldman Sachs &
Co. acting as joint book-running managers for the offering and as representatives of the underwriters. Leerink
Partners and Canaccord Genuity acted as co-managers for the offering. We raised approximately $94.0 million in
net proceeds in the IPO after deducting underwriting discounts and commissions of approximately $7.3 million
and other offering expenses of approximately $2.3 million. No offering expenses were paid directly or indirectly
to any of our directors or officers (or their associates) or persons owning ten percent or more of any class of our
equity securities or to any other affiliates.

As of December 31, 2015, we have used the majority of the net offering proceeds from our IPO, primarily to

fund clinical development of SAGE-547, IND-enabling activities and initiation of clinical development for
SAGE-217, IND-enabling activities for SAGE-689, research and development activities to find additional
product candidates and general corporate purposes. We invested the funds received in cash equivalents in
accordance with our investment policy. None of such payments were direct or indirect payments to any of our
directors or officers (or their associates), to persons owning ten percent or more of our common stock or to any
other affiliates. As described in our final prospectus filed with the SEC on July 17, 2014 pursuant to Rule 424(b)
under the Securities Act, we expect to use the remaining net proceeds from our IPO to continue to fund the costs
of our clinical development of SAGE-547 and SAGE-217, to fund Phase 1 clinical development of SAGE-689, if
we are able to satisfy the FDA’s request for additional data, and for other development activities, as well as for
working capital and general corporate purposes, including funding the costs of operating as a public company.

73

Item 6. Selected Consolidated Financial Data

The selected consolidated financial data set forth below are derived from our audited consolidated financial

statements and may not be indicative of future operating results. The following selected consolidated financial
data should be read in conjunction with Item 7, “Management’s Discussion and Analysis of Financial Condition
and Results of Operations” and the consolidated financial statements and the notes thereto included elsewhere in
this Annual Report. The consolidated selected financial data in this section are not intended to replace our
consolidated financial statements and the related notes included elsewhere in this Annual Report. Our historical
results are not necessarily indicative of our future results.

Consolidated statements of operations data:
Operating expenses:

Research and development
General and administrative

Total operating expenses

Loss from operations
Interest income, net
Other expense, net

Net loss and comprehensive loss

Accretion of redeemable convertible preferred

stock to redemption value

Net loss attributable to common stockholders

Net loss per share attributable to common
stockholders—basic and diluted(1)

Weighted average number of common shares used in

net loss per share attributable to common
stockholders—basic and diluted(1)

Consolidated balance sheet data:
Cash and cash equivalents(2)
Working capital(3)
Total assets
Redeemable convertible preferred stock
Common stock and additional paid-in capital
Total stockholders’ equity (deficit)

Year Ended December 31,

2015

2014

2013

2012

(in thousands, except for per share and per share data)

$

$

$

$

69,357
25,293

94,650

(94,650)
178
(23)

(94,495)

$

24,100
9,710

33,810

(33,810)
8
(9)

(33,811)

$

14,357
3,922

18,279

(18,279)
1
(3)

(18,281)

7,229
2,402

9,631

(9,631)
—

(1)

(9,632)

—

(2,294)

(7)

(4)

(94,495) $

(36,105) $ (18,288) $

(9,636)

(3.40) $

(1.67) $

(12.26) $

(8.62)

27,778,288

21,574,347

1,492,288

1,118,288

Year Ended December 31,

2015

2014

2013

2012

(in thousands)

$186,753
173,184
189,016
—
335,035
173,695

$127,766
121,065
129,665
—
188,730
121,885

$ 8,066
6,092
8,532
37,709
139
(31,536)

$ 2,802
1,407
2,995
14,970
—
(13,394)

(1) See Note 8 to our consolidated financial statements appearing elsewhere in this Annual Report for further
details on the calculation of basic and diluted net loss per share attributable to common stockholders.

(2) On January 12, 2016, we completed the sale of 3,157,894 shares of common stock in an underwritten public

offering at a price to the public of $47.50 per share, resulting in net proceeds of $140.4 million after
deducting underwriting discounts and commissions and estimated offering costs paid by us. This amount is
not included in the amounts shown.

(3) We define working capital as current assets less current liabilities.

74

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operation

We are a clinical-stage biopharmaceutical company committed to developing and commercializing novel
medicines to treat life-threatening central nervous system, or CNS, disorders, where there are inadequate or no
approved existing therapies. We are targeting CNS indications where patient populations are easily identified,
clinical endpoints are well-defined, and development pathways are feasible.

The following table summarizes the status of our development programs as of the date of this Annual

Report.

Our lead product candidate is SAGE-547, a proprietary intravenous formulation of allopregnanolone, a
naturally occurring neurosteroid that acts as a synaptic and extrasynaptic modulator of the GABAA receptor.
GABA is the major inhibitory neurotransmitter in the CNS, and mediates downstream neurologic and bodily
function via activation of GABAA receptors. We believe that allosteric modulation of the GABAA receptor has
the potential to be well-suited for the treatment of seizures and certain other CNS disorders because it allows for
the fine-tuning of neuronal signals rather than complete activation or complete inhibition. SAGE-547 is in Phase
3 clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus, or SRSE.
SRSE is a rare and life-threatening condition where a patient is in a state of continuous seizure called status
epilepticus, or SE, and all of the standard treatment regimens normally sufficient to stop the seizure activity have
failed. We expect to report top-line results from the global, randomized, double-blind, placebo-controlled Phase 3
trial of SAGE-547 in SRSE in the second half of 2016. If successful, we believe the results of the Phase 3 clinical
trial, together with other clinical data obtained from the SAGE-547 clinical program, and results of ongoing non-
clinical studies, could form the basis of a New Drug Application, or NDA submission, for SAGE-547.

We have also used SAGE-547 in proof-of-concept clinical trials to explore potential uses of GABAA
receptor modulators to treat post-partum depression, or PPD, a distinct and readily identified major depressive

75

disorder, and essential tremor, a debilitating neurological disorder that causes involuntary, rhythmic shaking with
no known cause. We are currently conducting an additional Phase 2 exploratory trial of SAGE-547 in the
treatment of severe PPD. We expect the data from these exploratory trials to guide the development of second-
generation GABAA receptor modulators for the applicable diseases.

Our next-generation product candidates, SAGE-217 and SAGE-689, also target the GABAA receptor
system. These compounds have been designed to have pharmaceutical properties that optimize both their non-
clinical profiles and potential clinical profiles for the treatment of certain seizure and non-seizure CNS disorders.
We are currently conducting a Phase 1 clinical trial of SAGE-217, which we expect to complete in the first half
of 2016. If the Phase 1 clinical trial of SAGE-217 supports further development, we plan to commence Phase 2
clinical trials of SAGE-217, initially in essential tremor and orphan epilepsies. SAGE-689 is in non-clinical
development. Our Phase 1 clinical trial of SAGE-689 has been delayed to respond to a request from the United
States Food and Drug Administration, or FDA, for additional non-clinical study data.

We are also studying novel compounds that target the NMDA receptor, a critical excitatory receptor system

in the brain implicated in a broad range of CNS disorders. The first product candidate selected for development
from this program is SAGE-718, an oxysterol-based NMDA positive allosteric modulator. We have begun non-
clinical studies of SAGE-718, with an initial development focus on two rare conditions, Smith-Lemli-Opitz
Syndrome and Anti-NMDA Receptor Encephalitis. Beyond these conditions, we believe measuring levels of
anti-NMDA antibodies or decreased levels of cerebrosterol, a naturally occurring oxysterol, may represent
biomarkers to identify for future study broader patient populations characterized by cognitive dysfunction and
neuropsychiatric symptoms resulting from NMDA receptor dysfunction or hypofunction. Examples of these
potential areas for future evaluation include certain types, aspects or subpopulations of a number of diseases such
as depression, Alzheimer’s disease, attention deficit hyperactivity disorder, schizophrenia, Huntington’s disease,
and neuropathic pain.

We expect to continue our focus on allosteric modulation of the GABAA and NMDA receptor systems in the

brain. The GABAA and NMDA receptor systems are broadly accepted as impacting many psychiatric and
neurological disorders, spanning disorders of mood, seizure, cognition, anxiety, sleep, pain, epilepsy, and
movement disorders among others. We believe that we will have the opportunity to develop molecules from our
internal portfolio to address a number of these disorders in the future. Our ability to identify and develop such
novel CNS therapies is enabled by our proprietary chemistry platform that is centered on a scaffold of chemically
modified endogenous neuroactive steroid compounds. We believe our know-how around the chemistry and
activity of allosteric modulators allows us to efficiently design molecules with different characteristics by
enabling us to control important properties such as half-life, brain penetration and the types of receptors with
which our compounds interact with the goal of developing product candidates that have the potential to bind with
targets in the brain with more precision, increased tolerability, and fewer off-target side effects than either current
CNS therapies or previous therapies which have failed in development.

SAGE was founded in 2010, based on leading research in the areas of brain function and neuroactive
steroids, to explore novel approaches to CNS therapeutics. Since our inception, we have continued to expand our
know-how related to CNS therapeutics through our research and development programs, and to pursue
intellectual property protection with respect to our proprietary chemistry platform. In addition, we have
assembled a strong management team that together has been a part of the successful discovery, development and
commercialization of more than 20 marketed CNS therapies.

We have not generated any revenue to date. We have incurred net losses in each year since our inception,

and we have an accumulated deficit of $161.3 million as of December 31, 2015. Our net losses were $94.5
million, $33.8 million and $18.3 million for the years ended December 31, 2015, 2014 and 2013, respectively.
These losses have resulted principally from costs incurred in connection with research and development activities
and general and administrative costs associated with our operations. We expect to incur significant expenses and
increasing operating losses for the foreseeable future.

76

We expect that our expenses will increase substantially in connection with our ongoing activities, as we:

‰

‰

‰

‰

‰

‰

‰

‰

‰

‰

advance clinical development of SAGE-547, our lead product candidate in our SE program, including
completing the Phase 3 clinical trial for SAGE-547 in SRSE and additional clinical and non-clinical
studies of SAGE-547 required for a NDA, advancing regulatory activities focused on potential filing of
the NDA, and initial preparations for a potential commercial launch;

continue to advance our efforts to establish proof of principle of the potential for use of GABAA
receptor modulators in PPD;

complete the Phase 1 clinical trial of SAGE-217 in healthy volunteers, and if successful, advance
development of SAGE-217 as an oral therapy for orphan epilepsies such as Dravet syndrome and Rett
syndrome, and in certain non-seizure indications such as essential tremor;

advance development of SAGE-689 as an adjunctive second-line therapy for the treatment of SE,
including conducting additional non-clinical studies, and potential clinical trials, if we are able to
successfully address the data request from the FDA;

advance our early-stage novel allosteric modulator for NMDA into non-clinical studies;

continue our research and development efforts for other drug candidates in the treatment of CNS
disorders;

seek regulatory approvals for our product candidates that successfully complete clinical development;

add personnel, including personnel to support our product development and future commercialization
efforts;

add operational, financial and management information systems, and;

maintain, leverage and expand our intellectual property portfolio.

As a result, we will need additional financing to support our continuing operations. Until such time that we

can generate significant revenue from product sales, if ever, we expect to finance our operations through a
combination of public or private equity or debt financings or other sources, which may include collaborations
with third parties. Arrangements with collaborators or others may require us to relinquish rights to certain of our
technologies or product candidates. In addition, we may never successfully complete development of any of our
product candidates, obtain adequate patent protection for our technology, obtain necessary regulatory approval
for our product candidates or achieve commercial viability for any approved product. Adequate additional
financing may not be available to us on acceptable terms, or at all. Our inability to raise capital as and when
needed would have a negative impact on our financial condition and on our ability to pursue our business
strategy. We will need to generate significant revenue to achieve profitability, and we may never do so.

We expect that our existing cash and cash equivalents as of December 31, 2015, in addition to the funds
raised by our public offering of common stock in January 2016, will enable us to fund our operating expenses
and capital expenditure requirements, based on our current operating plan, into the beginning of 2018. See
“—Liquidity and Capital Resources.”

Financial Operations Overview

Revenue

We have not generated any revenue from product sales since our inception and do not expect to generate
any revenue from the sale of products in the near future. If our developmental efforts result in clinical success
and regulatory approval or collaboration agreements with third parties for our product candidates, we may
generate revenue from those product candidates.

77

Operating Expenses

Our operating expenses since inception have consisted primarily of research and development activities and

general and administrative costs.

Research and Development Expenses

Research and development expenses, which consist primarily of costs associated with our product research

and development efforts, are expensed as incurred. Research and development expenses consist primarily of:

‰

‰

‰

‰

‰

‰

personnel costs, including salaries, benefits, stock-based compensation and travel expenses for
employees engaged in scientific research and development functions;

expenses incurred under agreements with contract research organizations, or CROs, and investigative
sites that conduct our non-clinical studies and clinical trials;

expenses associated with manufacturing clinical trial materials and developing external manufacturing
capabilities;

costs of outside consultants engaged in scientific research and development activities, including their
fees, stock-based compensation and travel expenses;

other expenses related to our non-clinical studies and clinical trials and expenses related to our
regulatory activities; and

payments made under our third-party licensing agreements.

Costs for certain development activities are recognized based on an evaluation of the progress to completion

of specific tasks using information and data provided to us by our vendors and our clinical sites.

We have been developing our product candidates and focusing on other research and development

programs, including exploratory efforts to identify new compounds, target validation for identified compounds
and lead optimization for our earlier-validated programs. Our direct research and development expenses are
tracked on a program-by-program basis and consist primarily of external costs, such as fees paid to investigators,
central laboratories, CROs and contract manufacturing organizations, or CMOs, in connection with our non-
clinical studies and clinical trials; third-party license fees related to our product candidates; and fees paid to
outside consultants who perform work on our programs. We do not allocate employee-related costs and other
indirect costs to specific research and development programs because these costs are deployed across multiple
product programs under research and development and, as such, are separately classified as unallocated research
and development expenses.

The following table summarizes our research and development expenses by program:

SAGE-547
SAGE-217
SAGE-689
Other research and development programs
Unallocated expenses

Total research and development programs

Year Ended December 31,

2015

2014

2013

$38,104
6,408
3,051
7,801
13,993
$69,357

(in thousands)
$ 9,137
2,764
3,058
3,088
6,053
$24,100

$ 3,918
1,129
2,772
3,388
3,150
$14,357

Research and development activities are central to our business. Product candidates in later stages of clinical
development generally have higher development costs than those in earlier stages of clinical development, primarily
due to the increased size and duration of later-stage clinical trials. We expect that our research and development
expenses will continue to increase in the foreseeable future as we continue or initiate clinical trials and non-clinical
studies for certain product candidates and pursue later stages of clinical development of our product candidates.

78

We cannot determine with certainty the duration and completion costs of the current or future clinical trials
of our product candidates or if, when, or to what extent we will generate revenue from the commercialization and
sale of any of our product candidates if approved for marketing and sale. The duration, costs, and timing of
clinical trials and development of our product candidates will depend on a variety of factors, including:

‰

‰

‰

‰

‰

‰

the scope, size, rate of progress, and expense of our ongoing as well as any additional non-clinical
studies, clinical trials and other research and development activities;

future clinical trial and non-clinical study results;

decisions by regulatory authorities related to our product candidates;

uncertainties in clinical trial enrollment rate or design;

significant and changing government regulation; and

the receipt and timing of any regulatory approvals, if any.

A change in the outcome of any of these variables with respect to the development of a product candidate

could mean a significant change in the costs and timing associated with the development of that product
candidate. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials
beyond those that we currently anticipate will be required for the completion of clinical development of a product
candidate, or if we experience significant delays in enrollment in any of our clinical trials, we could be required
to expend significant additional financial resources and time on the completion of clinical development.

General and Administrative Expenses

General and administrative expenses consist primarily of personnel costs, consisting of salaries, benefits, stock-

based compensation and travel expenses of our executive, finance, business and corporate development and other
administrative functions. General and administrative expenses also include expenses incurred under agreements with
third parties relating to evaluation, planning and preparation for a potential commercial launch, facilities and other
expenses, including rent, depreciation, maintenance of facilities, insurance and supplies; and professional fees for audit,
tax and legal services, including legal expenses to pursue patent protection of our intellectual property.

We anticipate that our general and administrative expenses will increase in the future as we increase our
headcount to support the expected growth in our business and the potential commercialization of our product
candidates. We also anticipate increased expenses associated with general operations, including costs related to
audit, legal, regulatory and tax-related services associated with maintaining compliance with exchange listing
and SEC requirements, director and officer insurance premiums, and investor relations costs. Additionally, we
anticipate an increase in payroll and related expenses as we continue to build our organizational capabilities and
as a result of our preparation for commercial operations, especially as it relates to the sales and marketing of our
product candidates, if approved.

Critical Accounting Policies and Significant Judgments and Estimates

Our consolidated financial statements are prepared in accordance with generally accepted accounting
principles in the United States. The preparation of our consolidated financial statements and related disclosures
requires us to make estimates and assumptions that affect the reported amount of assets, liabilities, revenue, costs
and expenses, and related disclosures. We believe that the estimates and assumptions involved in the accounting
policies described below may have the greatest potential impact on our consolidated financial statements and,
therefore, consider these to be our critical accounting policies. We evaluate our estimates and assumptions on an
ongoing basis. Our actual results may differ from these estimates under different assumptions and conditions. While
our significant accounting policies are described in more detail in the notes to our consolidated financial statements
appearing elsewhere in this Annual Report, we believe that the following accounting policies are those most critical
to the judgments and estimates used in the preparation of our consolidated financial statements.

79

Accrued Research and Development Expenses

As part of the process of preparing our consolidated financial statements, we are required to estimate our

accrued research and development expenses. This process involves reviewing open contracts and purchase
orders, communicating with our personnel to identify services that have been performed on our behalf and
estimating the level of service performed and the associated costs incurred for the services when we have not yet
been invoiced or otherwise notified of the actual costs. The majority of our service providers invoice us in arrears
for services performed, on a pre-determined schedule or when contractual milestones are met; however, some
require advanced payments. We make estimates of our accrued expenses as of each balance sheet date in our
consolidated financial statements based on facts and circumstances known to us at that time. Examples of
estimated accrued research and development expenses include fees paid to:

‰

‰

‰

‰

CROs in connection with performing research and development services on our behalf;

investigative sites or other providers in connection with clinical trials;

vendors in connection with non-clinical development activities; and

vendors related to product manufacturing, development and distribution of clinical supplies.

We base our expenses related to clinical trials on our estimates of the services received and efforts expended

pursuant to contracts with multiple CROs that conduct and manage clinical trials on our behalf. The financial
terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven
payment flows. There may be instances in which payments made to our vendors will exceed the level of services
provided and result in a prepayment of the clinical expense. Payments under some of these contracts depend on
factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing
service fees, we estimate the time period over which services will be performed, enrollment of patients, number
of sites activated and level of effort to be expended in each period. If the actual timing of the performance of
services or the level of effort varies from our estimate, we adjust the accrual or prepaid accordingly. Although we
do not expect our estimates to be materially different from amounts actually incurred, our understanding of the
status and timing of services performed relative to the actual status and timing of services performed may vary
and may result in us reporting expenses that are too high or too low in any particular period. To date, we have not
made any material adjustments to our prior estimates of accrued research and development expenses.

Stock-Based Compensation

We recognize compensation expense for all stock-based awards made to employees and nonemployee directors,
including grants of stock options and restricted stock, based on estimated fair value on date of grant, over the requisite
service period. For awards that vest upon achievement of a performance condition, we recognize compensation
expense when achievement of the performance condition is deemed probable over the implicit service period.

We have historically granted stock options with exercise prices equivalent to the fair value of our common

stock as of the date of grant.

We measure stock-based awards granted to nonemployee consultants at the fair value of the award on each

date on which the awards vest. Compensation expense is recognized over the period during which services are
rendered by such nonemployee consultants until completed. At the end of each financial reporting period prior to
the completion of the service, the fair value of these awards is re-measured using, for options, the then-current
fair value of our common stock and updated assumptions in the Black-Scholes option-pricing model and using,
for restricted stock, the then-current fair value of our common stock.

The fair value of each stock option grant is estimated using the Black-Scholes option-pricing model. Until

July 18, 2014, we were a private company and we lacked company-specific historical and implied volatility
information. Considering this and the short history of being a public company, we estimate our expected
volatility based on the historical volatility of our publicly traded peer companies and expect to continue to do so
until such time as we have adequate historical data regarding the volatility of our traded stock price. The

80

expected term of our options has been determined utilizing the “simplified” method for awards that qualify as
“plain-vanilla” options, while the expected term of our options granted to consultants and nonemployees has
been determined based on the contractual term of the options. The risk-free interest rate is determined by
reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods
approximately equal to the expected term of the award. Expected dividend yield is based on the fact that we have
never paid cash dividends and do not expect to pay any cash dividends in the foreseeable future.

The assumptions we used to determine the fair value of stock options granted to employees and

nonemployee directors are as follows, presented on a weighted average basis:

Expected dividend yield
Expected volatility
Risk free interest rate
Expected life of option

Year Ended December 31,

2015

2014

2013

0.00%
90.54%
1.59%

0.00%
98.86%
1.95%

0.00%
99.89%
1.66%

6.03 years

6.38 years

6.04 years

These assumptions represented our best estimates, but the estimates involve inherent uncertainties and the

application of our judgment. As a result, if factors change and we use significantly different assumptions or
estimates when valuing our stock options, our stock-based compensation expense could be materially different.
We recognize compensation expense for only the portion of awards that are expected to vest. In developing a
forfeiture rate estimate for pre-vesting forfeitures, we have considered our historical experience of actual
forfeitures. If our future actual forfeiture rate is materially different from our estimate, our stock-based
compensation expense could be significantly different from what we have recorded in the current period.

Stock-based compensation expense recognized during the years ended December 31, 2015, 2014, and 2013

was as follows:

Stock-based compensation expense:
Research and development
General and administrative

Year Ended December 31,

2015

2014

2013

(in thousands)

$ 5,924
9,316

$1,093
1,419

$15,240

$2,512

$38
23

$61

As of December 31, 2015, we had unrecognized stock-based compensation expense related to our unvested

service-based stock option awards of $31.5 million, which is expected to be recognized over the remaining
weighted average vesting period of 3.01 years. In addition, we have 358,976 shares of outstanding unvested stock
options that vest upon the achievement of certain performance criteria. Total unrecognized compensation related
to those awards was $7.8 million at December 31, 2015.

Recently Issued Accounting Pronouncements

In May 2014, the FASB issued guidance that outlines a single comprehensive model for entities to use in
accounting for revenue arising from contracts with customers and supersedes most current revenue recognition
guidance, including industry specific guidance. The guidance is based on the principle that an entity should
recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the
consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance
also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows
arising from customer contracts, including significant judgments and changes in judgments and assets recognized

81

from costs incurred to fulfill a contract. Entities have the option of using either a full retrospective or a modified
retrospective approach for the adoption of the new standard. The guidance becomes effective for us in the year
ending December 31, 2018, and we could early adopt the standard for the year ending December 31, 2017. We
are currently assessing the method of adoption and the impact that this new accounting guidance will have on our
consolidated financial statements and footnote disclosures.

In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements—Going Concern

(Subtopic 205-40). The new guidance addresses management’s responsibility to evaluate whether there is
substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote
disclosures. Management’s evaluation should be based on relevant conditions and events that are known and
reasonably knowable at the date that the financial statements are issued. The standard will be effective for the
first interim period within annual reporting periods beginning after December 15, 2016. Early adoption is
permitted. We are evaluating the effect that this guidance will have on our consolidated financial statements.

In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes, which

simplifies the classification of deferred tax assets and liabilities. The new standard requires that all deferred tax
assets and liabilities, along with any related valuation allowance, be classified as noncurrent on the balance sheet.
The standard is effective for interim and annual periods beginning after December 15, 2016 and allows for early
adoption using a full retrospective method or a prospective method. We have elected to early adopt the provisions of
this new standard using a prospective method. As a result, all deferred taxes as of December 31, 2015 are classified
as noncurrent on a net basis in our consolidated balance sheet, while prior periods remain as previously reported.

In February 2016, the Financial Accounting Standards Board (FASB) issued ASU 2016-02—Leases
(ASC 842), which sets out the principles for the recognition, measurement, presentation and disclosure of leases
for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual
approach, classifying leases as either finance or operating leases based on the principle of whether or not the
lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is
recognized based on an effective interest method or on a straight line basis over the term of the lease,
respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term
of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be
accounted for similar to existing guidance for operating leases today. ASC 842 supersedes the previous leases
standard, ASC 840 Leases. The standard is effective on January 1, 2019, with early adoption permitted. We are in
the process of evaluating the impact of this new guidance.

Results of Operations

Comparison of the Years Ended December 31, 2015 and 2014

The following table summarizes our results of operations for the years ended December 31, 2015 and 2014:

Operating expenses:

Research and development
General and administrative

Total operating expenses

Loss from operations
Interest income, net
Other expense, net

Net loss

82

Year Ended
December 31,

2015

2014

(in thousands)

Increase
(Decrease)

$ 69,357
25,293

$ 24,100
9,710

$ 45,257
15,583

94,650

33,810

60,840

(94,650)
178
(23)

(33,810)
8
(9)

(60,840)
170
(14)

$(94,495)

$(33,811)

$(60,684)

Research and development expenses

SAGE-547
SAGE-217
SAGE-689
Other research and development programs
Unallocated expenses

Year Ended
December 31,

2015

2014

$38,104
6,408
3,051
7,801
13,993

(in thousands)
$ 9,137
2,764
3,058
3,088
6,053

Increase
(Decrease)

$28,967
3,644
(7)
4,713
7,940

Total research and development programs

$69,357

$24,100

$45,257

Research and development expenses for the fiscal year ended December 31, 2015 were $69.4 million,
compared to $24.1 million for the year ended December 31, 2014. The increase of $45.3 million year over year
was primarily due to the following:

‰

‰

‰

‰

an increase of $29.0 million in expenses of our SAGE-547 program, due to the advancement of the
program into clinical development, including the completion of the Phase 1/2 clinical trial,
commencement of activities for our Phase 3 clinical trial, an increase in work related to CMC and
toxicology. For the years ended December 31, 2015 and 2014, payments made to consultants and
licensors in connection with the achievement of development milestones met by consultants and
licensors were $2.7 million and $0.4 million, respectively;

an increase of $3.6 million in expenses of our SAGE-217 program with advancement of the lead
optimization program through IND-enabling non-clinical development activities (e.g., toxicology
studies, process development, and drug substance manufacturing), filing of the IND and initiation of
the Phase 1 clinical trial in October 2015;

an increase of $4.7 million in expenses of our other research and development programs and discovery
efforts for our next clinical candidates and back-up programs; and

an increase of $7.9 million in unallocated expenses, including an increase of $4.8 million of non-cash
stock-based compensation expense, due to the hiring of additional full-time employees to support the
growth in our activities. The amount of non-cash stock-based compensation expense recorded to
research and development expense related to the achievement of performance-based vesting criteria
was $2.0 million for the year ended December 31, 2015. No stock-based compensation expense related
to the achievement of performance-based vesting criteria was recorded to research and development
expense for the year ended December 31, 2014.

General and administrative expenses

Personnel related
Professional fees
Commercial planning
Other

Total general and administrative expenses

Year Ended December 31,

2015

2014

Increase
(Decrease)

$14,927
4,333
3,076
2,957

$25,293

(in thousands)
$4,337
2,881
907
1,585

$9,710

$10,590
1,452
2,169
1,372

$15,583

General and administrative expenses for the years ended December 31, 2015 and 2014 were $25.3 million
and $9.7 million, respectively. The increase of $15.6 million in general and administrative expenses year over

83

year was primarily due to a $10.6 million increase in personnel-related costs due to the effects of hiring
additional full-time employees to support operations, finance, human resources, legal and early commercial
planning activities, including an increase of $7.9 million in non-cash stock-based compensation expense. The
amount of non-cash stock-based compensation includes amounts related to the achievement of the performance-
based vesting criteria of $2.7 million for the year ended December 31, 2015. No stock-based compensation
expense related to the achievement of performance-based vesting criteria was recorded to general and
administrative expenses for the year ended December 31, 2014. The increase of $1.5 million in professional fees
was primarily due to increased costs associated with being a public company, including costs related to audit,
legal, regulatory and tax-related services, as well as investor relations costs. The increase of $2.2 million in
commercial planning was associated preparations for a potential commercial launch.

Interest income, net

Interest income, net, for the years ended December 31, 2015 and 2014 was $0.2 million and $8,000,
respectively. The increase in interest income was primarily due to increased cash and cash equivalent balances
due to our July 2014 and April 2015 public offerings of common stock.

Other expense, net

Other expense, net was insignificant for the years ended December 31, 2015 and 2014.

Comparison of the Years Ended December 31, 2014 and 2013

The following table summarizes our results of operations for the years ended December 31, 2014 and 2013:

Operating expenses:

Research and development
General and administrative

Total operating expenses

Loss from operations
Interest income, net
Other expense, net
Net loss

Research and development expenses

SAGE-547
SAGE-689
SAGE-217
Other research and development programs
Unallocated expenses
Total research and development programs

Year Ended December 31,

2014

2013

Increase
(Decrease)

(in thousands)

$ 14,357
3,922
18,279
(18,279)
1
(3)
$(18,281)

$ 24,100
9,710
33,810
(33,810)
8
(9)
$(33,811)

$ 9,743
5,788
15,531
(15,531)
7
(6)
$(15,530)

Year Ended December 31,

2014

2013

Increase
(Decrease)

$ 9,137
3,058
2,764
3,088
6,053
$24,100

(in thousands)
$ 3,918
2,772
1,129
3,388
3,150
$14,357

$5,219
286
1,635
(300)
2,903
$9,743

Research and development expenses for the fiscal year ended December 31, 2014 were $24.1 million,
compared to $14.4 million for the year ended December 31, 2013. The increase of $9.7 million year over year
was primarily due to the following:
‰

an increase of $5.2 million in expenses of our SAGE-547 program. We initiated the Phase 1/2 clinical trial
of SAGE-547 in SRSE in early 2014;

84

‰

‰

‰

‰

an increase of $0.3 million in expenses of our SAGE-689 program with advancement of the lead
optimization program into IND-enabling non-clinical development (e.g. toxicology studies, process
development, and drug substance manufacturing);

an increase of $1.6 million in expenses of our SAGE-217 program with advancement of the lead
optimization program into IND-enabling non-clinical development (e.g. toxicology studies, process
development, and drug substance manufacturing);

a net decrease of $0.3 million in expenses of our other research and development programs reflecting a
focus on advancing SAGE-689 and SAGE-217 into IND-enabling non-clinical development, portfolio
priorities, and timing of investment in certain research programs; and

an increase of $2.9 million in employee related spending to support the growth in our research and
development activities, reflecting the effects of hiring additional, full-time employees during 2014.

General and administrative expenses

Personnel related
Professional fees
Facilities
Other

Total general and administrative expenses

Year Ended December 31,

2014

2013

Increase
(Decrease)

$4,337
3,788
370
1,215

$9,710

(in thousands)
$1,764
1,253
364
541

$3,922

$2,573
2,535
6
674

$5,788

General and administrative expenses for the years ended December 31, 2014 and 2013 were $9.7 million
and $3.9 million, respectively. The increase of $5.8 million in general and administrative expenses year over year
was primarily due to the $2.6 million increase in personnel related costs due to the effects of hiring additional,
full-time employees during 2014 to support operations, finance, human resources, and early commercial planning
activities as well as an increase in stock-based compensation expense costs and $2.5 million increase in
professional fees associated with being a public company, including costs related to audit, legal, regulatory and
tax-related services associated with maintaining compliance with exchange listing and SEC requirements, and
investor relations costs.

Other income, net

Interest income, net and other expense, net were insignificant for the years ended December 31, 2014 and

2013.

Liquidity and Capital Resources

Since our inception in April 2010, we have not generated any revenue and have incurred recurring net
losses. As of December 31, 2015, we had an accumulated deficit of $161.3 million. From our inception through
December 31, 2015, we have received net proceeds of $313.7 million from the sales of redeemable convertible
preferred stock, the issuance of convertible notes and the proceeds from our IPO and April 2015 follow-on
offering. On January 12, 2016, we completed the sale of 3,157,894 shares of common stock in an underwritten
public offering at a price to the public of $47.50 per share, resulting in net proceeds of $140.4 million after
deducting underwriting discounts and commissions and estimated offering costs paid by us.

As of December 31, 2015, our primary sources of liquidity were our cash and cash equivalents, which

totaled $186.8 million. We invest our cash equivalents and investments in highly liquid, interest-bearing
investment-grade and government securities to preserve principal.

85

The following table summarizes the primary sources and uses of cash for the periods presented below:

Net cash provided by (used in):
Operating activities
Investing activities
Financing activities

Years Ended December 31,

2015

2014

2013

(in thousands)

$ (70,681)
(198)
129,866

$ (27,042)
(128)
146,870

$(17,516)
(3)
22,783

Net increase in cash and cash equivalents

$ 58,987

$119,700

$ 5,264

Operating Activities

Cash used in operating activities for the fiscal year ended December 31, 2015 was $70.7 million, compared
to $27.0 million for the fiscal year ended December 31, 2014. The increase of $43.7 million year over year was
primarily due to the following:

‰ An increase of $60.7 million in cash used related to our net loss, primarily due to increased research
and development activities related to our lead programs in development and increased general and
administrative expenses due to increased headcount to support our operations;

‰ An increase of $13.9 million in non-cash charges, primarily due to an increase in stock-based

compensation expense due to increased hiring during the year, including $4.8 million of stock-based
compensation expense recognized upon the achievement of a performance-based vesting criteria; and

‰ An increase of $3.1 million in cash provided by changes in our operating assets and liabilities,
primarily due to the growth of the business and the timing of vendor invoicing and payments.

Cash used in operating activities for the fiscal year ended December 31, 2014 was $27.0 million, compared

to $17.5 million for the fiscal year ended December 31, 2013. The increase of $9.5 million year over year was
primarily due to the following:

‰ An increase of $15.5 million in cash used related to our net loss, primarily due to increased research
and development activities related to our lead programs in development and increased general and
administrative expenses due to increased headcount to support our operations;

‰ An increase of $2.5 million in non-cash charges, primarily due to an increase in stock-based

compensation expense due to increased hiring during the year; and

‰ An increase of $3.5 million in cash provided by changes in our operating assets and liabilities,
primarily due to the growth of the business and the timing of vendor invoicing and payments.

Investing Activities

During the years ended December 31, 2015 and 2014, we used $0.2 million and $0.1 million, respectively,

of cash for purchases of property and equipment. During the year ended December 31, 2013, cash used by
investing activities was insignificant.

Financing Activities

During the years ended December 31, 2015, 2014 and 2013, net cash provided by financing activities was
$129.9 million, $146.9 million and $22.8 million, respectively. Net cash provided by financing activities in the
year ended December 31, 2015 primarily consisted of $129.1 million of net proceeds from a follow-on
underwritten public offering of our common stock after deducting commissions and underwriting discounts and

86

offering costs. Net cash provided by financing activities in the year ended December 31, 2014 consisted
primarily of $94.0 million in net proceeds from our IPO on July 23, 2014 and $52.9 million from the issuance of
Series B and Series C redeemable convertible preferred stock. Net cash provided by financing activities in the
year ended December 31, 2013 consisted of $22.8 million from the issuance of Series A redeemable convertible
preferred stock and from the exercise of stock options.

Operating Capital Requirements

To date, we have not generated any revenue from product sales. We do not know when, or if, we will
generate any revenue from product sales. We do not expect to generate significant revenue from product sales
unless and until we obtain regulatory approval of and commercialize one of our current or future product
candidates. We anticipate that we will continue to generate losses for the foreseeable future, and we expect the
losses to increase as we continue the development of, and seek regulatory approvals for, our product candidates,
continue preparations for potential future commercialization, and begin to commercialize any products, if
approved. We expect to incur additional costs associated with general operations. In addition, subject to
obtaining regulatory approval of any of our product candidates, we expect to incur significant commercialization
expenses for product sales, marketing and manufacturing. Accordingly, we anticipate that we will need
substantial additional funding in connection with our continuing operations.

Based on our current operating plan, we expect that our existing cash and cash equivalents as of

December 31, 2015, in addition to the funds raised by our public offering of common stock in January 2016, will
enable us to fund our operating expenses and capital expenditure requirements into the beginning of 2018.
During that time, we expect that our expenses will increase substantially as we continue clinical development of
SAGE-547, including completing our Phase 3 clinical trial; complete Phase 1 clinical development for SAGE-
217 and advance the product candidate into Phase 2 clinical trials, if the Phase 1 clinical trial is successful;
advance SAGE-689 into Phase 1 clinical development, if permitted by the FDA; conduct additional proof-of-
concept studies of SAGE-547 in PPD; continue non-clinical studies of SAGE-718, our early-stage novel
allosteric modulator for NMDA; fund new and ongoing research and development activities and working capital,
and fund other general corporate purposes. Our current operating plan does not contemplate that all of these
activities will proceed at the same pace, or that all of these activities will be fully initiated or completed during
that time. We have based our estimates on assumptions that could change, and we may use our available capital
resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with the
development and commercialization of our product candidates, we are unable to estimate the amounts of
increased capital outlays and operating expenditures necessary to complete the development and
commercialization of our product candidates.

‰

‰

‰

‰

‰

‰

‰

‰

Our future capital requirements will depend on many factors, including:

the ability of our product candidates to progress through clinical development successfully;

the initiation, progress, timings, costs, and results of non-clinical studies and clinical trials for our existing
and future product candidates, and the costs of preparing regulatory filings;

the cost, timing, and outcome of regulatory reviews and approvals;

the number and characteristics of the product candidates we pursue and the nature and scope of the
development programs;

the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual
property rights and defending intellectual property-related claims;

the extent to which we acquire or in-license other products and technologies;

our ability to establish any future collaboration arrangements on favorable terms, if at all; and

the level and timing of costs associated with preparations for a potential commercial launch, including
manufacturing-related costs.

87

Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs

through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing
arrangements. Even if we believe we have sufficient funds for our current or future operating plans, we may seek
additional capital if market conditions are favorable or in light of specific strategic considerations. To the extent
that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of
our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences
that adversely affect the rights of our common stockholders. Debt financing, if available, may involve
agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring
additional debt, making capital expenditures or declaring dividends and may require the issuance of warrants,
which could potentially dilute the ownership interest of our stockholders. If we raise additional funds through
collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish
valuable rights to our technologies, future revenue streams or research programs or to grant licenses on terms that
may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when
needed, we may be required to delay, limit, reduce or terminate our product development or future
commercialization efforts or grant rights to develop and market products or product candidates that we would
otherwise prefer to develop and market ourselves.

Contractual Obligations and Commitments

The following table summarizes our contractual obligations at December 31, 2015 and the effect such

obligations are expected to have on our liquidity and cash flow in future periods:

Operating lease commitments(1)

Total(2)(3)(4)

Payments Due by Period

Total

Less Than
1 year

$6,926

$6,926

$978

$978

1-3 Years

3-5 Years

(in thousands)
$2,220

$2,330

$2,220

$2,330

More Than
5 years

$1,398

$1,398

Amounts related to contingent milestone payments are not considered contractual obligations as they are

contingent on the successful achievement of certain milestones. These contingent milestones may not be
achieved. We have not included any of these amounts in the table as we cannot estimate or predict when, or if,
these amounts will become due.

(1) We lease office space in Cambridge, Massachusetts under operating lease agreements that initially expire in
February 2022. The minimum lease payments in the table do not include related common area maintenance
charges or real estate taxes, which costs are variable.

(2) We have acquired exclusive and non-exclusive rights to use, research, develop and offer for sale certain
products and patents under licensing agreements, including amendments entered into in April and May
2014, and September 2015, with Washington University, CyDex Pharmaceuticals, Inc. and two with The
Regents of the University of California. The license agreements obligate us to make payments to the
licensors for license fees, milestones, license maintenance fees and royalties. We are obligated to make
future remaining milestone payments under these agreements of up to $34.1 million upon achieving certain
pre-commercialization milestones, such as clinical trials and regulatory approvals.

In the year ended December 31, 2015, clinical development and regulatory milestones were met for some of
the programs. We recorded research and development expense related to these milestones for the year ended
December 31, 2015 of $1.1 million.

(3) We enter into contracts in the normal course of business with CROs for clinical trials, non-clinical research
studies and testing, manufacturing and other services and products as part of general operations. These
contracts generally provide for termination upon notice, and therefore we believe that our non-cancelable
obligations under these agreements are not material.

88

(4) Under a January 2014 consulting agreement, we are obligated to make remaining milestone payments of up
to $1.5 million and to issue up to 87,303 shares of our common stock to a nonemployee consultant upon
achieving certain clinical trial milestones and regulatory approval milestones.

In the year ended December 31, 2015, the second and third clinical development milestones for one of the
programs included in the consulting agreement were met. We recorded research and development expense
for the year ended December 31, 2015 of $1.7 million, comprised of $0.5 million in cash and $1.2 million
related to the issuance of 23,809 shares of our common stock, related to the achievement of these
milestones.

Off-Balance Sheet Arrangements

We do not currently have, nor did we have during the periods presented, any off-balance sheet arrangements

as defined by SEC rules.

Item 7A. Quantitative and Qualitative Disclosures about Market Risk

We had cash and cash equivalents of approximately $186.8 million at December 31, 2015. The primary
objectives of our investment activities are to preserve principal, provide liquidity and maximize income without
significantly increasing risk. Our primary exposure to market risk relates to fluctuations in interest rates, which
are affected by changes in the general level of U.S. interest rates. Given the short-term nature of our cash and
cash equivalents, we believe that a sudden change in market interest rates would not be expected to have a
material impact on our financial condition and/or results of operation. We do not have any foreign currency or
other derivatives financial instruments.

We do not believe that our cash and cash equivalents have significant risk of default or illiquidity. While we
believe our cash and cash equivalents do not contain excessive risk, we cannot provide absolute assurance that in
the future our investments will not be subject to adverse changes in market value. In addition, we maintain
significant amounts of cash and cash equivalents at one or more financial institutions that are in excess of
federally insured limits.

Inflation generally affects us by increasing our cost of labor and clinical trial costs. We do not believe that

inflation had a material effect on our results of operations during the year ended December 31, 2015.

Item 8. Financial Statements and Supplementary Data

The financial statements required to be filed pursuant to this Item 8 are appended to this Annual Report. An

index of those financial statements is found in Item 15.

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

None.

Item 9A. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be

disclosed in the reports that we file or submit under the Securities and Exchange Act of 1934 is (1) recorded,
processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and
(2) accumulated and communicated to our management, including our President and Chief Executive Officer,
who is our principal executive officer and Chief Financial Officer, who is also our principal financial and
accounting officer, as appropriate, to allow timely decisions regarding required disclosure.

89

As of December 31, 2015, our management, with the participation of our principal executive officer and

principal financial and accounting officer, evaluated the effectiveness of our disclosure controls and procedures
(as defined in Rules 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934). Our management
recognizes that any controls and procedures, no matter how well designed and operated, can provide only
reasonable assurance of achieving their objectives, and management necessarily applies its judgment in
evaluating the cost-benefit relationship of possible controls and procedures. Our principal executive officer and
principal financial and accounting officer have concluded based upon the evaluation described above that, as of
December 31, 2015, our disclosure controls and procedures were effective at the reasonable assurance level.

Management’s Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial
reporting (as defined in Rule 13a—15(f) under the Exchange Act). Our internal control over financial reporting is
a process designed under the supervision of our principal executive officer and principal financial officer to
provide reasonable assurance regarding the reliability of financial reporting and the preparation of our financial
statements for external purposes in accordance with generally accepted accounting principles. Management
evaluated the effectiveness of our internal control over financial reporting using the criteria set forth by the
Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control—Integrated
Framework (the 2013 Framework). Management, under the supervision and with the participation of the
principal executive officer and principal financial officer, assessed the effectiveness of our internal control over
financial reporting as of December 31, 2015 and concluded that it was effective.

The effectiveness of our internal control over financial reporting as of December 31, 2015 has been audited

by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report,
which is included herein.

Changes in Internal Control over Financial Reporting

There were no changes to our internal control over financial reporting that occurred during the period

covered by this Annual Report that have materially affected, or are reasonably likely to materially affect, our
internal control over financial reporting.

Item 9B. Other Information

Not applicable.

90

PART III

Item 10. Directors, Executive Officers and Corporate Governance

The information required by this Item is incorporated herein by reference to the information that will be
contained in our proxy statement related to the 2016 Annual Meeting of Stockholders, which we intend to file
with the Securities and Exchange Commission within 120 days of the end of our fiscal year pursuant to General
Instruction G(3) of Form 10-K.

Item 11. Executive Compensation

The information required by this Item is incorporated herein by reference to the information that will be
contained in our proxy statement related to the 2016 Annual Meeting of Stockholders, which we intend to file
with the Securities and Exchange Commission within 120 days of the end of our fiscal year pursuant to General
Instruction G(3) of Form 10-K.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder
Matters

The information required by this Item is incorporated herein by reference to the information that will be
contained in our proxy statement related to the 2016 Annual Meeting of Stockholders, which we intend to file
with the Securities and Exchange Commission within 120 days of the end of our fiscal year pursuant to General
Instruction G(3) of Form 10-K.

Item 13. Certain Relationships and Related Transactions, and Director Independence

The information required by this Item is incorporated herein by reference to the information that will be
contained in our proxy statement related to the 2016 Annual Meeting of Stockholders, which we intend to file
with the Securities and Exchange Commission within 120 days of the end of our fiscal year pursuant to General
Instruction G(3) of Form 10-K.

Item 14. Principal Accounting Fees and Services

The information required by this Item is incorporated herein by reference to the information that will be
contained in our proxy statement related to the 2016 Annual Meeting of Stockholders, which we intend to file
with the Securities and Exchange Commission within 120 days of the end of our fiscal year pursuant to General
Instruction G(3) of Form 10-K.

PART IV

Item 15. Exhibits, Financial Statement Schedules

(a) The following documents are filed as part of this report:

(1) Financial Statements:

Report of Independent Registered Public Accounting Firm
Consolidated Balance Sheets
Consolidated Statements of Operations and Comprehensive Loss
Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and

Stockholders’ Equity (Deficit)

Consolidated Statements of Cash Flows
Notes to Consolidated Financial Statements

F-1
F-2
F-3

F-4
F-5
F-6

91

(2) Financial Statement Schedules:

All financial statement schedules have been omitted because they are not applicable, not required or the

information required is shown in the financial statements or the notes thereto.

(3) Exhibits. The exhibits filed as part of this Annual Report on Form 10-K are set forth on the Exhibit
Index immediately following our consolidated financial statements. The Exhibit Index is incorporated herein by
reference.

92

SIGNATURES

Pursuant to the requirements of the Section 13 or 15(d) of the Securities Exchange Act of 1934, the
Registrant has duly caused this Form 10-K to be signed on its behalf by the undersigned, thereunto duly
authorized.

SAGE THERAPEUTICS, INC.

Date: February 29, 2016

By: /s/ Jeffrey M. Jonas

Jeffrey M. Jonas, M.D.
Chief Executive Officer, President and Director
(Principal Executive Officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has

been signed by the following persons in the capacities indicated below and on the dates indicated:

Signature

Title

Date

/s/ Jeffrey M. Jonas

Jeffrey M. Jonas, M.D.

Chief Executive Officer, President and
Director (Principal Executive Officer)

February 29, 2016

/s/ Kimi Iguchi

Kimi Iguchi

/s/ Robert T. Nelsen

Robert T. Nelsen

/s/ Steven Paul

Steven Paul, M.D.

/s/ Kevin P. Starr

Kevin P. Starr

/s/ Howard Pien

Howard Pien

/s/ James Frates

James Frates

/s/ Michael F. Cola

Michael F. Cola

Chief Financial Officer (Principal Financial
and Accounting Officer)

February 29, 2016

February 29, 2016

February 29, 2016

February 29, 2016

February 29, 2016

February 29, 2016

February 29, 2016

Director

Director

Director

Director

Director

Director

93

Report of Independent Registered Public Accounting Firm

To the Board of Directors and Stockholders of
Sage Therapeutics, Inc.

In our opinion, the accompanying consolidated balance sheets and the related consolidated statements of
operations and comprehensive loss, of changes in redeemable convertible preferred stock and stockholders’
equity (deficit) and of cash flows present fairly, in all material respects, the financial position of Sage
Therapeutics, Inc. and its subsidiaries at December 31, 2015 and 2014, and the results of their operations and
their cash flows for each of the three years in the period ended December 31, 2015 in conformity with accounting
principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in
all material respects, effective internal control over financial reporting as of December 31, 2015, based on criteria
established in Internal Control—Integrated Framework (2013) issued by the Committee of Sponsoring
Organizations of the Treadway Commission (COSO). The Company’s management is responsible for these
financial statements, for maintaining effective internal control over financial reporting and for its assessment of
the effectiveness of internal control over financial reporting, included in Management’s Report on Internal
Control over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on these
financial statements and on the Company’s internal control over financial reporting based on our audits which
was an integrated audit in 2015. We conducted our audits in accordance with the standards of the Public
Company Accounting Oversight Board (United States). Those standards require that we plan and perform the
audits to obtain reasonable assurance about whether the financial statements are free of material misstatement
and whether effective internal control over financial reporting was maintained in all material respects. Our audits
of the financial statements included examining, on a test basis, evidence supporting the amounts and disclosures
in the financial statements, assessing the accounting principles used and significant estimates made by
management, and evaluating the overall financial statement presentation. Our audit of internal control over
financial reporting included obtaining an understanding of internal control over financial reporting, assessing the
risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal
control based on the assessed risk. Our audits also included performing such other procedures as we considered
necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

As discussed in Note 2 to the consolidated financial statements, the Company changed the manner in which it
classifies deferred income taxes in 2015.

A company’s internal control over financial reporting is a process designed to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in
accordance with generally accepted accounting principles. A company’s internal control over financial reporting
includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail,
accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable
assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance
with generally accepted accounting principles, and that receipts and expenditures of the company are being made
only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable
assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the
company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect
misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that
controls may become inadequate because of changes in conditions, or that the degree of compliance with the
policies or procedures may deteriorate.

/s/ PricewaterhouseCoopers LLP

Boston, Massachusetts
February 29, 2016

F-1

Sage Therapeutics, Inc. and Subsidiaries
Consolidated Balance Sheets
(in thousands, except share and per share data)

Assets
Current assets:

Cash and cash equivalents
Prepaid expenses and other current assets

Total current assets

Property and equipment, net
Restricted cash
Deferred offering costs
Deferred tax assets

Total assets

Liabilities and Stockholders’ Equity
Current liabilities:

Accounts payable
Accrued expenses
Deferred tax liabilities

Total current liabilities

Other liabilities

Total liabilities

Commitments and contingencies (Note 4)
Stockholders’ equity:

Preferred stock, $0.0001 par value; 5,000,000 shares authorized at
December 31, 2015 and 2014; no shares issued or outstanding at
December 31, 2015 and 2014

Common stock, $0.0001 par value; 120,000,000 shares authorized at

December 31, 2015 and 2014; 28,823,549 and 25,621,791 shares issued and
outstanding at December 31, 2015 and 2014, respectively

Additional paid-in capital
Accumulated deficit

Total stockholders’ equity

Total liabilities and stockholders’ equity

December 31,
2015

December 31,
2014

$ 186,753
1,738

$127,766
1,056

188,491
286
39
200
—

128,822
163
39
—
641

$ 189,016

$129,665

$

5,159
10,148
—

15,307
14

15,321

$

2,429
4,687
641

7,757
23

7,780

—

—

3
335,032
(161,340)

3
188,727
(66,845)

173,695

121,885

$ 189,016

$129,665

The accompanying notes are an integral part of these consolidated financial statements.

F-2

Sage Therapeutics, Inc. and Subsidiaries
Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share data)

Operating expenses:

Research and development
General and administrative

Total operating expenses

Loss from operations
Interest income, net
Other expense, net

Net loss and comprehensive loss

Accretion of redeemable convertible preferred stock to

redemption value

Net loss attributable to common stockholders

Net loss per share attributable to common stockholders—basic and

diluted

Year Ended December 31,
2014

2015

2013

$

$

$

$

69,357
25,293

94,650

(94,650)
178
(23)

(94,495)

$

24,100
9,710

33,810

(33,810)
8
(9)

(33,811)

14,357
3,922

18,279

(18,279)
1
(3)

(18,281)

—

(2,294)

(7)

(94,495) $

(36,105) $ (18,288)

(3.40) $

(1.67) $

(12.26)

Weighted average number of common shares used in net loss per
share attributable to common stockholders—basic and diluted

27,778,288

21,574,347

1,492,288

The accompanying notes are an integral part of these consolidated financial statements.

F-3

Sage Therapeutics, Inc. and Subsidiaries
Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit)
(in thousands, except share data)

Balances at December 31, 2012
Issuance of Series A Preferred Stock, net of

issuance costs of $18

Issuance of common stock from exercise of stock

options

Vesting of restricted stock
Accretion of redeemable convertible preferred

stock to redemption value

Issuance of common stock in payment of licensing

fees

Stock-based compensation expense
Net loss

Balances at December 31, 2013
Issuance of Series B Preferred Stock, net of

issuance costs of $30

Issuance of Series C Preferred Stock, net of

issuance costs of $110

Issuance of common stock from exercise of stock

options

Vesting of restricted stock
Issuance of common stock in payment of

consultant fees

Stock-based compensation expense
Accretion of redeemable convertible preferred

stock to redemption value

Conversion of redeemable convertible preferred

Series A, B and C Redeemable
Convertible Preferred Stock

Common Stock

Shares

Amount

Shares

Amount

Additional
Paid-in
Capital

Accumulated
Deficit

Total
Stockholders’
Equity
(Deficit)

15,000,000

$ 14,970

1,395,273

$— $ — $ (13,394)

$ (13,394)

22,750,000

22,732

—

—

—

—
—

—

—
—
—

—
—

7

—
—
—

3,174 —
176,695 —

—

—

47,619 —
—
—

—
—

37,750,000

37,709

1,622,761 —

9,999,999

14,970

8,973,905

37,890

—
—

—
—

—
—

—
—

—

—

—

—

—

87,475 —
138,108 —

15,872 —
—

—

127
2,512

1
20

(7)

64
61
—

139

—

—

40
14

—

—
—

—

—

1
20

(7)

—
—
(18,281)

(31,675)

64
61
(18,281)

(31,536)

—

—

—
—

—
—

—

—

40
14

127
2,512

2,294

—

—

(935)

(1,359)

(2,294)

stock to common stock

(56,723,904)

(92,863)

18,007,575

2

92,861

—

92,863

Initial public offering of common stock, net of

offering costs

Net loss

Balances at December 31, 2014

Issuance of common stock from exercise of stock

options

Vesting of restricted stock
Issuance of common stock under employee stock

purchase plan

Issuance of common stock in payment of

consultant fees

Stock-based compensation expense
Public offering of common stock, net of offering

costs
Net loss

Balances at December 31, 2015

—
—

—

—
—

—

—
—

—
—

—

—
—

—

—
—

—

—
—

—
—

5,750,000
—

1
—

93,969
—

25,621,791

3

188,727

—
(33,811)

(66,845)

93,970
(33,811)

121,885

417,475 —
128,051 —

3,852 —

603
17

127

23,809 —
—

—

1,211
15,176

—
—

—

—
—

603
17

127

1,211
15,176

2,628,571 —
—
—

129,171
—

—
(94,495)

129,171
(94,495)

$ —

28,823,549

$

3

$335,032

$(161,340)

$173,695

The accompanying notes are an integral part of these consolidated financial statements.

F-4

Sage Therapeutics, Inc. and Subsidiaries
Consolidated Statements of Cash Flows
(in thousands)

Cash flows from operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:

Stock-based compensation expense
Non-cash licensing and consulting fees
Depreciation
Changes in operating assets and liabilities:

Prepaid expenses and other current assets
Deferred offering costs
Accounts payable
Accrued expenses and other liabilities

Net cash used in operating activities

Cash flows from investing activities
Purchase of property and equipment

Net cash used in investing activities

Cash flows from financing activities
Proceeds from the issuance of Series A preferred stock, net of issuance costs
Proceeds from the issuance of Series B preferred stock, net of issuance costs
Proceeds from the issuance of Series C preferred stock, net of issuance costs
Proceeds from stock option exercise and employee stock purchase plan

issuances

Proceeds from public offering of common stock, net of commissions and

underwriting discounts
Payment of offering costs

Net cash provided by financing activities

Net increase in cash and cash equivalents

Cash and cash equivalents at beginning of period

Cash and cash equivalents at end of period

Supplemental disclosure of non-cash investing and financing activities
Accretion of redeemable convertible preferred stock to redemption value
Conversion of preferred stock to common stock
Public offering costs included in accounts payable or accrued expenses

Year Ended December 31,
2014

2015

2013

$ (94,495) $ (33,811) $(18,281)

15,240
1,211
115

(681)
(165)
2,690
5,404

2,512
127
51

(715)
—
441
4,353

61
64
47

(317)
—
674
236

(70,681)

(27,042)

(17,516)

(198)

(198)

(128)

(128)

(3)

(3)

—
—
—

—
14,970
37,890

22,732
—
—

730

40

51

129,720
(584)

96,255
(2,285)

—
—

129,866

146,870

22,783

58,987

119,700

127,766

8,066

5,264

2,802

$186,753

$127,766

$ 8,066

$ — $
2,294
$ — $ 92,863
$

$
$ —
$ — $ —

165

7

The accompanying notes are an integral part of these consolidated financial statements.

F-5

SAGE THERAPEUTICS, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

1. Nature of the Business

Sage Therapeutics, Inc. (“Sage” or the “Company”) is a clinical-stage biopharmaceutical company
committed to developing and commercializing novel medicines to treat life-altering central nervous system
(“CNS”) disorders, where there are inadequate or no approved existing therapies. The Company is targeting CNS
indications where patient populations are easily identified, clinical endpoints are well-defined, and development
pathways are feasible.

The Company was incorporated under the laws of the state of Delaware on April 16, 2010 and commenced
operations on January 19, 2011 as Sterogen Biopharma, Inc. On September 13, 2011, the Company changed its
name to Sage Therapeutics, Inc. under its Second Amended and Restated Certificate of Incorporation.

The Company is subject to risks and uncertainties common to companies in the biotech industry, including,

but not limited to, the risks associated with developing product candidates at each stage of non-clinical and
clinical development; the challenges associated with gaining regulatory approval of such product candidates; the
risks associated with commercializing pharmaceutical products, if we are able to obtain regulatory approval; the
potential for development by third parties of new technological innovations that may compete with the
Company’s products; the dependence on key personnel; the challenges of protecting proprietary technology; the
need to comply with government regulations; the high costs of drug development; and the uncertainty of being
able to secure additional capital when needed to fund operations.

The Company has incurred losses and negative cash flows from operations since its inception. As of
December 31, 2015, the Company had an accumulated deficit of $161.3 million. From its inception through
December 31, 2015, the Company has raised aggregate net proceeds of $90.6 million from the issuance of Series
A, Series B and Series C redeemable convertible preferred stock. In July 2014, the Company raised net proceeds
of $94.0 million from the sale of common stock in its initial public offering, (“IPO”). In April 2015, the
Company raised net proceeds of $129.1 million from the sale of common stock in a follow-on underwritten
public offering. In January 2016, the Company raised net proceeds of $140.4 million from the sale of common
stock in a follow-on underwritten public offering. Based on its current operating plans, the Company believes its
cash and cash equivalents balance of $186.8 million as of December 31, 2015, in addition to the funds raised
from the public offering of common stock in January 2016, will be sufficient to fund its anticipated level of
operations into the beginning of 2018.

2.

Summary of Significant Accounting Policies

The following is a summary of significant accounting policies followed in the preparation of these financial

statements.

Basis of Presentation

The accompanying consolidated financial statements include those of the Company and its subsidiaries after

elimination of all intercompany accounts and transactions. The accompanying consolidated financial statements
have been prepared in conformity with accounting principles generally accepted in the United States of America
(“GAAP”).

Use of Estimates

The preparation of consolidated financial statements in conformity with GAAP requires management to
make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of

F-6

contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of
revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less at the

date of purchase to be cash equivalents.

Restricted Cash

A deposit of $39 thousand was restricted from withdrawal as of December 31, 2015 and 2014. The
restriction is related to securing the Company’s facility lease and expires in 2022 in accordance with the
operating lease agreement. This balance is included in restricted cash on the accompanying balance sheets.

Property and Equipment

Property and equipment are recorded at cost and depreciated over their estimated useful lives using the

straight-line method. Upon retirement or sale, the cost of assets disposed of and the related accumulated
depreciation are removed from the accounts and any resulting gain or loss is credited or charged to income.
Repairs and maintenance costs are expensed as incurred.

Impairment of Long-Lived Assets

Long-lived assets consist of property and equipment. Long-lived assets to be held and used are tested for
recoverability whenever events or changes in business circumstances indicate that the carrying amount of the
assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an
impairment review include significant underperformance of the business in relation to expectations, significant
negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an
impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares
forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived
asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash
flows expected to result from the use of an asset are less than its carrying amount. The impairment loss would be
based on the excess of the carrying value of the impaired asset over its fair value, determined based on
discounted cash flows. To date, the Company has not recorded any impairment losses on long-lived assets.

Research and Development

Research and development expenses are comprised of costs incurred in performing research and

development activities, including salaries and benefits, overhead costs, depreciation, contract services and other
related costs. Research and development costs are expensed to operations as the related obligation is incurred.

Research Contract Costs and Accruals

The Company has entered into various research and development contracts with research institutions and
other companies both inside and outside of the United States. These agreements are generally cancelable, and
related payments are recorded as research and development expenses as incurred. The Company records accruals
for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company
analyzes progress of the studies, including the phase or completion of events, invoices received and contracted
costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any
reporting period. Actual results could differ from the Company’s estimates. The Company’s historical accrual
estimates have not been materially different from the actual costs.

F-7

Patent Costs

The Company expenses patent costs as incurred and classifies such costs as general and administrative

expenses in the accompanying statements of operations and comprehensive loss.

Stock-Based Compensation

The Company recognizes compensation expense for all stock-based awards made to employees and
nonemployee directors, including grants of stock options and restricted stock, based on estimated fair value on
date of grant, over the requisite service period.

For stock options and restricted stock issued to nonemployee consultants, the Company recognizes the fair

value of such instruments as an expense over the period in which the related services are received. The fair value
of the awards and measurement of related stock-based compensation is subject to periodic adjustments as the
underlying equity instruments vest. For awards that vest upon achievement of a performance condition, the
Company recognizes compensation expense when achievement of the performance condition is deemed probable
over the implicit service period.

The fair value of each option grant is estimated using the Black-Scholes option-pricing model. Through July

2014, the Company was a private company and lacks sufficient Company-specific historical and implied
volatility information. Therefore, the Company estimates expected volatility based on the historical volatility of
publicly traded peer companies and expects to continue to do so until such time as it has adequate historical data
regarding the volatility of its traded stock price. The expected term of the Company’s options has been
determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options, while the
expected term of its options granted to consultants and nonemployees has been determined based on the
contractual term of the options. The risk-free interest rate is determined by reference to the U.S. Treasury yield
curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the
award. Expected dividend yield is based on the fact that the Company never paid cash dividends and does not
expect to pay any cash dividends in the foreseeable future.

The Company also applies a forfeiture rate in order to calculate stock-based compensation expense. To the
extent actual forfeitures differ from the estimates, the difference will be recorded as a cumulative adjustment in
the period the estimates are revised. The Company recognizes compensation expense for only the portion of
awards that are expected to vest. Expected forfeitures are based on the Company’s historical experience and
management’s expectations of future forfeitures.

Basic and Diluted Net Loss Per Share

Upon the closing of the Company’s IPO in July 2014, all of the Company’s outstanding shares of

redeemable convertible preferred stock were converted into shares of common stock. Prior to this conversion, the
Company followed the two-class method when computing net loss per share as the Company had issued shares
that meet the definition of participating securities. The two-class method determines net loss per share for each
class of common and participating securities according to dividends declared or accumulated and participation
rights in undistributed earnings. The two-class method requires income available to common stockholders for the
period to be allocated between common and participating securities based upon their respective rights to receive
dividends as if all income for the period had been distributed. The Company’s redeemable convertible preferred
shares contractually entitled the holders of such shares to participate in dividends, but did not contractually
require the holders of such shares to participate in losses of the Company. Accordingly, the two-class method did
not apply for periods in which the Company reported a net loss or a net loss attributable to common stockholders
resulting from dividends or accretion related to its redeemable convertible preferred shares.

Basic net loss per share attributable to common stockholders is computed by dividing the net loss
attributable to common stockholders by the weighted average number of common shares outstanding for the

F-8

period. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net
loss attributable to common stockholders by the weighted average number of common shares outstanding for the
period, including potential dilutive common shares assuming the dilutive effect of outstanding stock options and
unvested restricted common shares, as determined using the treasury stock method. For periods in which the
Company has reported net losses, diluted net loss per common share attributable to common stockholders is the
same as basic net loss per common share attributable to common stockholders, since dilutive common shares are
not assumed to have been issued if their effect is antidilutive.

The Company reported a net loss attributable to common stockholders for the years ended December 31,

2015, 2014 and 2013.

Risks and Uncertainties

The product candidates developed by the Company require approvals from the U.S. Food and Drug
Administration or foreign regulatory agencies prior to commercial sales. There can be no assurance that the
Company’s current and future product candidates will receive the necessary approvals. If the Company fails to
successfully complete clinical development and generate results sufficient to file for regulatory approval or is
denied approval or approval is delayed, it may have a material adverse impact on the Company’s business and its
financial statements.

The Company is subject to risks common to companies in the development stage including, but not limited

to, dependency on the clinical success of its product candidates, ability to obtain regulatory approval of its
product candidates, the commercial success of its product, if approved, the need for substantial additional
financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and
consumers, significant competition and untested manufacturing capabilities.

Concentration of Credit Risk and of Significant Suppliers

Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily
of cash and cash equivalents. The Company has all cash and cash equivalents balances at two accredited financial
institutions, in amounts that exceed federally insured limits. The Company does not believe that it is subject to
unusual credit risk beyond the normal credit risk associated with commercial banking relationships.

The Company is dependent on third-party manufacturers to supply products for research and development
activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of
manufacturers to supply it with its requirements for the active pharmaceutical ingredients and formulated drugs
related to these programs. These programs could be adversely affected by a significant interruption in the supply
of active pharmaceutical ingredients and formulated drugs.

Income Taxes

The Company accounts for income taxes under the asset and liability method. Under this method, deferred

tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences
between financial statement carrying amounts of existing assets and liabilities and their respective tax bases.
Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which these temporary
differences are expected to be recovered or settled. Valuation allowances are provided if based on the weight of
available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.
During November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes, which
simplifies the presentation of deferred income taxes. The Company early adopted ASU 2015-17 effective
December 31, 2015 on a prospective basis.

F-9

Fair Value Measurements

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly
transaction between market participants at the measurement date. Financial assets and liabilities carried at fair
value are to be classified and disclosed in one of the following three categories:

Level 1 — Quoted market prices in active markets for identical assets or liabilities. At December 31, 2015

and 2014, the Company’s Level 1 assets consisted of money market funds totaling $186.8 million
and $127.8 million, respectively.

Level 2 — Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities;

quoted prices in markets that are not active; or other inputs that are observable or can be
corroborated by observable market data for substantially the full term of the assets or liabilities.
At December 31, 2015 and 2014, the Company had no Level 2 assets or liabilities.

Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to
the fair value of the assets or liabilities. At December 31, 2015 and 2014, the Company had no
Level 3 assets or liabilities.

The Company’s financial instruments generally consist of cash equivalents, accounts payable and accrued

expenses. The carrying amounts for the applicable financial instruments reported in the balance sheets
approximate their fair values at December 31, 2015 and 2014, respectively.

Deferred Offering Costs

The Company capitalizes certain legal, accounting and other third-party fees that are directly associated
with in-process equity financings as other assets until such financings are consummated. After consummation of
the IPO in July 2014, $2.3 million of these costs were recorded in stockholders’ equity as a reduction of
additional paid-in capital generated as a result of the IPO. After consummation of the follow-on public offering
of common stock in April 2015, $0.5 million of these costs were recorded in stockholders’ equity as a reduction
of additional paid-in capital generated as a result of the offering. As of December 31, 2015, the Company had
recorded deferred offering costs of $0.2 million which are shown as a non-current asset. They are for the follow-
on public offering that was consummated in January 2016.

Segment Data

The Company manages its operations as a single segment for the purposes of assessing performance and
making operating decisions. The Company’s singular focus is on advancing medicines to treat central nervous
system disorders, where there are inadequate or no approved existing therapies. All tangible assets are held
within the United States.

Comprehensive Loss

Comprehensive loss includes net loss as well as other changes in stockholders’ equity (deficit) that result
from transactions and economic events other than those with stockholders. For the years ended December 31,
2015, 2014 and 2013, there was no difference between net loss and comprehensive loss.

Public Offerings

On July 23, 2014, the Company completed the sale of 5,750,000 shares of its common stock in its IPO (the

“IPO”), at a price to the public of $18.00 per share, resulting in net proceeds to the Company of $94.0 million
after deducting underwriting discounts and commissions and offering costs paid by the Company. The shares
began trading on Nasdaq Global Market on July 18, 2014.

F-10

In connection with preparing for the IPO, the Company’s board of directors and stockholders approved a 1-

for-3.15 reverse stock split of the Company’s common stock effective July 2, 2014. All share and per share
amounts in the financial statements contained herein and notes thereto have been retroactively adjusted, where
necessary, to give effect to this reverse stock split. In connection with the closing of the IPO, all of the
Company’s outstanding redeemable convertible preferred stock automatically converted into shares of common
stock as of July 23, 2014, resulting in the issuance by the Company of an additional 18,007,575 shares of
common stock. The significant increase in common stock outstanding in July 2014 will impact the year-over-
year comparability of the Company’s net loss per share calculations over the next year.

On April 20, 2015, the Company completed the sale of 2,628,571 shares of common stock in an

underwritten public offering of its common stock at a price to the public of $52.50 per share, resulting in net
proceeds to the Company of $129.1 million after deducting underwriting discounts and commissions and offering
costs paid by the Company. A description of the sale of shares of common stock held in January 2016 is included
in Note 13.

Recently Issued Accounting Pronouncements

In May 2014, the FASB issued guidance that outlines a single comprehensive model for entities to use in
accounting for revenue arising from contracts with customers and supersedes most current revenue recognition
guidance, including industry specific guidance. The guidance is based on the principle that an entity should
recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the
consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance
also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows
arising from customer contracts, including significant judgments and changes in judgments and assets recognized
from costs incurred to fulfill a contract. Entities have the option of using either a full retrospective or a modified
retrospective approach for the adoption of the new standard. The guidance becomes effective for the Company in
the year ending December 31, 2018, and the Company could early adopt the standard for the year ending
December 31, 2017. The Company is currently assessing the method of adoption and the impact that this new
accounting guidance will have on its consolidated financial statements and footnote disclosures.

In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements—Going Concern

(Subtopic 205-40). The new guidance addresses management’s responsibility to evaluate whether there is
substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote
disclosures. Management’s evaluation should be based on relevant conditions and events that are known and
reasonably knowable at the date that the financial statements are issued. The standard will be effective for the
first interim period within annual reporting periods beginning after December 15, 2016. Early adoption is
permitted. The Company is evaluating the effect that this guidance will have on its consolidated financial
statements.

In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes, which
simplifies the classification of deferred tax assets and liabilities. The new standard requires that all deferred tax
assets and liabilities, along with any related valuation allowance, be classified as noncurrent on the balance sheet.
The standard is effective for interim and annual periods beginning after December 15, 2016 and allows for early
adoption using a full retrospective method or a prospective method. The Company has elected to early adopt the
provisions of this new standard using a prospective method. As a result, all deferred taxes as of December 31,
2015 are classified as noncurrent on a net basis in the Company’s consolidated balance sheet, while prior periods
remain as previously reported.

In February 2016, the Financial Accounting Standards Board (FASB) issued ASU 2016-02—Leases
(ASC 842), which sets out the principles for the recognition, measurement, presentation and disclosure of leases
for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual
approach, classifying leases as either finance or operating leases based on the principle of whether or not the

F-11

lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is
recognized based on an effective interest method or on a straight line basis over the term of the lease,
respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term
of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be
accounted for similar to existing guidance for operating leases today. ASC 842 supersedes the previous leases
standard, ASC 840 Leases. The standard is effective on January 1, 2019, with early adoption permitted. The
Company is in the process of evaluating the impact of this new guidance.

3. Balance Sheet Components

Property and Equipment, net

Property and equipment, net consists of the following:

Computer hardware and software
Furniture and equipment

Less: Accumulated depreciation

Property and equipment, net

Useful Life
(Years)

3
5

December 31,

2015

2014

(in thousands)

$ 400
147

$ 206
103

547
(261)

309
(146)

$ 286

$ 163

Depreciation expense for the years ended December 31, 2015, 2014 and 2013 was $0.1 million, $0.1 million

and $47 thousand, respectively.

Accrued Expenses

Accrued expenses consist of the following:

Development costs
Employee related expenses
Professional services
Other accrued expenses

4. Commitments and Contingencies

Operating Leases

December 31,

2015

2014

(in thousands)

$ 6,466
2,718
935
29

$2,788
1,279
574
46

$10,148

$4,687

The Company rents its 22,067 square foot office space under an operating lease that was expires in 2022. In

March 2013, the Company signed a sublease agreement to sublet 1,900 square feet. Rental income from this
sublease was $4 thousand per month. In September, 2015, this sublease was terminated.

Rent expense, net of sublease income, for the years ended December 31, 2015, 2014, and 2013, was $0.4

million, $0.3 million, and $0.3 million, respectively.

F-12

Future minimum lease payments under non-cancelable operating leases are as follows at December 31,

2015:

Years Ending December 31,

(in thousands)

2016
2017
2018
2019
2020
Thereafter

License Agreements

CyDex License Agreement

$ 978
1,088
1,132
1,154
1,176
1,398

$6,926

In September 2015, the Company and CyDex Pharmaceuticals, Inc. (“CyDex”) amended and restated their

existing commercial license agreement. Under the terms of the commercial license agreement as amended and
restated, CyDex has granted to the Company an exclusive license to CyDex’s Captisol drug formulation
technology and related intellectual property for the manufacture of pharmaceutical products incorporating the
Company’s compounds known as SAGE-547 and SAGE-689, and the development and commercialization of the
resulting products in the treatment, prevention or diagnosis of any disease or symptom in humans or animals
other than (i) the ocular treatment of any disease or condition with a formulation, including a hormone;
(ii) topical ocular treatment of inflammatory conditions; (iii) treatment and prophylaxis of fungal infections in
humans; and (iv) any ocular treatment for retinal degeneration.

As consideration for the inclusion of SAGE-689 in the license granted by CyDex, the Company paid to

CyDex $0.1 million, which was recorded as research and development expense in 2015 in connection with
execution of the amended and restated license agreement.

The Company is obligated to make milestone payments under the amended and restated license agreement
with CyDex based on the achievement of clinical development and regulatory milestones in the amount of $0.8
million in clinical milestones and $3.8 million in regulatory milestones for each of the first two fields with
respect to SAGE-547; $1.3 million in clinical milestones and $8.5 million in regulatory milestones for each of
the third and fourth fields with respect to SAGE-547; and $0.8 million in clinical milestones and $1.8 million in
regulatory milestones for one field with respect to SAGE-689.

For the year ended December 31, 2015, the Company recorded research and development expense and made
payments of cash of $0.8 million related to clinical development milestones that were met for this agreement. For
the years ended December 31, 2014 and 2013, the Company did not record any expense or make any milestone
or royalty payments.

Washington University License Agreement

In November 2013, the Company entered into a license agreement with Washington University whereby the

Company was granted exclusive, worldwide rights to develop and commercialize a novel set of neuroactive
steroids developed by Washington University. In exchange for development and commercialization rights, the
Company paid an upfront, non-refundable payment of $50 thousand and is required to pay an annual license
maintenance fee of $15 thousand on each subsequent anniversary date, until the first Phase 2 clinical trial for a
licensed product is initiated. The Company is obligated to make milestone payments to Washington University
based on achievement of clinical development and regulatory milestones of up to $0.7 million and $0.5 million,
respectively. Additionally, the Company fulfilled its obligation to issue to Washington University 47,619 shares

F-13

of common stock on December 13, 2013. The fair value of these shares totaling $0.1 million was recorded as
research and development expense in 2013.

The Company is obligated to pay royalties to Washington University at rates in the low single digits on net

sales of licensed products covered under patent rights and royalties at rates in the low single digits on net sales of
licensed products not covered under patent rights. Additionally, the Company has the right to sublicense and is
required to make payments at varying percentages of sublicensing revenue received, initially in the mid-teens and
descending to the mid-single digits over time.

For the year ended December 31, 2014, the Company did not record any expense or make any milestone or
royalty payments. In September 2015, a regulatory milestone was met for one of the programs. Accordingly, the
Company recorded research and development expenses and made a cash payment of $50 thousand in 2015.

University of California License Agreement

In October 2013, the Company entered into a non-exclusive license agreement with The Regents of the
University of California whereby the Company was granted a non-exclusive license to certain clinical data and
clinical material for use in the development and commercialization of biopharmaceutical products in the licensed
field, including status epilepticus and post-partum depression. In May 2014, the license agreement was amended
to add the treatment of essential tremor to the licensed field of use, materials and milestone fee provisions of the
agreement.

The Company will be required to pay to The Regents of the University of California clinical development

milestones of up to $0.1 million and pay royalties of less than 1% on net sales for a period of fifteen years
following the sale of the first commercial product.

The license will terminate on the earlier to occur of (i) 27 years after the effective date or (ii) 15 years after

the last-derived product is first commercially sold.

For the years ended December 31, 2014 and 2013, the Company did not record any expense or make any

milestone or royalty payments.

During 2015, three clinical development milestones were met. Accordingly, the Company recorded research

and development expenses and made cash payments totaling $0.1 million. In June 2015, the Company entered
into an exclusive license agreement with The Regents of the University of California whereby the Company was
granted an exclusive license to certain patent rights related to the use of allopregnanolone to treat various
diseases. In exchange for such license, the Company paid an upfront payment of $50 thousand and will make
annual maintenance fees of $15 thousand until the calendar year following the first sale, if any, of a licensed
product. The Company is obligated to make milestone payments following the achievement of specified
regulatory and sales milestones of up to $0.7 million and $2.0 million in the aggregate, respectively. Following
the first sale, if any, of a licensed product, the Company is obligated to pay royalties at a low single digit
percentage of net sales, if any, of licensed products, subject to specified minimum annual royalty amounts.
Unless terminated by operation of law or by acts of the parties under the terms of the agreement, the license
agreement will terminate when the last-to-expire patents or last-to-be abandoned patent applications expire,
whichever is later.

Consulting Agreement

In January 2014, the Company entered into a consulting agreement with a nonemployee advisor whereby

the Company is obligated to make cash payments of up to $2.0 million and to issue up to 126,984 shares of
common stock upon attainment of certain clinical development and regulatory milestones.

F-14

In January and March 2014, the first clinical development milestones for each of two programs included in
the consulting agreement were met. Accordingly, the Company recorded research and development expense for
the year ended December 31, 2014 of $0.2 million, comprised of $50 thousand in cash and $0.1 million related to
the issuance of 15,872 shares of the Company’s common stock.

During the year ended December 31, 2015, the second and third clinical development milestones for one of

the programs included in the consulting agreement was met. Accordingly, the Company recorded research and
development expense for the year ended December 31, 2015 of $1.7 million, comprised of $0.5 million in cash
and $1.2 million related to the issuance of 23,809 shares of the Company’s common stock, related to the
achievement of these milestones.

5. Redeemable Convertible Preferred Stock

The Company has newly authorized preferred stock amounting to 5,000,000 shares as of December 31, 2015

and 2014. The newly authorized preferred stock was classified under stockholders’ equity (deficit) as of
December 31, 2015 and 2014.

As of December 31, 2014 and 2013, the Company’s Certificate of Incorporation, as amended and restated,
authorized the Company to issue no shares and 37,750,000, respectively, shares of $0.0001 par value preferred
stock. In July 2014, all issued and outstanding redeemable convertible preferred stock was converted to common
stock, see Note 2.

The Company had issued Series A, Series B and Series C redeemable convertible preferred stock
(collectively, the “Redeemable Preferred Stock”). The Redeemable Preferred Stock was classified outside of
stockholders’ equity (deficit) as of December 31, 2013 because the shares contained redemption features that are
not solely within the control of the Company.

On March 18, 2013, the Company issued an additional 5,000,000 shares in the second funding of the second

tranche of Series A Preferred Stock at $1.00 per share, resulting in net proceeds of $5.0 million.

On July 1, 2013, the Company issued an additional 5,000,000 shares in the third funding of the second

tranche of Series A Preferred Stock at $1.00 per share, resulting in net proceeds of $5.0 million.

On September 12, 2013, the Company issued an additional 12,500,000 shares in the third tranche of Series

A Preferred Stock at $1.00 per share, resulting in net proceeds of $12.5 million.

On October 18, 2013, the Company issued 250,000 shares of Series A Preferred Stock at $1.00 per share,

resulting in net proceeds of $0.3 million.

On October 15, 2013, the Company entered into a Stock Purchase Agreement whereby the Company would

issue up to $20.0 million of Series B redeemable convertible preferred stock (“Series B Preferred Stock”) at
$1.50 per share. The initial purchase and sale in the amount of $10.0 million could have occurred once certain
development milestones had been successfully achieved. The second tranche of $10.0 million could be issued
after the initial closing and at the discretion of the Board of Directors. In November 2013, the Company met the
development milestones to issue the first tranche of the Series B Preferred Stock.

On January 7, 2014, the Company issued 6,666,666 shares of Series B Preferred Stock at $1.50 per share,

resulting in net proceeds of $10.0 million.

On February 12, 2014, the Company issued 3,333,333 shares of Series B Preferred Stock at $1.50 in a
second closing, resulting in net proceeds of $5.0 million. At that time, the Company decided not to draw on the
remaining $5.0 million of the second tranche of the Series B Preferred Stock.

F-15

The Company incurred issuance costs of $30 thousand in 2014 with the issuance of the Series B Preferred

Stock which were recorded as a reduction of the proceeds received.

On March 11, 2014, the Company entered into a Stock Purchase Agreement whereby the Company issued

8,973,905 shares of Series C redeemable convertible preferred stock (“Series C Preferred Stock”) at $4.2345 per
share for net proceeds of $38.0 million.

The Company incurred issuance costs of $0.1 million in 2014 with the issuance of the Series C Preferred

Stock which were recorded as a reduction of the proceeds received.

6. Common Stock

As of December 31, 2015 and 2014, the Company has authorized 120,000,000 shares of common stock with

a par value of $0.0001 per share.

Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the
Company’s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the
Board of Directors, if any. As of December 31, 2015 and 2014, no dividends have been declared.

7.

Stock-Based Compensation

2014 Stock Option Plan

On July 2, 2014, the Company’s stockholders approved the 2014 Stock Option and Incentive Plan (the

“2014 Stock Option Plan”), which became effective upon the completion of the IPO. The 2014 Stock Option
Plan provides for the grant of restricted stock awards, incentive stock options and non-statutory stock options.
The 2014 Stock Option Plan replaced the Company’s 2011 Stock Option and Grant Plan (the “2011 Stock Option
Plan”). The Company will no longer grant stock options or other awards under the 2011 Stock Option Plan. Any
options or awards outstanding under the 2011 Stock Option Plan remained outstanding and effective. As of
December 31, 2015, the total number of shares reserved under all equity plans is 3,862,172, and the Company
had 859,363 shares available for future issuance under such plans.

The 2014 Stock Option Plan provides for an annual increase, to be added on the first day of each fiscal year,

by up to 4% of the Company’s issued and outstanding shares of common stock on the immediately preceding
December 31.

Terms of restricted stock awards and stock option agreements, including vesting requirements, are

determined by the Board of Directors or the Compensation Committee of the Board of Directors, subject to the
provisions of the applicable stock option plan. Options and restricted stock awards granted by the Company
generally vest based on the grantee’s continued service with the Company during a specified period following
grant. Awards granted to employees generally vest ratably over four years, with a 25% cliff vesting at the one
year anniversary for new employee awards. During 2013, the Company also granted a pool of option awards
which vest ratably over one year. All awards are exercisable from the date of grant for a period of ten years.

During 2015, the Company granted 497,100 options to employees to purchase shares of common stock that

contain performance-based vesting criteria, primarily related to achievement of certain clinical and regulatory
development milestones related to the Company’s product candidates. Recognition of stock-based compensation
expense associated with these performance-based stock options commences when the performance condition is
considered probable of achievement, using management’s best estimates. During the quarter ended June 30,
2015, the achievement of one milestone was considered probable and that milestone was achieved during the
quarter ended September 30, 2015. The related expense was recognized over the estimated service period. This
milestone represents 35% of the performance-based grants that were made during 2015. The achievement of the

F-16

remaining milestones was deemed to be not probable as of December 31, 2015 and therefore no expense has been
recognized related to these awards. During the year ended December 31, 2015, the Company recognized stock-
based compensation expense of $4.8 million related to stock options with performance-based vesting criteria.

Stock-based compensation expense recognized during the years ended December 31, 2015, 2014, and 2013

was as follows:

Stock-based compensation expense:
Research and development
General and administrative

Year Ended December 31,

2015

2014

2013

(in thousands)

$ 5,924
9,316

$1,093
1,419

$15,240

$2,512

$38
23

$61

For stock option awards, the fair value of the options is estimated at the grant date using the Black-Scholes

option-pricing model, taking into account the terms and conditions upon which options are granted. The fair
value of the options is amortized on a straight-line basis for awards to employees and on a graded basis for
awards to non-employees over the requisite service period of the awards for awards to employees and graded
vesting is used for non-employees. The weighted average grant date fair value per share relating to outstanding
stock options granted under the Company’s stock option plans during the years ended December 31, 2015, 2014
and 2013 was $34.08, $14.33 and $0.38, respectively.

The fair value of each option granted to employees and nonemployee directors during the years ended
December 31, 2015, 2014 and 2013 under the Company’s stock option plans has been calculated on the date of
grant using the following weighted average assumptions:

Expected dividend yield
Expected volatility
Risk free interest rate
Expected term

Year Ended December 31,

2015

2014

2013

0.00%
90.54%
1.59%

0.00%
98.86%
1.95%

0.00%
99.89%
1.66%

6.03 years

6.38 years

6.04 years

Expected dividend yield: The Company has not paid and does not anticipate paying any dividends in the

foreseeable future.

Risk-free interest rate: The Company determined the risk-free interest rate by using a weighted average

equivalent to the expected term based on the U.S. Treasury yield curve in effect as of the date of grant.

Expected volatility: As the Company has only been a public company since July 2014, there is not sufficient
historical volatility for the expected term of the options. Therefore, the Company used an average historical share
price volatility based on an analysis of reported data for a peer group of comparable companies.

Expected term (in years): Expected term represents the period that the Company’s stock option grants are

expected to be outstanding. As the Company has only been a public company since July 2014, there is not
sufficient historical term data to calculate the expected term of the options. Therefore, the Company elected to
utilize the “simplified” method to estimate the expected term of option grants issued to employees. Under this
approach, the weighted average expected life is presumed to be the average of the vesting term and the
contractual term of the option.

F-17

Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual
forfeitures differ from estimates. The Company estimates forfeitures based on historical termination behavior.
For the years ended December 31, 2015, 2014, and 2013, a forfeiture rate of 10% was applied.

For options granted to nonemployees, the expected life of the option used is ten years, which is the
contractual term of each such option. All other assumptions used to calculate the grant date fair value are
generally consistent with the assumptions used for options granted to employees.

The table below summarizes activity related to stock options:

Outstanding as of December 31, 2014
Granted
Exercised
Forfeited

Outstanding as of December 31, 2015

Vested or expected to vest as of December 31,

2015

Exercisable as of December 31, 2015

Shares

1,996,615
1,516,307
(417,475)
(92,638)

3,002,809

2,421,859

723,895

Weighted
Average Exercise
Price

Weighted Average
Remaining Life (in
years)

$ 7.01
45.64
1.44
26.93

$26.67

$24.89

$14.47

8.98

8.67

8.60

8.27

Aggregate
Intrinsic Value

(in thousands)
$59,362

$96,479

$82,344

$31,729

As of December 31, 2015, the Company had unrecognized stock-based compensation expense related to its

unvested service-based stock option awards of $31.5 million, which is expected to be recognized over the
remaining weighted average vesting period of 3.01 years. The total fair value of shares vested for the years ended
December 31, 2015, 2014 and 2013 was $9.2 million, $1.0 million, and $9 thousand, respectively. In addition,
the Company has 358,976 shares of outstanding unvested stock options that vest upon the achievement of certain
performance criteria. Total unrecognized compensation related to those awards was $7.8 million at December 31,
2015.

The intrinsic value of stock options exercised during the years ended December 31, 2015 and 2014 was

$28.4 million and $2.4 million, respectively, and the intrinsic value of stock options exercised during the year
ended December 31, 2013 was zero.

Restricted Stock Awards

During the year ended December 31, 2013, the Company granted restricted stock awards to certain officers,

employees, directors, and consultants of the Company. During the years ended December 31, 2015, 2014 and
2013, the Company recorded $0.3 million, $0.2 million and $11 thousand, respectively, of stock-based
compensation expense related to its restricted stock. The table below summarizes activity relating to restricted
stock:

Outstanding as of December 31, 2014
Issued
Vested
Forfeited
Repurchased

Outstanding as of December 31, 2015

F-18

Shares

170,832

—

(128,051)

—
—

42,781

As of December 31, 2015, the Company had unrecognized stock-based compensation expense related to its

unvested restricted stock awards of $34 thousand, which is expected to be recognized over the remaining
weighted average vesting period of 0.56 years.

During the years ended December 31, 2015 and 2014, no shares of restricted stock were issued. During the

year ended December 31, 2013, current and former employees of the Company purchased a total of 130,158
shares of restricted stock, resulting in proceeds of $50 thousand.

Unvested shares are subject to repurchase by the Company, at the issuance price, upon the employee’s
termination at the Company’s sole discretion. In the year ended December 31, 2014, the Company repurchased
6,778 shares of restricted common stock issued to employees at their $0.04 original purchase price per share.

2014 Employee Stock Purchase Plan

On July 2, 2014, the Company’s stockholders approved the 2014 Employee Stock Purchase Plan. A total of

282,000 shares of common stock were initially authorized for issuance under this plan. The 2014 Employee
Stock Purchase Plan became effective upon the completion of the IPO. As of December 31, 2015, 3,852 shares
have been issued under this plan. Included in accrued liabilities at December 31, 2015 is $64 thousand of stock
compensation expense related to an enrollment period for which the related shares had not been issued as of
December 31, 2015.

8. Net Loss Per Share

Basic and diluted net income (loss) per share attributable to common stockholders was calculated as follows

for the years ended December 31, 2015, 2014 and 2013:

Year Ended December 31,

2015

2014

2013

Basic net loss per share attributable to common stockholders:
Numerator:

Net loss attributable to common stockholders

(in thousands)

$

(94,495) $

(36,105) $ (18,288)

Denominator:

Weighted average shares of common stock outstanding—basic
Dilutive effect of shares of common stock equivalents resulting
from common stock options and preferred common stock (as
converted)

27,778,288

21,574,347

1,492,288

—

—

—

Weighted average common stock outstanding—diluted

27,778,288

21,574,347

1,492,288

Net loss per share attributable to common stockholders—basic and

diluted

$

(3.40) $

(1.67) $

(12.26)

F-19

The following common stock equivalents outstanding as of December 31, 2015 and 2014, were excluded

from the computation of diluted net loss per share attributable to common stockholders for the periods presented
because including them would have been anti-dilutive:

Options to purchase common stock
Restricted stock
Employee Stock Purchase Plan

9.

Income Taxes

Year Ended December 31,

2015

2014

2,643,833
42,781
3,307

1,621,906
170,067
—

2,689,921

1,791,973

There is no provision for income taxes because the Company has historically incurred operating losses and

maintains a full valuation allowance against its net deferred tax assets. The reported amount of income tax
expense for the years differs from the amount that would result from applying domestic federal statutory tax rates
to pretax losses primarily because of changes in valuation allowance.

A reconciliation of U.S. statutory rate to the Company’s effective tax rate is as follows:

Tax due at statutory rate
State taxes, net of federal
Permanent items
Foreign rate differential
Federal and state credits
Change in valuation allowance
Other

Year Ended December 31,

2015

2014

2013

34.0% 34.0% 34.0%
4.5
4.0
(0.9)
(1.0)
(3.1) —
8.5
9.0
(46.0)
(43.1)
—
0.1

5.2
(0.1)
—
1.5
(40.5)
(0.1)

0.0% 0.0% 0.0%

Significant components of the Company’s net deferred tax asset at December 31, 2015 and 2014 are as

follows:

Net operating losses
Capitalized start-up costs
Accounting method change
Tax credit carryforwards
Accrued expenses
Depreciation and amortization
Stock options
Others

Total net deferred tax asset before valuation allowance

Valuation allowance

Net deferred tax asset

F-20

December 31,

2015

2014

(in thousands)

44,172
2,335
(1,347)
17,013
1,062
716
5,097
21

21,907
2,514
(2,020)
4,433
494
332
623
20

69,069
(69,069)

28,303
(28,303)

—

—

As of December 31, 2015, the Company had federal and state net operating loss carryforwards of $131.5 million
and $130.7 million, respectively, which begin to expire in 2031. As of December 31, 2015, the Company had federal
and state research and development tax credits carryforwards of $1.6 million and $0.7 million, respectively, which
begin to expire in 2031 and 2027, respectively. As of December 31, 2015, the Company had federal orphan drug tax
credit carry forwards of $16.4 million, which begin to expire in 2034. At December 31, 2015, the Company has excess
equity based compensation tax deductions related to net operating losses for federal and state purposes of $18.9 million
and $18.9 million respectively. The Company has excess equity based compensation related to credits for federal and
state purposes of $1.3 million and $0.2 million, respectively. These excess tax benefits have not been included in the
net deferred tax assets before valuation allowance since these benefits would be credited directly to additional paid in
capital if subsequently recognized through a reduction in taxes payable.

As of December 31, 2015, net deferred tax assets increased approximately $40.8 million primarily due to the

operating loss and tax credits incurred during the year. This increase in net deferred tax assets was offset by a
corresponding increase in the valuation allowance.

Management of the Company has evaluated the positive and negative evidence bearing upon the

realizability of its deferred tax assets, which are comprised principally of net operating loss carryforwards and
capitalized start-up costs. Under the applicable accounting standards, management has considered the Company’s
history of losses and concluded that it is more likely than not that the Company will not recognize the benefits of
federal and state deferred tax assets. Accordingly, a full valuation allowance of $69.1 million and $28.3 million
has been established at December 31, 2015 and 2014, respectively.

Pursuant to Section 382 of the Internal Revenue Code, certain substantial changes in the Company’s ownership
may result in a limitation on the amount of net operating loss carryforwards and tax carryforwards that may be used
in future years. Utilization of the net operating loss (“NOL”) and tax credit carryforwards may be subject to a
substantial annual limitation under Section 382 of the Internal Revenue Code of 1986 due to ownership change
limitations that have occurred previously or that could occur in the future. These ownership changes may limit the
amount of NOL and tax credit carryforwards that can be utilized annually to offset future taxable income and tax,
respectively. The Company has not completed a study to assess whether an ownership change has occurred, or
whether there have been multiple ownership changes since its formation, due to significant complexity and related
costs associated with such a study. There could also be additional ownership changes in the future which may result
in additional limitations on the utilization of NOL carryforwards and credits. Further, until a study is completed and
any limitation is known, no amounts are being presented as an uncertain tax position.

The Company applies the authoritative guidance on accounting for and disclosure of uncertainty in tax
positions, which requires the Company to determine whether a tax position of the Company is more likely than
not to be sustained upon examination, including resolution of any related appeals of litigation processes, based on
the technical merits of the position. For tax positions meeting the more likely than not threshold, the tax amount
recognized in the financial statements is reduced by the largest benefit that has a greater than fifty percent
likelihood of being realized upon the ultimate settlement with the relevant taxing authority.

The following is a rollforward of the Company’s unrecognized tax benefits:

Unrecognized tax benefits—as of the beginning of the year
Gross increases—current period tax positions
Gross decreases—tax positions of prior periods

Unrecognized tax benefits—as of the end of the year

F-21

Year Ended December 31,

2015

2014

2013

(in thousands)
$ 2,880

—
(2,880)

$ —

$1,477
1,403
—

$2,880

$—
—
—

$—

During 2014, the Company filed an application for change in accounting method with the IRS to capitalize

start-up costs that were historically deducted and included as part of the NOL carryforward through
December 31, 2013. As a result, the Company’s unrecognized tax benefits, which historically related to start-up
costs, are zero at December 31, 2015.

The Company will recognize interest and penalties related to uncertain tax positions in income tax expense
when in a taxable income position. As of December 31, 2015 and 2014, the Company had no accrued interest or
penalties related to uncertain tax positions and no amounts have been recognized in the Company’s statement of
operations.

The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the

normal course of business, the Company is subject to examination by federal and state jurisdictions, where
applicable. There are currently no pending tax examinations, and the Company’s tax returns are open under
statute from 2012 to the present. The tax attributes prior to 2012 may still be adjusted upon examination. The
Company’s policy is to record interest and penalties related to income taxes as part of the tax provision.

During November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes,
which simplifies the presentation of deferred income taxes. This ASU requires that deferred tax assets and liabilities
be classified as non-current in a statement of financial position. The standard is effective for public companies for
fiscal years beginning after December 31, 2016, including interim periods within that reporting period. Early
adoption is permitted for any interim and annual financial statements that have not yet been issued. The Company
early adopted ASU 2015-17 effective December 31, 2015 on a prospective basis. Adoption of this ASU resulted in a
reclassification of the current deferred tax liability to a non-current deferred tax liability, which is netted with the
long-term deferred tax asset in its consolidated balance sheet as of December 31, 2015. No prior periods were
retrospectively adjusted.

10. Employee Benefit Plan

The Company maintains a 401(k) profit sharing plan (the “Plan”) for its employees. Each participant in the

Plan may elect to contribute a portion of his or her annual compensation to the Plan subject to annual limits
established by the Internal Revenue Service. Effective November 1, 2014, the Company instituted an employer
match of 50% of eligible contributions up to 6% of employee contributions. For the years ended December 31,
2015 and 2014, the Company contributed $0.2 million and $15 thousand, respectively.

11. Related Party Transactions

Since inception, the Company has received consulting and management services from Third Rock Ventures

LLC, which through its affiliates, owned 16.4% of the Company’s common stock at December 31, 2015. The
Company recorded expenses of $21 thousand, $0.2 million, and $0.6 million for these services for the years
ended December 31, 2015, 2014, and 2013, respectively.

F-22

12. Selected Quarterly Financial Data (Unaudited)

The following table contains quarterly financial information for 2015 and 2014. The Company believes that

the following information reflects all normal recurring adjustments necessary for a fair statement of the
information for the periods presented. The operating results for any quarter are not necessarily indicative of
results for any future period.

First
Quarter

Second
Quarter

2015

Third
Quarter

Fourth
Quarter

Total

Total operating expenses
Loss from operations
Net loss and comprehensive loss
Net loss attributable to common stockholders
Net loss per share attributable to common

stockholders—basic and diluted

Total operating expenses
Loss from operations
Net loss and comprehensive loss
Net loss attributable to common stockholders
Net loss per share attributable to common

stockholders—basic and diluted

13. Subsequent Event

$ 16,897
(16,897)
(16,871)
(16,871)

(in thousands, except per share amounts)
$ 24,082
(24,082)
(24,035)
(24,035)

$ 25,059
(25,059)
(25,027)
(25,027)

$ 28,612
(28,612)
(28,562)
(28,562)

$ 94,650
(94,650)
(94,495)
(94,495)

$

(0.66) $

(0.90) $

(0.84) $

(0.99) $

(3.40)

2014

First
Quarter

Second
Quarter

Third
Quarter

Fourth
Quarter

Total

(in thousands, except per share amounts)

$ 5,790
(5,790)
(5,790)
(6,116)

$ 6,188 $ 9,471
(9,471)
(9,468)
(9,859)

(6,188)
(6,192)
(7,769)

$ 12,361
(12,361)
(12,361)
(12,361)

$ 33,810
(33,810)
(33,811)
(36,105)

$ (3.70) $ (4.57) $ (0.50) $

(0.48) $

(1.67)

On January 12, 2016, the Company completed the sale of 3,157,894 shares of its common stock at a price to

the public of $47.50 per share, resulting in net proceeds to the Company of $140.4 million after deducting
underwriting discounts and commissions and estimated offering expenses payable by the Company.

F-23

Exhibit
No.

3.1

3.2

4.1

4.2

10.1+

10.2*

10.3*

10.4*

10.5

10.6+

10.7+

10.8+

10.9+

Exhibit List

Description

Fifth Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect
(incorporated by reference to Exhibit 3.2 of the Registrant’s Current Report on Form 8-K
(File No. 000-36544) filed on July 25, 2014)

By-laws of the Registrant and the amendments thereto, as currently in effect (incorporated by
reference to Exhibit 3.4 of the Registrant’s Current Report on Form 8-K (File No. 000-36544) filed
on July 25, 2014)

Specimen Common Stock Certificate (incorporated by reference to Exhibit 4.1 of the Registrant’s
Registration Statement on Form S-1 (File No. 333-196849) filed on July 8, 2014)

Second Amended and Restated Investors’ Rights Agreement by and among the Registrant and
certain of its stockholders dated March 11, 2014 (incorporated by reference to Exhibit 4.2 of the
Registrant’s Registration Statement on Form S-1 (File No. 333-196849) filed on July 8, 2014)

2014 Stock Option and Incentive Plan and forms of award agreements thereunder (incorporated by
reference to Exhibit 10.1 of the Registrant’s Registration Statement on Form S-1
(File No. 333-196849) filed on July 8, 2014)

Exclusive License Agreement by and between the Registrant and Washington University, dated
November 11, 2013 (incorporated by reference to Exhibit 10.3 of the Registrant’s Registration
Statement on Form S-1 (File No. 333-196849) filed on July 8, 2014)

Amended and Restated Commercial License by and between the Registrant and CyDex
Pharmaceuticals, Inc., dated September 25, 2015 (incorporated by reference to Exhibit 10.1 of the
Registrant’s Quarterly Report on Form 10-Q (File No. 001-36544) filed on November 6, 2015.

Non-Exclusive License Agreement by and between the Registrant and the Regents of University of
California, dated October 23, 2013, as amended May 14, 2014 (incorporated by reference to
Exhibit 10.5 of the Registrant’s Registration Statement on Form S-1 (File No. 333-196849) filed
on July 8, 2014)

Lease Agreement, by and between the Registrant and ARE-MA Region No. 38, LLC, dated
December 11, 2011, as amended by First Amendment to Lease, by and between ARE-MA Region
No. 38, LLC, dated October 26, 2012, and Second Amendment to Lease, by and between ARE-
MA Region No. 38, LLC, dated May 9, 2013 (incorporated by reference to Exhibit 10.6 of the
Registrant’s Registration Statement on Form S-1 (File No. 333-196849) filed on July 8, 2014)

Offer letter by and between the Registrant and Jeffrey M. Jonas, dated July 18, 2013 (incorporated
by reference to Exhibit 10.7 of the Registrant’s Registration Statement on Form S-1
(File No. 333-196849) filed on July 8, 2014)

Offer letter by and between the Registrant and Albert J. Robichaud, dated September 25, 2011
(incorporated by reference to Exhibit 10.8 of the Registrant’s Registration Statement on Form S-1
(File No. 333-196849) filed on July 8, 2014)

Offer letter by and between the Registrant and Stephen J. Kanes, dated May 21, 2013 (incorporated
by reference to Exhibit 10.9 of the Registrant’s Registration Statement on Form S-1
(File No. 333-196849) filed on July 8, 2014)

Offer letter by and between the Registrant and Kimi Iguchi, dated February 7, 2013 (incorporated
by reference to Exhibit 10.10 of the Registrant’s Registration Statement on Form S-1
(File No. 333-196849) filed on July 8, 2014)

Exhibit
No.

10.10+

10.11+

10.12+

10.13+

10.14+

10.15

10.16

10.17*

10.18+

10.19+

10.20+

10.21+

10.22+

10.23+

10.24+

10.25*

Description

Non-Solicitation, Confidentiality and Assignment Agreement by and between the Registrant and
Jeffrey M. Jonas, dated August 19, 2013 (incorporated by reference to Exhibit 10.11 of the
Registrant’s Registration Statement on Form S-1 (File No. 333-196849) filed on July 8, 2014)

Non-Solicitation, Confidentiality and Assignment Agreement by and between the Registrant and
Albert J. Robichaud, dated November 7, 2011 (incorporated by reference to Exhibit 10.12 of the
Registrant’s Registration Statement on Form S-1 (File No. 333-196849) filed on July 8, 2014)

Non-Solicitation, Confidentiality and Assignment Agreement by and between the Registrant and
Stephen J. Kanes, dated July 17, 2013 (incorporated by reference to Exhibit 10.13 of the
Registrant’s Registration Statement on Form S-1 (File No. 333-196849) filed on July 8, 2014)

Non-Solicitation, Confidentiality and Assignment Agreement by and between the Registrant and
Kimi Iguchi, dated March 8, 2013 (incorporated by reference to Exhibit 10.14 of the Registrant’s
Registration Statement on Form S-1 (File No. 333-196849) filed on July 8, 2014)

Senior Executive Cash Incentive Bonus Plan (incorporated by reference to Exhibit 10.15 of the
Registrant’s Registration Statement on Form S-1 (File No. 333-196849) filed on July 8, 2014)

Form of Indemnification Agreement to be entered into between the Registrant and its directors
(incorporated by reference to Exhibit 10.16 of the Registrant’s Registration Statement on Form S-1
(File No. 333-196849) filed on July 8, 2014)

Form of Indemnification Agreement to be entered into between the Registrant and its officers
(incorporated by reference to Exhibit 10.17 of the Registrant’s Registration Statement on Form S-1
(File No. 333-196849) filed on July 8, 2014)

Supply Agreement by and between the Registrant and CyDex Pharmaceuticals, Inc., dated
December 13, 2012, as amended August 21, 2013 and April 30, 2014 (incorporated by reference to
Exhibit 10.18 of the Registrant’s Registration Statement on Form S-1 (File No. 333-196849) filed
on July 8, 2014)

2014 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.19 of the
Registrant’s Registration Statement on Form S-1 (File No. 333-196849) filed on July 8, 2014)

Offer Letter by and between the Registrant and Thomas D. Anderson, dated April 15, 2014
(incorporated by reference to Exhibit 10.20 of the Registrant’s Registration Statement on Form S-1
(File No. 333-196849) filed on July 8, 2014)

Severance and Change In Control Agreement between the Registrant and Jeffrey M. Jonas, dated
September 25, 2014 (incorporated by reference to Exhibit 10.20 of the Registrant’s Annual Report
on Form 10-K (File No. 001-36544) filed on March 6, 2015)

Severance and Change In Control Agreement between the Registrant and Kimi Iguchi, dated
September 30, 2014 (incorporated by reference to Exhibit 10.21 of the Registrant’s Annual Report
on Form 10-K (File No. 001-36544) filed on March 6, 2015)

Severance and Change In Control Agreement between the Registrant and Stephen J. Kanes, dated
September 30, 2014 (incorporated by reference to Exhibit 10.22 of the Registrant’s Annual Report
on Form 10-K (File No. 001-36544) filed on March 6, 2015)

Severance and Change In Control Agreement between the Registrant and Albert J. Robichaud,
dated September 25, 2014 (incorporated by reference to Exhibit 10.23 of the Registrant’s Annual
Report on Form 10-K (File No. 001-36544) filed on March 6, 2015)

Severance and Change In Control Agreement between the Registrant and Thomas D. Anderson,
dated September 26, 2014 (incorporated by reference to Exhibit 10.24 of the Registrant’s Annual
Report on Form 10-K (File No. 001-36544) filed on March 6, 2015)

Exclusive License Agreement by and between the Registrant and the Regents of the University of
California, dated June 6, 2015 (incorporated by reference to Exhibit 10.1 of the Registrant’s
Quarterly Report on Form 10-Q/A (File No. 001-36544) filed on October 31, 2015)

Exhibit
No.

10.26

10.27

10.28

10.29

21.1

23.1

31.1

31.2

Description

Third Amendment to Lease, by and between Registrant and ARE-MA Region No. 38, LLC, dated
as of September 9, 2015 (incorporated by reference to Exhibit 10.3 of the Registrant’s Quarterly
Report on Form 10-Q (File No. 001-36544) filed on November 6, 2015)

Fourth Amendment to Lease, by and between the Registrant and ARE-MA Region No. 38, LLC,
dated as of October 27, 2015 (incorporated by reference to Exhibit 10.4 of the Registrant’s
Quarterly Report on Form 10-Q (File No. 001-36544) filed on November 6, 2015)

Amendment No. 3 to Supply Agreement, by and between the Registrant and CyDex
Pharmaceuticals, Inc., dated September 25, 2015 (incorporated by reference to Exhibit 10.2 of the
Registrant’s Quarterly Report on Form 10-Q (File No. 001-36544) filed on November 6, 2015)

Fifth Amendment to Lease, by and between the Registrant and ARE-MA Region No. 38, LLC,
dated as of December 9, 2015

Subsidiaries of the Registrant

Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm

Certification of Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the
Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of
2002

Certification of Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the
Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of
2002

32.1**

Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS

XBRL Instance Document

101.SCH

XBRL Taxonomy Extension Schema Document

101.CAL

XBRL Taxonomy Extension Calculation Document

101.DEF

XBRL Taxonomy Extension Definition Linkbase Document

101.LAB

XBRL Taxonomy Extension Labels Linkbase Document

101.PRE

XBRL Taxonomy Extension Presentation Link Document

(+) Management contract or compensatory plan or arrangement.
(*)
(**) The certifications furnished in Exhibit 32.1 hereto are deemed to accompany this Annual Report on

Confidential treatment has been granted by the Securities and Exchange Commission as to certain portions.

Form 10-K and will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of
1934, as amended. Such certifications will not be deemed to be incorporated by reference into any filings
under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except
to the extent that the Registrant specifically incorporates it by reference.

Sage Therapeutics is committed to

making life better for patients with

debilitating central nervous system (CNS)

disorders by discovering, developing and

delivering important new medicines to

ANNUAL MEETING

address these conditions.

THE ANNUAL MEETING OF STOCKHOLDERS

EXECUTIVE LEADERSHIP

JEFF JONAS, M.D.
Chief Executive Officer

STEVE KANES, M.D.
Chief Medical Officer

AL ROBICHAUD, PH.D.
Chief Scientific Officer

KIMI IGUCHI
Chief Financial Officer

TOM ANDERSON
Chief Commercial Strategy Officer

JIM DOHERTY, PH.D.
SVP, Research

ANNE MARIE COOK, J.D.
SVP, General Counsel

HEINRICH SCHLIEKER, PH.D.
SVP, Technical Operations

ERIN LANCIANI
SVP, People and Organizational Strategy

BOARD OF DIRECTORS

KEVIN STARR

JEFF JONAS, M.D.

STEVEN PAUL, M.D.

HOWARD H. PIEN

JAMES M. FRATES

MICHAEL C. COLA

will be held at
9:00 a.m. EDT on June 22, 2016 at
Sage Therapeutics
215 First Street
Cambridge, MA 02142

INDEPENDENT AUDITORS

PRICEWATERHOUSECOOPERS LLC

125 High Street
Boston, MA 02110
(617) 530-5000

INVESTOR INQUIRIES

Email: ir@sagerx.com
Phone: (617) 299-8377

STOCK LISTING

NASDAQ: SAGE

TRANSFER AGENT

The transfer agent is responsible, among other things,
for handling stockholder questions regarding lost stock
certificates, address changes, including duplicate mailings,
and changes in ownership or name in which shares are held.
These requests may be directed to the transfer agent at the
following address:

COMPUTERSHARE TRUST COMPANY

250 Royall Street
Canton, MA 02021
http://www.computershare.com/us/contact/

SEC FORM 10-K

A copy of Sage’s annual report on Form 10-K filed with the
Securities and Exchange Commission is available free of
charge from the company’s Investor Relations Department
by calling (617) 299-8377, emailing ir@sagerx.com or
sending a written request to Sage’s Investor Relations
Department at:

INVESTOR RELATIONS
Sage Therapeutics
215 First Street
Cambridge, MA 02142

CORPORATE HEADQUARTERS
215 First Street 
Cambridge, MA 02142 
(617) 299-8380 
ir@sagerx.com

www.SageRx.com

NASDAQ: SAGE